 
Stat Analysis Plan V3 
 A Phase 3, Multicenter Study with a 36- Week Open -Label Period Followed by a Randomized 
Double-Blind Withdrawal Period from Week 36 to Week 104 to Evaluate the Long- Term 
Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease -
Modifying Antirheumatic Drug –Naive Patients with Active Psoriatic Arthritis  
 [STUDY_ID_REMOVED] 
Approval Date: 25- Oct-2018 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 1
LY24398211.Statistical A nalysis Plan:
I1F-MC-RHBF:  Phase 3, Multicenter Study  with a 36 -Week 
Open -Label Period Followed by  a Randomized Double -
Blind Withdrawal Period from Week 36 to Week 104 to 
Evaluate the Long -Term Efficacy and Safety  of 
Ixekizumab (LY2439821) 80 mg Every  2 Weeks in Biologic 
Disease -Modify ing A ntirheumatic Drug –Naive Patients 
with A ctive Psoriatic A rthritis
Confidential Information
The information contained in this Statistical Analysis Plan (SAP) is confidential and the 
information contained within it may not be reproduced or otherwise disseminated without 
the approval of Eli Lilly and Company or its subsidiaries.  This document and its associated 
attachments or appendices are s ubject to United States Freedom of Information Act 
Exemption 4.
Ixekizumab (LY2439821) Psoriatic Arthritis
Study I1F -MC-RHBF is a Phase 3, multicenter study with a 36 -week initial open -label 
treatment period examining the effect of ixekizumab 80 mg every 2 weeks (Q2W ) in 
patients with active psoriatic arthritis (PsA) who are conventional disease -modifying 
antirheumatic drug (cDMARD) inadequate responders (IRs) and biologic disease -modifying 
antirheumatic drug (bDMARD)- naive followed by a randomized, double -blind withdrawal 
period from W eek 36 to W eek 104 examining the effect of ixekizumab 80 mg Q2W  
compared to that of placebo.  
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol I1F -MC-RHBF
Phase 3
Statistical Analysis Plan Version 1 electronica lly signed and approved by Lilly:
30 October 2015
Statistical Analysis Plan Version 2 electronically signed and approved by Lilly :
20 April 2017
Statistical Analysis Plan Version 3electronically signed and approved by Lilly 
on date provided below
Approval Date: 25-Oct-2018 GMT
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 2
LY24398212.Table of Contents
Section Page
1. Statistical Analysis Plan: I1F -MC-RHBF:  Phase 3, Mult icenter 
Study  with a 36 -Week Open -Label  Period Foll owed by  a 
Randomized Double -Blind Wi thdrawal  Period from Week 36 to 
Week 104 to Evaluate the Long -Term  Efficacy and Safet y of 
Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Bio logic 
Disease -Modifying Antirheumat ic Drug –Naive Patients with Active 
Psori atic Arthri tis................................................................................................................ 1
2. Table of Contents ................................................................................................................ 2
3. Revisio n History ................................................................................................................. 8
4. Study  Objectives ............................................................................................................... 11
4.1. Primary Object ive........................................................................................................ 11
4.2. Secondary  Object ives................................................................................................... 11
4.
3. Exploratory  Objectives .................................................................................................11
5. Study  Design ..................................................................................................................... 13
5.1. Summary  of Study  Design ............................................................................................ 13
5.2. Determinat ion of Sample Size ...................................................................................... 17
5.3. Method of Assignment to Treatment ............................................................................ 17
6. A Pri ori Stati stical Methods .............................................................................................. 18
6.1. General Considerations ................................................................................................ 18
6.1.1. General Considerations for Analyses during Period 2 (Init ial 
Open -Label  Treatm ent Period)
............................................................................. 19
6.1.1.1. Initial Open -Label  Treatment Peri od Popul ation............................................. 19
6.1.2. General Considerations for Analyses during Period 3 
(Rando mized Double -Blind Wit hdrawal Period) .................................................. 19
6.1.2.1. Randomized Wit hdrawal ITT and Rando mized 
Withdrawal Safet y Populati ons....................................................................... 19
6.1.2.2. Relapse Population ......................................................................................... 21
6.1.3. General Considerations for Analyses during Period 2 and 
Period 3 Combined (Init ial Open -Label  Treatment and 
Randomized Double -Blind Wi thdrawal  Periods) .................................................. 22
6.1.3.1. Ixekizumab 80 mg Q2W -Treated Patients from the 
Randomized Wit hdrawal ITT Populat ion........................................................ 22
6.1.3.2. Nonrando mized Populat ion............................................................................. 23
6.1.4. General Considerations for Analyses during Period 4 (Post
-
Treatment Follow -up Peri od) ............................................................................... 23
6.2. Adjustments for Covari ates.......................................................................................... 24
6.3. Handling of Dropouts or Missing Data ......................................................................... 24
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 3
LY24398216.3.1. Nonresponder Imputation (NRI) for Clinical Response ........................................ 24
6.3.2. Modified Baseline Observat ion Carried Forward (mBOCF) .................................24
6.4. Multicenter Studi es...................................................................................................... 25
6.5. Multiple Com parisons/Mult iplicit y............................................................................... 25
6.6. Use of an “Efficacy  Subset” of Pati ents........................................................................ 25
6.6.1. Analysis Populat ions............................................................................................ 25
6.7. Patient Disposi tion....................................................................................................... 26
6.8. Patient Characteri stics.................................................................................................. 27
6.8.1. Previous Therapy for Psoriat ic Arthri tis............................................................... 32
6.8.2. Historical Illness and Preexist ing Condit ions........................................................ 33
6.9. Treatment Compliance .................................................................................................33
6.10. Concomitant Therapy ................................................................................................... 35
6.11. Efficacy Analyses ........................................................................................................ 36
6.11.1. Primary Outcome and Methodology ..................................................................... 48
6.11.2. Secondary  Efficacy  Analyses ............................................................................... 48
6.11.3. Sensit ivity Analyses ............................................................................................. 48
6.12. Bioanaly tical and Pharm acokinetic/Pharm acodynamic Methods ................................... 48
6.13. Safety Analyses ............................................................................................................ 48
6.13.1. Extent of Exposure ............................................................................................... 49
6.13.2. Adverse Events .................................................................................................... 50
6.13.3. Deaths, Other Serious Adverse Events, and Other Notable 
Adverse Events .................................................................................................... 53
6.13.3.1.     Deaths ............................................................................................................ 53
6.13.3.2. Serious Adverse Event Analyses ..................................................................... 53
6.13.3.3. Other Si gnificant Adverse Events ................................................................... 54
6.13.4. Depressio n and Sui cide-Related Pati ent Reported Outcomes ................................ 54
6.13.5. Clinical Laboratory  Evaluat ion............................................................................. 55
6.13.5.1. Leukocy tes (WBC) and Pl atelets.................................................................... 58
6.13.5.2. Neutrophil Fo llow-Up.................................................................................... 58
6.13.6. Vital Signs and Other Physical Findings ............................................................... 59
6.13.7. Speci al Safet y Topi cs including Adverse Events of Special 
Interest ................................................................................................................. 61
6.13.8. Immunogenicit y................................................................................................... 74
6.13.8.1. Definit ions and Terms .................................................................................... 74
6.13.8.1.1. Sample Category  Definit ions.................................................................... 74
6.13.8.1.2. Patient Category  Definit ions..................................................................... 75
6.13.8.1.3. Definit ions for Clinical Interpretation of Assay  
Results ...................................................................................................... 76
6.13.8.2. Immunogenicit y Analyses .............................................................................. 78
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 4
LY24398216.13.8.2.1. Analyses of Characteristics of ADA Immune 
Response .................................................................................................. 80
6.13.8.2.2. Analyses of Treatment -Emergent ADA Effects on 
Efficacy .................................................................................................... 81
6.13.8.2.3. Analyses of Treatment -Emergent ADA on Specific 
Adverse Events ......................................................................................... 82
6.14. Subgroup Analyses ....................................................................................................... 82
6.14.1. Efficacy Subgroup Analysis ................................................................................. 82
6.14.2. Safety Subgroup Analysis .................................................................................... 84
6.15. Analysis for Australian Submissio n.............................................................................. 85
6.16. Analysis for United Kingdo m National Institute for Health and 
Care Excellence Submissio n......................................................................................... 85
6.17. Protocol  Deviat ions...................................................................................................... 85
6.18. Interim Analyses and Data Monitoring ....................................................................... 100
6.19. Planned Exploratory
 Analyses .................................................................................... 100
6.19.1. Planned Exploratory  Efficacy Analysis .............................................................. 100
6.19.2. Planned Exploratory  Heal th Outcom es/Qualit y-of-Life 
Analyses ............................................................................................................ 115
6.20. Annual Report Analyses ............................................................................................. 130
6.21. Clinical Trial Registry  Analyses ................................................................................. 130
7. Unblinding Plan .............................................................................................................. 131
8. References ...................................................................................................................... 132
9. Appendices ..................................................................................................................... 136
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 5
LY2439821Table of Contents
Table Page
Table RHBF.6.1. Geographic Regio ns...................................................................................... 25
Table RHBF.6.2. Date of First Inject ion by Period and Analysis Populat ion.............................. 27
Table RHBF.6.3. Descript ion and Derivat ion of Primary  and Secondary
 Efficacy  
Outcom es...................................................................................................... 37
Table RHBF.6.4. Descript ion of Primary  and Secondary Efficacy  Analyses .............................. 42
Table RHBF.6.5. Categori cal Criteria f or Abnorm al Treatment -Emergent Bl ood 
Pressures and Pulse Measurement, and Categorical Criteria for Weight 
Changes for Adults ........................................................................................ 61
Table RHBF.6.6. Definit ions and Analyses o f Speci al Safety  Topi cs Including Adverse 
Events of Special Interest ............................................................................... 63
Table RHBF.6.7. TE-ADA Status Dichotomous Variables for AE analysis ............................... 79
Table RHBF.6.8. Ident ification and Act ion of Im portant Protocol  Deviat ions........................... 87
Table RHBF.6.9. Descript ion and Derivat ion of Addit ional Exploratory  Outcom es................. 101
Table RHBF.6.10. Descript ion of Planned Exploratory  Efficacy  Analyses ........................... 106
Table RHBF.6.11. Descript ion and Derivat ion of Healt h Outcom es and Qualit y-of-Life 
Measures ..................................................................................................... 116
Table RHBF.6.12. Descript ion of Planned Exploratory  Heal th Outcomes and Qualit y-
of-Life Analyses .......................................................................................... 124
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 6
LY2439821Table of Contents
Figure Page
Figure RHBF.5.1. Illustrati on of  study  design for Clinical Protocol I1F -MC-RHBF. ............. 15
Figure RHBF.6.1. Sample definit ions.................................................................................... 75
Figure RHBF.6.2. Patient categories (evaluable/unevaluable) based on sample status at 
baseline and post -baseline. ............................................................................. 76
Figure RHBF.6.3. Relationship of terms for clinical interpretation of assay results for 
evaluable pat ients.......................................................................................... 77
Figure RHBF.6.4. Flow chart of ADA assessment with clinical interpretation of the 
various result possibilit ies.............................................................................. 78
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 7
LY2439821Table of Contents
Appendix Page
Appendix 1. Algori thm for Cal culat ing Classification for Psoriatic Arthritis 
(CASPAR) Total Score ................................................................................ 137
Appendix 2. Algori thm for Cal culat ing Coates Criteria for Minimal Disease Activit y 
(MDA) ........................................................................................................ 138
Appendix 3. Algori thm for Cal culat ing Jo int Coun ts........................................................ 139
Appendix 4. Algori thm for Cal culating the Health Assessment Quest ionnaire –
Disabili ty Index (HAQ -DI).......................................................................... 140
Appendix 5. Algori thm for Determining American College of Rheumatology  (ACR) 
Response ..................................................................................................... 142
Appendix 6. Derivat ion of SF -36v2 ®Health Survey , Acute Version Scores .................... 144
Appendix 7. Anti-infect ive Medicat ions and Anatomical Therapeutic Chemical 
(ATC) Code List and Programming Guide................................................... 150
Appendix 8. MedDRA Preferred Terms for Each Category  Associ ated wi th Criterion 
2 for Anaphylact ic Allergic React ions/Hypersensitivit y Events.................... 156
Appendix 9. Allergic React ions/Hypersensit ivity MedDRA Preferred Terms ................... 158
Appendix 10. Algori thm for Cal culat ing Co mposite Psoriatic Disease Act ivity Index 
(CPDAI) ...................................................................................................... 161
Appendix 11. Lilly -defined MedDRA V21.0 Preferre d Term s for Inflammatory  
Bowel  Disease (IBD) ................................................................................... 163
Appendix 12. Lilly -defined MedDRA V21.0 Preferred Terms for Opportunist ic 
Infect ions (OI) ............................................................................................. 165
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 8
LY24398213.Revision History
Statistical Analysis Plan (SAP) Version 1 was approved on 30 October 2015 prior to first patient 
visit.
Two protocol amendments were completed after the SAP Version 1 was approved.  Protocol 
amendment (a) was approved on 10 February  10 2016 and protocol  amendment (b) was 
approved on 21 March  2017.    
Statistical Analysis Plan (SAP) Version 2was approved on 20 April 2017 prior to unblinding of 
patients randomized in the double -blind rando mized withdrawal period .  
The changes 
incorporated in SAP Versio n 2are as fo llows: 
Conventional disease -modifying ant irheumat ic drug (cDMARD) use was added 
as a stratifi cation parameter to the primary  analysis l og-rank m odel.  Protocol  I1F-
MC-RHBF (RHBF) Section 12.2.6.1 indicates that only geographic region is used 
as a stratification parameter in the model.  However, cDMARD use (past, current) 
is also a stratificat ion parameter in the rando mizat ion scheme and should be added 
to the primary analysis model.
Similarly, cDMARD use will be added as stratification parameter to the logist ic 
regression model for the categorical efficacy and health outcomes analyses (see 
Protocol Secti on 12.2.1.2).
Psori atic arthritis (PsA) subt ypes will not be included in the baseline pat ient 
characterist ic analysis.  Although this was stated in the protocol, the informat ion 
is not collected. 
The missing data imputation method, modified baseline observat ion carri ed 
forward (mBOCF) was added to the SAP.  This method will be used in addit ion to 
last observat ion carri ed forward (LOCF).  If a case arises in which using these 2 
methods i s not consistent, the mBOCF method will be the primary  method.
Clarified the popul ation for the Health Assessment Questionnaire –Disabilit y 
Index ( HAQ -DI) total  score improvement ≥0.35 analysis.  Patients need to have 
baseline HAQ -DI total score ≥0.35 to be considered for improvement.
Clarified the definit ion for the ana lysis on tender entheseal po ints will be based on 
the assessment of the 18 entheseal po ints.  
Corrected the derivat ion for durati on of  exposure for Peri od 2 and Peri od 3 
combined. 
Updates to the safet y analysis per program safet y analysis plan (PSAP) Ver sion 7.
Updates to the immunogenicit y analysis per PSAP Version 7. 
Clarified that the l ongitudinal  analyses will be summarized by treatment week 
instead of by visit and through 40 weeks of treatment.
Added secondary  analyses for C -reactive protein (CRP).
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 9
LY2439821Statistical Analysis Plan (SAP) Version 3was approved prior to unblinding o f patients 
rando mized in the double -blind rando mized wit hdrawal period .  The changes incorporated in 
SAP Version 3are as fo llows: 
Added analyses for disease activit y in PsA ( DAP SA).
Removed analyses for DLQI (0).
Clarified t hat longitudinal analyses will be done by treatment week through the last 
observat ion for the Rando mized Double- Blind Wi thdrawal Peri od and the Rel apse 
Period.
Clarified that only  analyses wi thin the Rando mize d Double -Blind Wit hdrawal Period will 
include missing data imputations (NRI for categorical endpo ints and mBOCF for 
continuous endpo ints).
Clarified that pre -existing condi tions are defined as having a start date prior to the date of 
inform ed consent and not prior to the date of first study  drug injection.
Clarified that the treatment compliance calculat ion for Peri od 3 does not include the 
loading dose.
Removed analyses for trea tment com pliance and protocol  deviat ionanalyses for the 
relapse period and the combined Periods 2 and 3.
Clarified that the time -to endpoints in Period 3 arecalculated wi th respect to the start of 
Period 3 and not Period 2.
Removed a majority of the safety analyses for the post -treatm ent follow-up peri od.
Clarified that categori cal analyses assessed during Period 3 will be assessed through 40 
weeks of randomized treatment with the except ion of the proportion of patients who 
relapse.  The analyses for the proporti on of  patients who rel apse will be assessed over the 
entire rando mized wit hdrawal study  periodwith cumulat ive rate .  Addit ionally , the 
proporti on of  patients who relapse will be described by  treatm ent week for the ent ire 
rando mized withdrawal stud y period.
Removed l aboratory  and vi tal sign analyses for change from baseline to each scheduled 
post-baseline visit.
Removed l aboratory  and vi tal sign box pl ots.
Added laboratory  shift tabl es for neutrophils , leukocy tes, pl atelets, and lymphocy tes.
Removed commo n adverse event section and moved the exposure -adjusted analysis 
details to the general considerat ion sect ion.
Removed the regi on pooling statem ent. 
For AESI s:
oremoved analyses for elevated hepat ic criteria; 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 10
LY2439821oremoved the TEAE table for opportunist icinfect ions by preferred term; 
oremoved TEAE table for ISRs by  preferred term  within high-level terms; and
oremoved analyses for IBD and ILD with the except of TEAE by  preferred tem  by 
max severit y by preferred term within category . 
Added a protocol deviat ionfor patients who start on IXE in the Rando mized Double -
Blind Wit hdrawal Period prior to experiencing a relapse (no longer meet ing Coates 
criteria for MDA in Period3).  These patients will also be removed from the PPS.
Updated the derivat ion of the protocol  deviati ons for entry  criteria [1] and [4] .
Updated the statist ical model for tes ting efficiacy  subgroup interacti ons to the Cox -
proproti onal hazards model.
Added Appendix 2 for calculat ing Coates criteria for minimal disease activit y (MDA).
Clarified the algorithmfor calculat ing Jo int Count s (see Appendix 3).
AESIs were updated per the updated with changes fro m the PSAP Veri ons 7 and 8.
Made other minor ty pographical correcti ons and clarifications not affecting content.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 11
LY24398214.Study  Objectives
4.1. Primary  Objective
The primary  object ive of the study  is to com pare ixekizumab 80 mg every  2 weeks (Q2W) wi th 
placebo in m aintenance of treatment response, as measured by the time -to rel apse during the 
rando mized double -blind withdrawal period in cDMARD inadequate responders (cDMARD- IR) 
and bio logic DMARD -naive (bDMARD- naive) pati ents wi th active PsA who meet 
rando mizat ion criteria (Coates criteria for minimal disease act ivity [MDA] for 3 consecutive 
months over 4 consecutive visit s).
4.2. Secondary Objectives
The secondary  objectives of the study  are:
to com pare ixekizumab 80 mg Q2W with placebo in maintenance of treatment 
response, as measured by the proportion of pat ients who meet relapse criteria 
during the randomized double -blind withdrawal period in cDMARD -IR and 
bDMARD -naive patients with act ive PsA who meet randomization criteria 
(Coates criteria for MDA for 3 consecutive mo nths over 4 consecutive visits)
to evaluate the time -to loss of response for each individual component of MDA in 
the randomized double -blind withdrawal period
to evaluate time -to first m eeting Coates cri teria for MDA during the init ial open -
label treatment period (Period 2)
to evaluate time -to achieving Coates criteria for MDA during the init ial open -
label treatment period (Period 2) (Coa tes cri teria for MDA for 3 consecutive 
months over 4 consecutive visit s)
to assess the efficacy  of ixekizumab 80 mg Q2W after disease relapse after 
rando mizat ion in the rando mized double -blind treatm ent peri od
to assess the effect of treatment response as measured by the HAQ -DI of  
ixekizumab 80 mg Q2W throughout the study.
4.3. Exploratory Objectives 
The exploratory  objectives of the study are:
to assess the clinical factors that predict Coates criteria for MDA
to assess the time -to achi eve other com posite measurem ents of l ow disease 
activit y, such as Disease Act ivity Score m odified to include the 28 diarthrodial
joint count, based on C -reactive protein (DAS28 -CRP), Psoriat ic Arthrit is Disease 
Activity Score (PASDAS), Com posite Psori atic Disease Act ivity Index ( CPDAI), 
and others during the init ial open -label treatment period (Period 2)
to assess the changes in healt h utilit y (European Qualit y of Life –5 Dimensi ons 5 
Level [EQ -5D 5L]), Work Productivit y and Activit y Impairment –Specific Healt h 
Problem, and Dermatol ogy Life Qualit y Index (DLQI) throughout the study
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 12
LY2439821to assess the changes in the healt h outcom e endpoints Fat igue Severit y Numeric 
Rating Scale (NRS) score, Itch NRS score (in the subgroup of patients with 
psori atic skin lesio ns involving ≥3% body  surface a rea [BSA] at baseline), Quick 
Inventory  of Depressive Symptom atology-self report 16 items (QIDS -SR16) 
score, and Medical Outcomes Study  36-Item Short Form  Heal th Survey  (SF-36) 
Physical Co mponent Summary (PCS), and Mental Component Summary (MCS) 
scores and the 8associated domains o f SF-36 (Physical Funct ioning, Role 
Physical, Bodily  Pain, General Healt h, Vi tality, Soci al Functi oning, Rol e 
Emotional, and Mental  Heal th) throughout the study
to explore bio markers of disease or drug activit y that m ay be contained in serum, 
plasma, and who le-blood messenger ribonucleic acid (RNA) and 
deoxy ribonucleic acid (DNA) samples
to assess the pharmacokinet ic (PK)/pharmacodynamic (PD) relat ionship and 
immunogenicit y of ixekizumab throughout the study  by:
ocharacterizi ng the PK of ixekizumab, determining the magnitude of within-
and between -patient variability, and i dentifying the potenti al intrinsic and 
extrinsic factors that may  have an effect on the PK of ixekizumab
ocharacterizing the exposure -response relationships for efficacy  endpoints (for 
example, proportion of patients achieving Coates criteria for MDA fro m 
Week 36 through Week 64 and the maintenance of treatment effects), and 
ident ifying potential factors that may impact the efficacy endpo ints
oevaluat ing the po tential devel opment of ant i-ixekizumab ant ibodies and its 
impact on patient safet y, efficacy , and PK of ixekizum ab.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 13
LY24398215.Study  Design
5.1. Summary of Study Design
Study  RHBF is a Phase 3, mult icenter study  with a 36 -week init ial open -label treatm ent peri od 
examinin g the effect of ixekizumab 80 mg Q2W in patients with act ive PsA who are cDMARD -
IRs and are bDMARD naive fo llowed by  a randomized double -blind wit hdrawal period from 
Week 36 to Week 104 examining the effect of ixekizumab 80 mg Q2W compared with that of 
placebo.  Pati ents who do not meet the randomized withdrawal criteria will cont inue on 
ixekizumab 80 mg Q2W uninterrupted during the rando mized double -blind wit hdrawal period.  
All rando mized pat ients who no longer meet Coates criteria for MDA at any visit af ter entering 
the randomized double -blind withdrawal period will receive ixekizumab 80 mg Q2W for the 
remainder of the study  period.  In addi tion, efficacy  and safet y will be assessed for up to a total 
of 2 years for patients who participate throughout the entire 2-year study.  
The study  consists of 4 periods:
Period 1:   screening period (Visits 1 and 1A) last ing from 4 to 30 day s before 
Week 0 (Visit 2)
Period 2:   initial open -label treatment period fro m Week 0 (baseline, Visit 2) up 
to Week 36 (Visit 12) 
Period 3: randomized double -blind withdrawal period from Week 36 to Week 
104 (Visit 29).  Patients who have been treated with ixekizumab 80 mg Q2W for 
at least 36 weeks and have achieved 4 consecut ive visit s of m eeting Coates 
criteria for MDA from Week 3 6 up to Week 64 will be eligible for randomizat ion
at the visit at which these criteria are met.  
Period 4:   post -treatm ent follow-up period occurring fro m the early  terminat ion 
visit (ETV) or the last scheduled visit for a minimum o f 12 weeks after that visit, 
up to 24 weeks if the patient’s neutrophil count is low.  All pat ients withdrawing 
from the study  after receiving even 1 dose of study treatment will proceed directly 
to Peri od 4.  
Figure RHBF. 5.1illustrates the study  design.
All procedures to be conducted during the study
, including timing of all procedures, are indicated 
in the study  schedule (Protocol Attachment 1).  Selected study  procedure s should be performed 
before administration of the investigational product, as applicable, according to the study  
schedule.  Protocol Section 10.4 describes collection of laboratory  samples; Protocol  
Attachm ent2 lists the specific laboratory  tests that wi ll be performed for this study .  
Patients di scont inuing fro m the study  who have received at least 1 dose of invest igational 
product should complete the early terminat ion visit (ETV) before proceeding to the post -
treatm ent follow-up peri od (Peri od 4).  For the management of patient safet y, all patients shoul d 
be monitored through the post -treatm ent follow-up peri od at l east as frequent ly as indicated on 
the study  schedule (Protocol Attachment 1).  
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 14
LY2439821All treatment groups are described in Protocol Sectio n 9.1.   Details of the administration of the 
investigat ional product are described in Protocol Section 9.1.1, special treatment considerat ions 
are outlined in Protocol Section 9.5.1, and the use of the study  drug administrati on log is detailed 
in Protocol Sectio n 9.5.2.  
Excluded and restricted therapies are detailed in Protocol Section 9.8.  
Pharmacokinet ic sampling is detailed in Protocol Section10.4.4.  
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 15
LY2439821See footnotes on the following page.
Figure RHBF. 5.1. Illustration of study design for Clinical Protocol I1F -MC-RHBF.

I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 16
LY2439821Abbreviations :  LV = date of last visit; LY = LY2439821 (ixekizumab); MDA = minimal disease activity; n =number of patients; Q2W = ever y 2 weeks; RW = 
randomized withdrawal; V = study visit; w = study week.
aThe initial open -label treatment period (Period 2) encompasses Week 0 up to Week 36.  During Period 2, all patients will receive op en-label ixekizumab 
80mg Q2W.
bBetween Week 36 and Week 64 (inclusive), patients who have been treated with ixekizumab 80 mg Q2W for at least 36 weeks and h ave achieved 
4consecutive visits of meeting Coates criteria for MDA will be eligible for randomiz ation at the visit at w hich these criteria are met.  Eligible patients will be 
randomized in a 1:1 ratio to 1 of 2 treatment arms:  ixekizumab 80 mg Q2W or placebo Q2W.  Patients will remain in their RW t reatment arms until they no 
longer meet Coates crite ria for MDA, at which point they will receive ixekizumab 80 mg Q2W.  Patients who do not meet Coates criteria for MDA at 
Week 52 are not eligible for randomization.
cPatients who do not meet the RW eligibility criteria by Week 64 will remain on ixekizumab 80 mg Q2W uninterrupted for the duration of Period 3.  
dPatients who no longer meet Coates criteria for MDA during Period 3 (the RW period) will be switched to ixekizumab 80 mg Q2W.   Patients who continue to 
meet Coates criteria for MDA during Period 3 (the RW period) will continue treatment until Week 104 and move to Period 4 (the post -treatment follow -up 
period).
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 17
LY24398215.2. Determination of Sample Size
Approximately  400 pati ents will enter the init ial open -label treatment period.  It is expected that 
approximately  34% of  the pati ents will  meet the rando mizat ion criteria for the randomized 
doubl e-blind wit hdrawal period.  Approximately 136 patients will b e rando mized in a 1:1 ratio 
into ixekizumab 80 mg Q2W and placebo treatment groups (68 patients per treatment group).  
This assumpt ion is based on Study  RHAP Week 24 results and est imating the number of patients 
achieving Coates criteria for MDA for 3 cons ecutive mo nths over 4 consecut ive visits of meet ing 
MDA.  
It is assumed that approximately  60% and 20% of pati ents in the pl acebo and ixekizumab groups, 
respectively , who enter the randomized double -blind withdrawal period will relapse (no longer 
meet Coa tes cri teria for MDA).  According to these assumptions, a total o f 39 pati ents m ust m eet 
relapse cri teria in the combined treatment groups to achieve 95% power to test the superiorit y of 
ixekizumab 80 mg Q2W to placebo for time -to relapse at a 2 -sided 0.05 significance l evel.  
The dropout rate before relapse for patients randomized in the rando mized double -blind 
withdrawal  period is assumed to be 10%.  Sample size and power calculat ions were calculated 
using nQuery+nTerim 3.0.
Randomization and relapse ra tes will be monitored to assess whether the number of patients who 
enter the init ial open -label treatment period should be increased to ensure sufficient sample size 
and power for the randomized wit hdrawal period.
5.3. Method of Assignment to Treatment
Patients who meet the eligibilit y criteria for randomizat ionany time from Week 36 through 
Week 64 will be rando mized to double -blind treatment groups as determined by  a 
computer -generated random sequence using an interactive web -response system (IWRS).  The 
IWRS will be used to assign double -blind invest igational product to each patient.  Site personnel 
will confirm that they  have l ocated the correct assigned invest igational product package by  
entering a confirmat ion number found on the package into the IWRS.  Pat ients will be stratified 
by geographic region and cDMARD use (past use, current use) at the time of rando mizat ion in 
Period 3.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 18
LY24398216.A Priori Statistical Methods
6.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  (hereafter 
Lilly) .  The stati stical analyses will be performed using SAS ®Versi on 9.2 or hi gher.
Continuous data will be summarized in terms of the number of observations, mean, standard 
deviat ion (SD), minimum, median, and maximum.  The minimu m and maximum  will be 
reported to the same number of decimal places as the raw data recorded in the database.  The 
mean and median will be reported to 1 more decimal place than the raw data recorded in the 
database.  The SD will be reported to 2 more decim al places than the raw data recorded in the 
database.  In general, the maximum number of decimal places reported shall be 4 for any  
summary statist ic.
Categorical data will be summarized in terms of the number of patients in the analysis 
popul ation, the nu mber of pat ients providing data at the relevant time po int, frequency  counts, 
and the percentages corresponding to the appropriate method.  Percentages will be presented to 
1decimal place.  Percentages will not be presented for zero counts.
Change from ba seline will be calculated as the post -baseline value minus the baseline value.  
Percent change fro m baseline is defined as (100 x [post -baseline –baseline] / baseline).  Percent 
improvement from baseline is calculated as the posit ive percent change from b aseline if a higher 
value at postbaseline means improvement from baseline.  Similarly, percent improvement fro m 
baseline is calculated as the negat ive percent change fro m baseline if a lower value at 
postbaseline means improvement from baseline.
Data colle cted at ETVs will be mapped to the next planned visit number for that patient.  For by -
visit and by -treatm ent-week summaries, only visits in which a measure was scheduled to be 
collected will be summarized.  Unplanned/unscheduled measurements will be exclu ded from  the 
mixed -effects m odel of repeated m easures (MMRM) analysis.  However, the data will st ill be 
used in other analyses as indicated in the SAP.  Such analyses will include, but are not limited to, 
shift analyses and change fro m baseline to last -observat ion(e.g.,mBO CF)endpo int analyses.
All confidence intervals (CIs) and statist ical tests will  be 2-sided wi th an level o f 0.05 unless 
otherwi se specified.  P -values that are greater than or equal to 0.001, and less than or equal to 
0.999, will be p resented to 3 decimal places.  All other p -values which are less than 0.001 will be 
presented as <0.001, while p -values greater than 0.999 will be presented as >0.999.  Confidence 
intervals will be presented to one more decimal place than the raw data.
Age, sex, and race will be reported on all by -patient list ings unless otherwise specified.  Sex will 
be abbreviated as fo llows:  female (F) and male (M).  Race will be abbreviated as fo llows:  
American Indian or Alaska Native (AI), Asian (AS), Black or Africa n American (BL), Native 
Hawaiian or other Pacific Islander (NH), White (WH), and Mult iple (MU).
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 19
LY24398216.1.1. General Considerations for Analyses during Period 2 (Initial 
Open -Label Treatment Period)
6.1.1.1. Initial Open -Label Treatment Period Population
Efficacy, health outcom es, and safet y data collected in Period 2 will be summarized for 
ixekizumab 80 mg Q2W without inferent ial stati stics.
Baseline for Period 2 is defined as the last available value on or before the first inject ion of 
ixekizumab 80 mg Q2W in Period 2 and in m ost cases will be the value recorded at Week 0 
(Visit 2).  F or pati ents who do not take any  injecti ons of  ixekizumab 80 mg Q2W in Period 2, the 
last available value prior to Week 0 (Visit 2) will be their baseline.  The baseline period is 
defined as the st art of screening and ends prior to the first inject ion of ixekizumab 80 mg Q2W at 
Week 0 (Visit 2).  If the date of first injection is missing, the date of Visit 2 will be used.
Period 2 starts at the time of first inject ion of ixekizumab 80 mg Q2W (or aft er the date of 
Visit2, if the date of first inject ion is missing) and ends for the fo llowing study  events:
Prior to the first injection of study  treatm ent in the rando mized double -blind withdrawal 
period (Peri od 3) for patients who meet the randomizat ion criteria,
Week 64 (Visit 19) for patients who do not meet the randomization criteria, or
Visit of early  discontinuat ion of study  treatm ent in the initial open -label treatment.
Kaplan -Meier estimates will be used to estimate the survival curve for time- to variables.
For l ongitudinal  cont inuous and categorical efficacy an d heal th outcom e vari ables, summaries 
will be performed by treatment week through the last observation during the study  period.  The 
last observat ion is defined as the value reported for the last visit prior to the first inject ion of 
rando mized study treatment for patients who randomize or the value reported for Week 64 (Visit 
19) for patients who do not meet randomizat ion criteri aor the l ast observat ion prior to 
discontinuat ion for pati ents who discontinue early .
6.1.2. General Considerations for Analyses during Period 3 
(Randomized Double -Blind Withdrawal Period)
6.1.2.1. Randomized Withdrawal ITT and Randomized Withdrawal Safety 
Populations
Efficacy, health outcomes, and safet y data collected in Period 3 will be summarized and 
treatm ent group com parisons (ixekizumab 80 mg Q2W versus placebo ) will be performed for 
rando mized patients.
Period 3 starts at the first inject ion of study  treatment after randomization (or at randomizat ion if 
missing the first inj ection of study  treatm ent) and ends at the following study  events:
Relapse (no longer meet ing Coates criteria for MDA),
Week 104 (Visit 29) for patients who do not relapse, or
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 20
LY2439821Visit of early  discontinuat ion of study  treatm ent in the rando mized double -blind
withdrawal  period.
For the efficacy and healt h outcome analyses, baseline is defined as the last available value on or 
before the first inject ion of study  treatm ent in Period 2 and in most cases will be the value 
recorded at Week 0 (Visit 2).  If the date of first injecti on is missing, the date of Week 0 (Visit 2) 
will be used.  For the safet y analysis, baseline is defined as the last available value on or before 
the first inject ion of rando mized study treatment in Period 3.  If the date of first inject ionis 
missing, the date of rando mizat ion will be used.
The Kaplan -Meier product limit method will be used to estimate the survival curves for time -to 
variables.  Treatment comparisons will be performed using a log -rank test with treatment, 
geographi c regi on,and cDMARD use (past use, current use) at the time of rando mizat ion in 
Period 3, in the m odel.  Time -to analyses will be calculated in weeks fro m the date of first 
inject ion on the randomized study  treatm ent in Period 3 (see Section 6.11.1 ). 
For l ongitudinal  cont inuous and categorical efficacy and health outcome variables, the analysis 
will be summarized by  randomized treatm ent week through 40 weeks of rando mized treatment.   
For the proportion of patients who relapse, addit ional descript ive summar ieswill be provi ded by  
rando mized treatment week beyo nd 40 -week wi thout inferent ial statistics. 
The primary  analysis of the categorical efficacy  and heal th outcome variables will use a logist ic 
regression wit h treatment, geographic region, and cDMARD use (past use, current use) at the 
time of rando mizat ion in Period 3, in the model.  Secondary analysis o f the categori cal efficacy  
and healt h outcome variable s will  be conducted using the Fisher’s exact test.  In general, m issing 
data will be imputed using the nonresponder imputation ( NRI) m ethod.   For relapse analysis, the 
cumulative relapse will be provided at each randomized treatment week and is defined as a 
relapse on or before therandomized treatm ent week or a study  treatm entdiscont inuat ion.  If a 
patient has missing components for Coates criteria for MDA that resul ts in missing MDA at a 
particular visit, the patient will not be considered as relapse. 
The primary analyses for all cont inuous efficacy and healt h outcome variables, change from 
baseline to endpoint, and percent improvement from baseline analyses, will be made using 
MMRM.  Secondary  analyses will be performed using an analysis o f covari ance ( ANCOVA) 
model.
The MMRM includes treatment group, baseline measure, geographic region, cDMARD use (past 
use, current use), treatment week, baseline measure -by-treatm ent week interacti on term , and 
treatm ent week -by-treatm ent interacti on term  as fixed factor s.  The covariance structure to model 
the within-patient errors will be unstructured.  If the unstructured covariance matrix results in a 
lack of convergence, the heterogeneous Toeplitz covariance structure, followed by  the 
heterogeneous autoregressive cov ariance structure will be used.  The Kenward- Roger m ethod 
will be used to estimate the deno minator degrees of freedo m.  For each treatment comparison 
perform ed, the l east squares (LS) mean for each treatment group, an estimate of the difference 
between tre atments, corresponding 95% CI and p -value will be presented.  The estimate, 95% 
CI, and p -value for the overall difference between treatments over Period 3 will also be presented 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 21
LY2439821for each treatm ent com parison.  Ty pe III tests for the LS means will be used for the stati stical 
comparison.
The ANCOVA model includes treatment as a factor and baseline value, geographic regio n, and 
cDMARD use (past use, current use) as covariates.  Missing data will be imputed using the 
mBOCF.  Ty pe III sum s of squares for the LS means will be used for the statist ical co mpar ison.  
For each treatment comparison performed, the LS mean for each treatment group, an est imate of 
the difference between treatments, corresponding 95% CI and p- value will be presented.  Type 
III sum s of squa res for the LS means will be used for the statist ical com parison.
The Fisher’s exact test will be used for all adverse event (AE), baseline, discont inuat ion, and 
other categorical data.  Adverse event data will be analyzed using exposure -adjusted incidence
rates (per 100 patient y ears).  Summary tables co mparing exposure -adjusted incidence rate (that 
is, person -time- adjusted incidence rates ) over the ent ire time period will be generated where total 
number of patients who experienced the TEAE for each PT wil l be divided by the sum of all 
patients’ time (in 100 years) of exposure during the treatment period.  The entire time on study  
during the treatment period will be used instead of the time up to the first event (for th ose 
patients that have an event) due to implementation and display considerat ions.  These tables will 
include the total  number of pati ents in each treatment group, the total person y ears, the incidence 
rate ([number of patients with the event / total person years]*100), the relat ive risk (all 
ixekizumab in numerator), and p- value.  Both the relat ive risk and p -value will be derived fro m a 
Poisson regressio n model with treatm ent as explanatory  variable.  The p -value will be based on 
the likelihood ratio test.  Statist ical compar isons will be applied at each MedDRA level (that is, 
SOC, and PT).
Continuous vital sign and laboratory  values will be analyzed by  an ANCOVA m odel with 
treatm ent and baseline value as independent variables.  Other con tinuous variables will be 
analyzed by t -tests unless otherwise stated.
6.1.2.2. Relapse Population
For pati ents who randomize and subsequent ly relapse in Period 3, efficacy, healt h outcomes, and 
safet y data collected between relapse and the end of Period 3 will be summarized by the 
rando mized treatment group (ixekizumab 80 mg Q2W or Placebo) without inferent ia
l statistics 
for the rel apse pe riod.  
For the efficacy and healt h outcomes analyses, baseline is defined as the last available value on 
or before the init ial first inject ion of ixekizumab 80 mg Q2W in Period 2 and in most cases will 
be the value recorded at Week 0 (Visit 2).  If the da te of first inject ion is missing, the date of 
Visit 2 will  be used.  For the safet y analysis, baseline is defined as the last available value on or 
before relapse in Period 3.
The rel apse peri od, for the rel apse popul ation,starts at the time of first inje ction of ixekizumab 
80mg Q2W fo llowing rel apse and ends on the date of Week 104 (Visit 29) or the visit of early 
discontinuat ion.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 22
LY2439821A subset of the efficacy  and heal th outcom es (refer to Section 6.11.2 ) will be summarized after 
the re-treatm ent of ixekizumab 80 mg Q2W for: 
the relapse populati on
the relapse populati on who, foll owing relapse, were re -treated wi th ixekizumab 
80mg Q2W after relapse for at least 16 weeks.  
Categorical safet y measures will be summarized wit h incidence rates.  
For l ongitudinal  cont inuous and categorical efficacy an d heal th outcom e vari ables, summaries 
will be performed by treatment week through the last observation during the study  period.  The 
last observat ion is defined as the value reported for Week 104 (Visit 29) or the last observation 
prior to di scontinuati on for pati ents who discontinue early .
6.1.3. General Considerations for Analyses during Per iod 2 and 
Period 3 Combined (Initial Open -Label Treatment and 
Randomized Double -Blind Withdrawal Periods)
6.1.3.1. Ixekizumab 80 mg Q2W -Treated Patients from the Randomized 
Withdrawal ITT Population
For pati ents who are randomized in Period 3, efficacy , heal th outc omes, and safet y data collected 
in Period 2 and Period 3 combined will be summarized for ixekizumab 80 mg Q2W wit hout 
inferential statistics.
For efficacy , heal th outcom es, and safet y analyses, baseline is defined as the last available value 
on or before t he first init ial injection o f ixekizumab in Period 2 and in most cases will be the 
value recorded at Week 0 (Visit 2) .  If the date of first injection is missing, the date of Visit 2 
will be used.
For pati ents who are randomized in Period 3, the combined Period 2 and Period 3 will start after 
the first init ial inject ion of ixekizumab 80 mg Q2W in Period 2 (or after the date of Visit 2, if the 
date of first inject ion is missing) and ends at the follo wing study  events:
Relapse (no longer meet ing Coates criteria for MDA),
Week 104 (Visit 29) for patients who do not relapse, or
Visit of early  discontinuat ion of study  treatm ent in the rando mized double -blind 
withdrawal  period.
That i s, Peri od 2 and Peri od3 combined will end prior to the first inject ion of placebo for 
patients who randomize to placebo in Period 3.
A subset of the efficacy  and heal th outcom es (refer to Section 6.11.2 ) will be summarized.
Categorical safet y measures will be summarized wit h incidence rates.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 23
LY2439821For l ongitudinal  cont inuous and categorical efficacy an d heal th outcom e vari ables, summaries 
will be performed by treatment week through the last observation during the study  period.  The 
last observat ion is defined as fo llows:
the value reported for the last visit prior to the first injection o f placebo for pati ents who 
rando mize to placebo in Period 3, 
the value reported for the relapse visit for patients rando mized to ixekizumab 80 mg 
Q2W and who relapse,  
the value reported at Week 10 4(Visit 29) for pati ents randomized to ixekizumab 80 mg 
Q2W and who do not relapse , or
the last observat ion prior to discont inuation for patients who discont inue early and for 
patients who do not relapse .
6.1.3.2. Nonrandomized Population
For pati ents who are not randomized in Period 3, efficacy , heal th outcomes, and safet y data 
collected in Period 2 and Period 3 combined will be summariz ed for ixekizumab 80 mg Q2W 
without inferent ial statistics.
For efficacy , heal th outcom es, and safet y analyses, baseline is defined as the last available value 
on or before the first injection of ixekizumab 80 mg Q2W in Period 2 and in most cases will be 
the value recorded at Week 0 (Visit 2) .  If the date of first inject ion is missing, the date of Visit 2 
will be used.
Period 2 and Peri od 3 combined, for the nonrandomized pat ients, starts at the first inject ion of 
ixekizumab 80 mg Q2W in Period 2 (or after the date of Vi sit 2, if  the date of first inject ion is 
missing) and ends at the fo llowing study  events :Week 104 (Visit 29) or Visit of early 
discontinuat ion of study  treatm ent in the Initial Open -Label  Treatment period or randomized 
doubl e-blind withdrawal  period.
A subset of the efficacy  and heal th outcom es (refer to Section 6.11.2 ) will be summarized.
Categorical safet y measures will be summarized wit h incidence rates.
For l ongitudinal  cont inuous and categorical efficacy an d heal th outcom e vari ables, summaries 
will be performed by treatment week through the last observation during the study  period.  The 
last observat ion is defined as the value reported for Week 104 (Visit 29) or the last observation 
prior to di scontinuati on for pati ents who discontinue early .
6.1.4. General Considerations for Analyses during Period 4 (Post -
Treatment Follow -up Period)
Safety data collected in Period 4 will be sum marized by  treatm ent group wi thout inferent ial 
statist ics.  Patients will be analyzed according to th e treatment they  were taking before entering 
Period 4.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 24
LY2439821Baseline is defined as the last available value on or before entering Period 4.  Period 4 starts at 
Visit801 and ends at the last visit prior to study  discontinuation.
Categorical safet y measures will be summarized wit h incidence rates.
6.2. Adjustments for Covariates
The rando mizat ion at the beginning of the Period 3 (randomized double -blind withdrawal period) 
is stratified by geographic region and cDMARD use (past use, current use) at the time of 
rando mizat ion in Period 3.  Unless otherwise specified, all categorical efficacy and healt h 
outcom e analyses during Period 3 on the randomized withdrawal inten t-to-treat (ITT) populat ion 
will include geographic region in the analysis model.  Unless otherwise specified, all cont inuous 
efficacy  and healt h outcom e analyses during Period 3 on the randomized withdrawal ITT 
popul ation will include geographic regio n and cDMARD use (past use, current use) at the time 
of rando mizat ion in Period 3, in the analysis model.
In general for Period 3, when an MMRM is to be used for analyses, baseline value, and baseline -
by-treatment week interacti ons will be included as covariat es; when an ANCOVA is to be used 
for analyses, baseline value will be included as a covariate.
6.3. Handling of Dropouts or Missing Data
6.3.1. Nonresponder Imputation (NRI) for Clinical Response 
For secondary  analyses assessed during Period 3, p atients will  be consi dered a nonresponder for 
the NRI analysis if they do not meet the clinical response criteria or have missing clinical 
response data at any  specified analysis t ime point.  All nonresponders at any specified time point 
as well as all pat ients who di scont inue study  treatment before the specified analysis time point, 
for any  reason, will  be defined as a nonresponder for the NRI analysis.  Patients without at least 
1 observat ion on study  treatm ent will  also be defined as a nonresponder for t he NRI analysis.   
The NRI analyses will be performed on categorical efficacy and healt h outcome variables.
6.3.2. Modified Baseline Observation Carried Forward (mBOCF)
A mBOCF analysis forPeriod 3 through 40 weeks of randomized treatment will be performed on 
allcontinuous efficacy and healt h outcome variables.  In this approach the baseline observat ion 
will be carried forward to the corresponding endpoint for evaluation for patients who discontinue 
study  treatm ent due to an AE or death.  The last non -missing obs ervat ion before discont inuat ion 
of study  treatm ent will be carried forward to the corresponding primary  endpoint for evaluat ion 
for pati ents who discont inue study  treatm ent for any  reason other than due to an AE.  Patients 
without at l east 1 post-baseline observat ion will not be included for evaluat ion with the except ion 
of patients who di scont inue study  treatm ent due to an AE.
Period 2, combined periods 2 and 3, and Relapse Period summaries will also include a mBOCF 
summary. Summaries will be performed on all cont inuous efficacy and healt h outcom e 
variables.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 25
LY24398216.4. Multicenter Studies
This study  will be conducted by  multiple invest igators at mult iple sites internat ionally.  The 
countri es will  be categori zed into geographic regions, as described in Table RHBF. 6.1, f or 
analysis.
Table RHBF. 6
.1. Geographic Regions
Geographic Region Country
Africa South Af rica
Central America Mexico
North America United States
Eastern Europe Bulgaria, Czech Republic, Estonia,  Poland,  Russia, Slovak Republic, and Ukraine
Western Europe Spain and United Kingdom
Unless otherwise specified, the statist ical analysis models w ill adjust for geographic region at the 
time of rando mizat ion.
For analysis of the primary  endpoint, the presence of a treatment -by-region interacti on will be 
tested at 10% significance level for the rando mized withdrawal ITT populat ion.  Where there is 
evidence of an interact ion (p<.10), descriptive statistics will be used to assess whether the 
interact ion is quant itative (that is, the treatment effect is consistent in direct ion but not the size of 
effect is not consistent) or qualitat ive (the treatment is beneficial for some but not other regions).
6.5. Multiple Comparisons/Multiplicity
There will be no adjust ment for multiple com parisons in this study .
6.6. Use of an “Efficacy Subset” of Patients
The per protocol set (PPS) is defined below in Sectio n 6.6.1 and is an Efficacy Subset of 
patients.  Analysis details for the PPS can be found in Sect ion 6.11. 1.
6.6.1. Analysis Populations
Unless otherwise specified, efficacy, healt h outcomes, and safet y summaries for Period 2 (init ial 
open -label treatment period) will be conducted on the initial open -label treatment period 
population , defined as all pat ients who receive at least 1 inject ion of  ixekizumab in Period 2.  
Efficacy and healt h outcomes analyses for Period 3 (randomized double -blind withdrawal 
period) will  be conducted on the randomized withdr awal intent -to-
treat (ITT) population , 
defined as all rando mized patients, even if the patient does not receive the correct treatment or 
otherwi se does not fo llow the protocol .  Pati ents will  be analyzed according to the treatment to 
which they  were assign ed.
The primary  analyses will  be repeated using the PPS.The PPS is defined as patients included in 
the randomized withdrawal ITT population who are compliant with therapy, who do not have 
significant protocol  deviat ions (refer to Secti on 6.17), and whose invest igator’s site did not have 
significant good clinical practice (GCP) issues that occurred during the rando mized, double -blind 
withdrawal  period which woul d requi re reporting to regulatory  agencies .  Com pliance wi th 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 26
LY2439821therapy  is defined to be missing no more than 20% of expected doses and not missing 2 
consecut ive doses (all inject ions at a visit are counted as 1 dose) during the randomized do uble-
blind treatment period.  Patients will be analyzed according to the treatment to which they were 
assigned.
Safety analyses for Period 3 will be conducted on the randomized withdrawal safety 
population , defined as all rando mized patients who receive at least 1 injection o fstudy  treatm ent 
after randomizat ion.  Patients will be analyzed according to the treatment to which they  were 
assigned.
Efficacy and healt h outcomes summaries for Period 2 and Period 3 combined will be conducted 
on the Ixekizumab 80 m g Q2W -Treated Patients:  Nonrandomized Population and 
Randomized Withdrawal ITT Population , defined as all pat ients who were not randomized 
and who receive at least 1 inject ion of ixekizumab and all rando mized pat ients who receive at 
least 1 i nject ion ofstudy treatm ent after randomization, respectively.
Safety summaries for Period 2 and Period 3 combined will be conducted on the Ixekizumab 
80mg Q2W- Treated Patients:  Nonrandomized Population and Randomized Withdrawal 
Safety Population , defined as all pat ients who were not randomized and who receive at least 1 
inject ion of ixekizumab and all rando mized pat ients who receive at least 1 injection o fstudy  
treatm ent after randomizat ion, respect ively.  Efficacy, health outcomes, and safety summaries 
will be cond ucted on the relapse population , defined as all rando mized pat ients who relapsed 
(no longer m et Coates cri teria for MDA) after randomizat ion and who receive at least 1 inject ion 
of ixekizumab after relapse.
Safety analyses for Period 4 (post -treatm ent follow-up period) will be conducted on the follow -
up period population , defined as all pat ients who receive at least 1 inject ion of study  treatm ent 
at any  time during Period 2 and Period 3 and have entered the post -treatm ent follow-up peri od.  
Patients will  beanalyzed according to the treatment they  were taking before entering Period 4.
6.7. Patient Disposition
Patient fl ow will be summarized from entered to randomized to complet ion.
Analysis populations will be listed and summarized by  treatm ent group for all ente red patients.
Patient disposi tion from study  and study  treatm ent will  be listed for all entered patients.
Patient disposi tion from study  treatm ent will be summarized with reasons for disposit ion for:
Period 2 (init ial open -label treatm ent peri od populati on),
Period 3 (randomized wit hdrawal ITT populat ion), 
Relapse period (relapse populat ion), and
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m the 
rando mized withdrawal ITT populat ion, and nonrando mized population).
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 27 
LY2439821 Patient disposition for Period 3 will be compared  between treatment groups using the Fisher’s 
exact test for the randomized  withdrawal ITT population. 
Patient disposition from study treatment by vis it will be summarized with reasons for:  
 Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W-treated patients from the 
randomized withdrawal ITT populat ion, and nonrandomized population). 
Patient disposition from study by visit will be summarized with reasons for disposition for: 
 Period 4 (post-treatment follow-up period population). 
Time-to study treatment discontinuation due to an AE (in weeks) will be summarized by 
treatment group and graphically presented using Kaplan-Meier technique.  The log-rank test will 
be used to compare time-to study treatment discontinuation between treatment groups for 
randomized withdrawal ITT population. 
Time-to study treatment disconti nuation will be calculated as: 
݊݋݅ݐܽݑ݊݅ݐ݊݋ܿݏ݅݀	ݐ݊݁݉ݐܽ݁ݎݐ	ݕ݀ݑݐݏ	݂݋	݁ݐܽܦ െ݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ ൅1
7 
The date of first injection varies across the period a nd the analysis populations.  Table RHBF.6.2  
defines the date of first injection for each period and analysis population. 
Table RHBF.6.2. Date of First Injection by Period and Analysis Population 
Period Analysis Population Date of First Injection 
Period 2 initial open-label treatment population date of the first injection of ixekizumab 
80 mg Q2W in Period 2 
Period 3 randomized withdrawal ITT population date of the first injection of study 
treatment after randomization in Period 3 
Relapse Period relapse population date of the first injection of ixekizumab 
80 mg Q2W after relapse 
Combined Periods 2 and 3 ixekizum ab 80 mg Q2W-treated patients 
from the randomized withdrawal IIT 
population date of the first injection of ixekizumab 80 mg Q2W in Period 2 
Combined Periods 2 and 3 nonrandomized population date of the first injection of ixekizumab 
80 mg Q2W in Period 2 
Abbreviations:  ITT = intent-to-treat; Q2W = every 2 weeks. 
 
Patient allocation by region, countr y, and center/site will be summarized with number of patients 
who entered the study, number of patients who en tered the initial open-label treatment period, 
number of patients discontinued from study treatment, and number of patients discontinued from 
study. 
6.8. Patient Characteristics 
Patient characteristics will be listed for all entered patients and summarized for the following 
populations: 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 28 
LY2439821  initial open-label trea tment period population 
 randomized withdrawal ITT population 
 relapse population 
 nonrandomized population 
The continuous variables will be summarized using descriptive statistics and the categorical 
variables will be summarized using fr equency counts and percentages.   
For the randomized withdrawal ITT population, comparisons between treatment groups will be 
conducted using an analysis of variance (ANOVA)  model with treatment group as a factor for 
continuous data, and using the Fishe r’s exact test for categorical da ta.  (For categorical variables 
that have more than 2 categories, Monte Carlo estimates of exact p-values will be used.) 
The following patient characteristics will be summarized: 
 Age (in years):  calculated using an imputed date of birth of July  1 in the year of 
birth collected in the electronic case re port form (eCRF).  Age will be calculated 
as:   
 Age = floor((intck(‘month’, brthdt c, rfstdtc) - (day(rfstdtc) <  
 day(brthdtc)))/12)  where brthdtc = Imputed date of birth,  and rfstdtc = patient reference start  
 date (that is, the date when patient is first exposed to study treatment) 
 Age group:  <65 years, ≥65 years to <75 years, ≥ 75 years 
 Age group:  <40 years, ≥40 years  
 Gender 
 Age groups within gender 
 Race:  AI, AS, BL, NH, WH, MU 
 Ethnicity:  Hispanic or Latino, Not Hispanic or Latino, Not Applicable 
 Country:  South Africa, Mexico, Bulg aria, Czech Republic, Estonia, Poland, 
Russia, Slovak Republic, Ukraine, Un ited States (US), Spain, and United 
Kingdom (UK) 
 Geographic region:  Europe, US, Rest of the World 
 Geographic region:   
o Africa (South Africa) 
o Central America (Mexico) 
o North America (US) 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 29 
LY2439821 o Eastern Europe (Bulgaria, Czech Repub lic, Estonia, Poland, Russia, Slovak 
Republic, and Ukraine) 
o Western Europe (Spain and UK) 
 Geographic region at the time of randomi zation for the randomized withdrawal 
ITT population: 
o Africa (South Africa) 
o Central America (Mexico) 
o North America (US) 
o Eastern Europe (Bulgaria, Czech Repub lic, Estonia, Poland, Russia, Slovak 
Republic, and Ukraine) 
o Western Europe (Spain and UK) 
 Height (cm):   last non-missing result before first study treatment injection 
 Weight (kg):   last non-missing result before first study treatment injection 
 Weight category:  <100 kg, ≥100 kg 
 Weight category:  <80 kg, ≥80 kg and <100 kg, ≥100 kg 
 Body mass index (BMI) (kg/m 2):  BMI will be calculated as: 
	ܫܯܤሺ݉	/	݃݇ଶሻൌ	ݐ݄ܹ݃݅݁ሺ݃݇ሻ
ሺ	ݐ݄݃݅݁ܪ ሺ݉ሻሻଶ 
 BMI category:  underweight (<18.5 kg/m 2); normal (≥ 18.5 and <25 kg/m 2); 
overweight ( ≥25 and <30 kg/m 2); obese ( ≥30 and 40 kg/m 2); extreme obese 
(≥40 kg/m 2) 
 Waist circumference (cm) 
 Alcohol use:  never, current, former 
 Caffeine use:  never, current, former 
 Tobacco use:  never, current, former 
 Number of pipefuls, cigarettes, cigars, and smokeless (pinches) tobacco consumed 
per day 
 Time since PsA onset (years) – calculated as 
(date of informed consent – date of PsA onset + 1) / 365.25 
Patients who have a completely missing date of onset will have a missing value for the 
time since PsA onset, otherwise, “January” and “01” will be imputed for the missing 
month and day respectively in cases where these 2 date components are missing.   
 Time since PsA diagnosis (years) – calculated as 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 30 
LY2439821 (date of informed consent – date of PsA diagnosis + 1) / 365.25  
Patients who have a completely missing date of diagnosis will have a missing value for 
the time since diagnosis, otherwise “January ” and “01” will be imputed for the missing 
month and day respectively in cases where for these 2 date components are missing. 
 Time since plaque psoriasis (Ps)  onset (years) – calculated as 
(date of informed consent – date of Ps onset + 1) / 365.25 
Patients who have a completely missing date of onset will have a missing value for the time since Ps onset, otherwise, “January” a nd “01” will be imputed for the missing month 
and day respectively in cases where these 2 date components are missing. 
 Time since Ps diagnosis (years) – calculated as 
(date of informed consent – date of Ps diagnosis + 1) / 365.25 
Patients who have a completely missing date of diagnosis will have a missing value for the time since diagnosis, otherwise “January ” and “01” will be imputed for the missing 
month and day respectively in cases where for these two date components are missing. 
 Previous cDMARD use (none, past use, current use) for: 
o methotrexate (MTX)  
o sulfasalazine (SSZ)  
o leflunomide (LEF)  
o hydroxychloroquine (HCQ)  
o cyclosporine (CSA)  
o apremilast 
 Previous cDMARD use (past use, current use) 
 Previous cDMARD use at the time of randomization for the randomized 
withdrawal ITT and safety populations: 
o Previous cDMARD use (yes, no) for: 
 methotrexate  
 sulfasalazine  
 leflunomide  
 hydroxychloroquine  
 cyclosporine  
 apremilast  
o Previous cDMARD use; yes or no 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 31
LY2439821Methotrexate dose at baseline (weekly)
Methotrexate dose at the time of randomizat ion for the rando mized withdrawal 
ITT and safet y popul ations
Tender j oint count (TJC) based on 68 jo ints
Swollen jo int count (SJC) based on 66 joints
Physician’s global assessment of disease activit y (mm)
Patient’s gl obal assessment of di sease act ivity (mm)
Patient’s assessment of jo int pain (mm)
Health Assessment Questi onnaire –Disabilit y Index total  score
C
-reactive pro tein(mg/L)
C-reactive protein categories; >6 mg/L or ≤6 mg/L
classificat ion for psori atic arthrit is (CASPAR) total score (see Appendix 1 for 
additional details)
Rheum atoid Factor Posi tive (RF+); yes or no
Anti-cyclic citrullinated pepti de posi tive (Anti -CCP +); y es or no
Disease Act ivity Score m odified to include the 28 diarthrodial joint count, based 
on C -reacti ve protein
Enthesit is (based on 18 point entheseal po int assessment); yes or no
Enthesit is (Spondyloarthrit is Research Consortium of Canada [SPARCC] >0); yes 
or no
Spondyloarthrit is Research Consortium o f Canada for pati ents wi th baseline 
Enthesit is (SPARCC>0)
Enthesit is (Leeds Enthesit is Index [LEI]>0); yes or no
Leeds Enthesit is Index for pati ents wi th baseline enthesit is (LEI >0)
Dactylit is (as reported on the eCRF); yes or no
Dactylit is (Leeds Dact ylitis Index –Basic [LDI -B] >0); y es or no
Leeds Dact ylitis Index –Basic for patients with baseline dact ylitis (LDI -B >0)
Modified CPDAI without the spinal disease assessment (Ankylo sing Spondylit is 
Qualit y of Life Quest ionnaire [AsQoL] and Bath Ankylosing Spondylit is Disease 
Activity Index [ BASDAI])
Psori asis Area and Severit y Index (PASI) total score for patients who have 
baseline plaque psoriasis (PASI >0)
Psori asis Area and Severit y Index total  score for pati ents who have baseline 
psori atic lesio n(s) invo lving BSA ≥3%
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 32
LY2439821Psori asis Area and Severit y Index total score ≥12 for patients who have baseline 
plaque psori asis (PASI >0); yes or no
Psori asis Area and Severit y Index total score ≥12 for patients who have baseline 
psori atic lesio n(s) invo lving BSA ≥3%: y es or no
Static Physician Global Assessment (sPGA) score for patients who have baseline 
plaque psori asis (sPGA >0)
Static Physician Global Assessment ≥3 for patients who have baseline plaque 
psori asis (sPGA >0); y es or no
Moderate to severe psoriasis (defined as PASI ≥12, sPGA ≥3, and BSA ≥10%); 
yes or no
Percentage of BSA for patients who have baseline plaque psor iasis (BSA >0)
Body  surface area ≥3%; yes or no for patients with baseline plaque psoriasis 
(BSA >0)
Body  surface area ≥10%; yes or no for patients with baseline plaque psoriasis 
(BSA >0)
Itch NRS score for patients who have baseline psoriat ic lesion(s) in volving BSA 
≥3%
Fatigue Severit y NRS score
Quick Inventory  of Depressive Symptom atology-self report 16 items total score
Medical Outcomes Study  36-Item Short Form  Heal th Survey  PCS score
Medical Outcomes Study  36-Item Short Form  Heal th Survey  MCS score
Dermatology  Life Qualit y Index total  score for patients who have baseline 
psori atic lesio n(s) invo lving BSA ≥3%
Latent tuberculosis (TB); y es or no.
6.8.1. Previous Therapy for Psoriatic Arthritis
The number and percentage of patients who received previous therapy  for PsA (as recorded on 
the Previous Therapy:  Psoriatic Arthritis eCRF page) will be summarized by treatment group, 
overall and Preferred Term (PT).  The number and percentage of pat ients with each reason for 
discontinuing previous therapy  for PsA will also be presented by  treatm ent group.  
Previous therapy  for PsA will be summarized for the fo llowing populati ons:
initial open -label treatment period populat ion
rando mized withdrawal ITT populat ion
nonrando mized population 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 33
LY2439821Treatment group comparisons for the randomized withdrawal ITT population will be conducted 
using the Fisher’s exact test.  
Listing of previous therapy for PsA will be provided for the init ial open -label treatment period 
popul ation.
6.8.2. Historical Illness and Preexisting Conditions
Historical illnesses and preexist ing condit ions will be classified using the latest versio n of the 
Medical Dict ionary for Regulatory  Activities (MedDRA) dict ionary.  Preexist ing condit ions for 
the Open -label Treatment Period (Period 2) are defined as those condit ions recorded on the Pre-
existing Conditions and AEs or the Historical Events eCRF pages with a start date prior to the 
date of informed consent and no end date (that is, the event is ongoing) or an end date after the 
date of informed consent.  Adverse events occurring prior to the date of first study inject ion will 
also be reported as preexist ing condit ion for the open -label treatment period (Period 2).  
Preexist ing condit ions for subsequent treatment periods are defined as th ose preexist ing 
condi tions and AEs which are ongoing at the treatment period baseline.  If a preexist ing 
condi tion worsens in severit y on or after date of inform ed consent , it will  be considered an AE 
from the date of worsening onwards.  Note that condit ions with a partial or missing start date will 
be assumed to be “not preexist ing” unless there is evidence, through comparison of partial dates, 
to suggest otherwise.  Patients will only  be counted once, regardless of how many  condi tions are 
included under t he same System Organ Class (SOC) and PT.
The number and percentage of patients with historical illnesses and preexist ing condit ions will 
be provided by  treatm ent group, overall and by SOC and PT for each treatment period.  
Preexist ing condit ions will be s ummarized for the fo llowing periods and populat ions:
initial open -label treatment period populat ion;
rando mized withdrawal ITT populat ion
Historical illnesses will be summarized for the fo llowing populations:
initial open -label treatment period populat ion
rando mized withdrawal ITT populat ion
nonrando mized population
Treatment group comparisons for randomized withdrawal ITT Population will be conducted 
using Fisher’s exact test. 
Listing of historical illnesses and preexist ing conditions will be provided for initial open -label 
treatm ent peri odpopulation.
6.9. Treatment Compliance
The rando mizat ion schedule will be listed by  center f or the randomized wit hdrawal ITT 
popul ation.  Study  treatm ent di spensed will be list ed (including the clinical trial [CT] Lot 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 34 
LY2439821 number) for all entered patients.  Study treatment administration and compliance will be listed 
for all entered patients. 
Throughout Period 2 and Period 3, patients wi ll record information in a Study Drug 
Administration Log (captured in the Exposure eCRF page), includi ng the date, time, and 
anatomical location of administration of investigational product,  syringe number, who 
administered the investigational product, and the reason if the inves tigational product was not 
fully administered.   
Treatment compliance (%) for each patient will be calculated as: 
100	ൈ݀݁ݎ݁ݐݏ݅݊݅݉݀ܽ	ݏ݊݋݅ݐ݆ܿ݁݊݅	݂݋	ݎܾ݁݉ݑ݊	݈ܽݐ݋ܶ
ܾ݀݁݅ݎܿݏ݁ݎ݌	ݏ݊݋݅ݐ݆ܿ݁݊݅	݂݋	ݎܾ݁݉ݑ݊	݈ܽݐ݋ܶ 
o Number of injections prescribed (that is, expected) will be calculated as:  
 For Period 2: 
2൅	݀݋݅ݎ݁݌	ݕ݀ݑݐݏ	݄݁ݐ	݊݅	ݏ݇݁݁ݓ	݂݋	ݎܾ݁݉ݑܰ
2 
 For Period 3: 
	݀݋݅ݎ݁݌	ݕ݀ݑݐݏ	݄݁ݐ	݊݅	ݏ݇݁݁ݓ	݂݋	ݎܾ݁݉ݑܰ
2 
Note that the number of injections disp ensed will vary across patients for each 
study period by analysis popul ation, refer to Section 6.1 for the study period 
duration definitions by analysis populations. 
Note there are 2 ixekizumab 80 mg in jections at Week 0 and there is 1 
ixekizumab 80 mg or placebo injection ev ery 2 weeks, thereafter, starting at 
Week 2.   
o For patients who discontinue during Period 2 or Period 3, the number of injections 
prescribed can be derived from the IWRS study drug dispense dataset.   
o The total number of injections administer ed will be derived using the response to 
the question “Was dose administer ed?” on the Exposure eCRF page. 
A patient will be considered overall compliant for Peri od 2 or Period 3 if he/she is missing no 
more than 20% of the expected doses, does not  miss 2 consecutive doses, and does not over-dose 
(that is, take more injections at the same time point than specified in the protocol) within the 
respective study period. Treatment compliance with investigational pr oduct will be summarized for the following 
periods: 
 Period 2 (initial open-label treatment period population) 
 Period 3 (randomized withdr awal safety population) 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 35
LY2439821Treatment group comparisons will be conducted for Period 3 for the rando mized withdrawal 
safet y popul ation using the Fisher’s exact test.
6.10. Concomitant Therapy
Previous therapy  is defined as therapy  that starts and ends before the first day  of stud y treatm ent 
in Period 2.
Concomitant therapy  for each treatm ent peri od (Peri od 2, Peri od 3, and Period 2 and Period 3 
combined) is defined as the therapy  that starts before, on, or after the first day  of study  treatm ent 
in the treatment period and before t he last visit date in the treatment period, and has either no end 
date (the therapy  is ongoing) or an end date on or after the first day  of study  treatm ent in the 
treatm ent peri od.  Noti ce, concomitant therapy  will belong to a peri od if the therapy  starts and 
ends on the exact same day  as the first day  of study  treatm ent in the study  period.
Concomitant therapy  for the post -treatment fo llow-up period (Period 4) is defined as the therapy  
that starts before, on, or after the last visit date of Period 3 or ETV and continues into Period 4, 
that is, either no end date (the therapy  is ongoing) or an end date after the last visit date of 
Period3 or ETV.
The fo llowing summaries will be provided:
Previous therapy  by World Heal th Organizati on (WHO) Anatomical Therape utic 
Chemical ( ATC) Level 4 and WHO PT
oInitial Open -Label  Treatment Peri od Popul ation
Concomitant therapy  by WHO ATC Level 4 and WHO PT for:
oPeriod 2 (init ial open -label treatm ent peri od populati on)
oPeriod 3 (randomized wit hdrawal safety  popul ation)
oRelapse Period (relapse population)
oCombined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents 
from the rando mized wit hdrawal safety  popul ation, and nonrando mized 
popul ation).
Com parisons between treatment groups will be conducted for Period 3 f or the 
rando mized withdrawal safet y popul ation using the Fisher’s exact test. 
A by-patient listing of all prior and conco mitant medicat ions will be provi ded for the 
initial open -label treatment period populat ion. 
If a partial or completely missing medicat ion start date/time or end date/time is present, the 
following imputati on rul es will be utilized in the analysis: 
For the start date: 
oIf year, m onth, and day  are missing, then use the consent date.
oIf eit her m onth or month and day  are missing, then use January 1.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 36
LY2439821oIf only  day is missing, impute the first day  of the m onth.
For the start time:
oImpute as 23:59.
For the end date: 
oIf year, m onth, and day  are missing, then use the patient’s last visit date.
oIf eit her m onth or month and day  are missing, then use December 31.
oIf only  day is missing, then use the last day  of the m onth.
oThe imputed date will not be beyo nd the patient’s last visit date.
For the end time:
oImpute as 23:59.
If there is any doubt, the medication will be flagged as concomitant.
6.11. Efficacy Analyses
Table RHBF. 6.3includes the descript ion and derivation of the primary  and secondary  efficacy  
outcom es.
Table
RHBF. 6.4provides the detailed analyses including analysis t ype, method and imputation, 
popul ation, time point, and comparisons for p
rimary an d secondary  efficacy analyses.
I1F-MC-RHBF Statistical Analysis Plan Version 3  Page 37 
LY2439821 Table RHBF.6.3. Description and Derivation of Primary and Secondary Efficacy Outcomes 
Measure Description Variable Derivation / Comment Imputation 
Approach if 
with Missing 
Components 
Coates Criteria for 
Minimal Disease 
Activity (MDA) Uses a composite of 7 key outcome measures 
(includes PASI) used in PsA to encompass all of 
the domains of the disease to measure the overall 
state of a patients’ disease (Coates et al. 2010; Coates and Helliwell 2010). MDA Flag Patients are classi fied as achieving MDA if 
they fulfill 5 of 7 outcome measures: 
1. TJC ≤1 
2. SJC ≤1 
3. PASI total score ≤ 1 or BSA ≤ 3 
4. patient pain VAS score of ≤15 
5. patient global VAS score of ≤20 
6. HAQ-DI score ≤0.5 
7. tender entheseal points (of 18 entheseal points) ≤1 
See Appendix 2  for complete details. If the patient achieves MDA 
with the non-
missing measures, then impute as achieving MDA; otherwise, the 
result is missing. 
Modified Coates 
Criteria for Minimal Disease Activity (MDA) Uses a composite of 7 key outcome measures (includes sPGA) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients’ disease (Mease et al. 2013). MDA-sPGA Flag Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 
1. TJC ≤1 
2. SJC ≤1 
3. sPGA (0,1) or BSA ≤3 
4. patient pain VAS score of ≤15 
5. patient global VAS score of ≤20 
6. HAQ-DI score ≤0.5 
7. tender entheseal points (of 18 entheseal points) ≤1 
See Appendix 2  for complete details. If the patient achieves MDA with the non-missing measures, then 
impute as 
achieving MDA; otherwise, the result is missing. 
Tender Joint Count (TJC) The number of tender and painful joints will be determined by examination of 68 joints (34 joints 
on each side of the patient’s body).  The 68 joints 
to be assessed and classified as tender or not tender.  TJC total score Adjusted sum of the pain/tenderness for all 68 
joints: 
 
൬	ݏݐ݊݅݋݆	ݎ݁݀݊݁ݐ	݈ܽݑ݀݅ݒ݅݀݊݅	݈ܾ݁ܽݑ݈ܽݒ݁	݄݁ݐ	݂݋	݉ݑݏ
ݏݐ݊݅݋݆	݈ܾ݁ܽݑ݈ܽݒ݁	݂݋	ݎܾ݁݉ݑ݊൰	ܺ68  
 See Appendix 3  for complete details. If more than half 
of the joints are 
nonevaluable, the 
total score will be missing. 
I1F-MC-RHBF Statistical Analysis Plan Version 3  Page 38 
LY2439821 Measure Description Variable Derivation / Comment Imputation 
Approach if 
with Missing 
Components 
Swollen Joint 
Count (SJC) The number of swollen joints will be determined by examination of 66 joints (33 joints on each side of the patient’s body).  The 66 joints to be 
assessed and classified as swollen or not swollen. SJC total score Adjusted sum of the pain/tenderness for all 66 
joints. 
 
൬	ݏݐ݊݅݋݆	݈݈݊݁݋ݓݏ	݈ܽݑ݀݅ݒ݅݀݊݅	݈ܾ݁ܽݑ݈ܽݒ݁	݄݁ݐ	݂݋	݉ݑݏ
ݏݐ݊݅݋݆	݈ܾ݁ܽݑ݈ܽݒ݁	݂݋	ݎܾ݁݉ݑ݊൰	ܺ66
 See Appendix 3 for complete details. If more than half of the joint s are nonevaluable, the 
total score will 
be missing. 
Patient’s Assessment of Pain 
Visual Analog 
Scale (VAS) Assesses the patient’s current level of joint pain 
by marking a vertical tick on a 100-mm 
horizontal VAS.
 Patient Pain 
VAS Range: 0 to 100 mm Single item, missing if 
missing 
Patient’s Global 
Assessment of Disease Activity Visual Analog Scale (VAS) Assesses the patient’s overall assessment of his or her PsA activity by marking a 100-mm horizontal VAS. Patient Global VAS Range: 0 to 100 mm 0 represents no disease activity 100 represents extremely active disease activity Single item, missing if missing 
Patient’s Assessment of Physical Function 
Health Assessment 
Questionnaire–Disability Index (HAQ-DI) Patient-reported standardized questionnaire that is commonly used in PsA total measure disease-associated disability (assessment of physical 
function).  It consists of 24 questions referring to 
8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily activities HAQ-DI score Sum of the highes t sub-category scores within 
8 categories and adjusted for aids/devices and/or help from another person. 
See Appendix 4  for complete details. The patient must 
have a score for at least 6 of the 8 
categories. If 
there are <6 categories completed, a HAQ-DI will be missing 
American College of Rheumatology 
Responder Index 
(ACR) ACR Responder Index:  a composite of clinical, laboratory, and functional measures in PsA to 
assess relief of signs and symptoms; responses 
are presented as the minimal numeric disease assessment criteria.  ACR20 Flag  
ACR50 Flag 
 ACR70 Flag See Appendix 5  for details. 
 See Appendix 5  
for details. 
 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 39
LY2439821Measure Descriptio n Variable Derivation / CommentImputation 
Approach if 
with Missing 
Components
C-Reactive Protein
(CRP)The ACR Core Set measure of acute
phase rea ctant. It will be measured
with a high sensitivity assay at the
central laboratory to help assess the
effect of ixekizumab on the patient’s
PsACRP (mg/L)
Change 
from 
baseline in 
CRP (mg/L)
% 
improvemen
t in CRP 
(mg/L)Raw laboratory result, no derivation will be 
applied with the exception of converting the 
units to mg/L when the results are reported in 
units other than mg/LSingle lab 
measure, missing
if missing
Static Physician 
Global Assessment 
(sPGA)For patients with plaque psoriasis, the physician’s 
global assessment of the patient’s psoriasis (Ps) 
lesions at a given time point (European 
Medicines Agency [EMA] 2004 [WWW]).  
Plaques are assessed for induration, erythema, 
and scaling, and an overall rating of psoriasis 
severity  is given.sPGA score Rang e from 0 to 5: clear (0), minimal (1), mild 
(2), moderate (3), severe (4), or very severe (5).Single item, 
missing if 
missing
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 40
LY2439821Measure Descriptio n Variable Derivation / CommentImputation 
Approach if 
with Missing 
Components
Psoriasis Area and 
Severity  Index 
(PASI)For patients with plaque psoriasis, combines 
assessments of the extent of body -surface 
involvement in 4 anatomical regions (head and 
neck, trunk, arms, and legs) and the severity of 
scaling (S), redness (R), and plaque 
induratio n/infiltration thickness (T) in each 
regio n, yielding an overall score of 0 for no 
psoriasis to 72 for the most sev ere disease 
(Fredriksson and Pettersson 1978).  Severity is 
rated for each index (R, S, T) on a 0 -4 scale (0 for 
no involvement up to 4 for severe involvement):
0 = none
1 = slight
2 = moderate
3 = severe
4 = very severe
The body is divided into 4 anatomical regions 
comprising the head (h), upper limb (u), trunk (t), 
and lower limb (l).  In each of these areas, the 
fraction of total BSA affected is graded on a 0 -6 
scale (0 for no involvement; up to 6 for 90% -
100% involve ment): 
0 = 0% (clear)
1 = >0% to <10%
2 = 10% to <30%
3 = 30% to <50%
4 = 50% to <70%
5 = 70% to <90%
6 = 90% to 100%
The various body regions are weighted to reflect 
their respective proportion of BSA.PASI total 
scoreThe composite PASI score is calcula ted by 
multiplying the sum of the individual -severity 
scores for each area by the weighted area -of-
involvement score for that respective area, and 
then summing the 4 resulting quantities as 
follows: 
PASI = 0.1(R h+ Th+ Sh)Ah+ 0.2(R u+ Tu+ 
Su)Au+ 0.3(R t+ Tt+ St)At+ 0.4(R l+ Tl+ 
Sl)Al
Where,
Rh, Ru, Rt, Rl= redness score of plaques 
on the head, upper limb, trunk, and lower 
limb, scored 0-4 respectively;
Th, Tu, Tt, Tl= thickness score of plaques 
on the head, upper limb, trunk, and lower 
limb, score d 0-4 respectively;
Sh, Su, St, Sl= scaliness score of plaques 
on the head, upper limb, trunk, and lower 
limb, scored 0-4 respectively; 
Ah, Au, At, Al= numerical value 
translation of % area of psoriatic 
involvement score for the head, upper limb, 
trunk, and lower limb, respectively.
PASI scores are treated as a continuous score, 
with 0.1 increments within these values. If any individual 
score is missi ng, 
the PASI score 
will not be 
calculated, hence 
missing.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 41
LY2439821Measure Descriptio n Variable Derivation / CommentImputation 
Approach if 
with Missing 
Components
Percentage of Body 
Surface Area 
(BSA)The investigator will evaluate the percentage 
involvement of psoriasis on each patient’s BSA 
on a continuous scale from 0% (no involvement) 
to 100% (full invo lvement), in which 1% 
corresponds to the size of the patient’s hand 
(including the palm, fingers, and thumb) 
(Natio nal Psoriasis Foundation [NPF] 2009).BSA Collected as a single scale.  Range from 0% to 
100%.Single item, 
missing if 
missing
Abbreviations:  ACR20/50/70 = 20%, 50%, or 70% improvement in American College of Rheumatology criteria; PsA = psoriatic arth ritis; PGA = static 
physician global assessment.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 42
LY2439821Table RHBF. 6.4. Description of Pr imary and Secondary Efficacy A nalyses
Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1)Comparison/Time 
Point Analysis Type
Coates Criteria 
for Minimal 
Disease 
Activity  
(MDA)Time-to achieve 
Coates criteria for 
MDADescriptive Statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Initial open -label treatment 
period populationAssessed Period 2 Secondary analysis: 
1. Time-to achieve 
Coates criteria for 
MDA
2. Time-to achieve 
Coates criteria for 
MDA for 3 
consecutive months 
over 4 consecutive 
visits
Relapse populatio n Assessed during  
Relapse PeriodSecondary analysis: 
Time-to achieve Coates 
criteria for MDA
Relapse population who have 
completed 16 weeks on 
relapse treatmentAssessed during  
Relapse PeriodSecondary analysis: 
Time-to achieve Coates 
criteria for MDA for 3 
consecutive months over 
4consecutive visits
Proportio n of patients 
achieving MDADescriptive Statistics Initial open -label treatment 
period populationAssessed Period 2 Secondary analysis
Relapse population Assessed during  
Relapse PeriodSecondary analysis
Relapse population who have 
completed 16 weeks on 
relapse treatmentAssessed during  
Relapse PeriodSecondary analysis
Time-to relapse (no 
longer meeting Coates 
criteria for MDA)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n and PPSAssessed during Period 3 Primary  analy sis 
comparing IXE80Q2W 
vs. placebo (see Section 
6.11.1)
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 43
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1)Comparison/Time 
Point Analysis Type
Proportio n of relapse 
patientsLogistic regression analysis 
andFisher’s exact test with 
cumulative rate
Descriptive statisticsRandomized withdrawal ITT 
populatio nAssessed during Period 3 
(by Treatment Week)
through 40 weeks of 
randomized treatment , 
then descriptive beyond 
40 weeksSecondary analysis 
assessed during Period 3 
Modified 
Coates Criteria 
for Minimal 
Disease 
ActivityTime-to achieve 
modified Coates 
criteria for MDADescriptive statistics for 
IXE80Q2WInitial open -label treatment
period populationAssessed during Period 2 Sensitivity analysis: 
1. Time-to achieve 
Coates criteria for 
MDA
2. Time-to achieve 
Coates criteria for 
MDA for 3 
consecutive months 
over 4 consecutive 
visits
Time-to relapse of 
modified Coates 
criteria for MDALog-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio nwho met modified 
Coates Criteria for MDA at 
time of randomizationAssessed during Period 3 Sensitivity analysis
Proportio n of relapse 
patients of modified 
Coates criteria for 
MDALogistic regression 
(primary ) and Fisher’s exact 
test (secondary) with 
cumulative rate
Descriptive statisticsRandomized withdrawal ITT 
populatio nwho met modified 
Coates Criteria for MDA at 
time of randomizationAssessed during Period 3 
(by Treatment Week)
through 40 weeks of 
randomized treatment , 
then descriptive beyond 
40 weeksSensitivity analysis
Tender Joint 
Count (TJC)Time-to TJC >1 (loss 
of response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who had TJC ≤1 
at time of randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve TJC 
≤1Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who had 
TJC >1 at time of relapseAssessed during Relapse 
PeriodSecondary analysis
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 44
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1)Comparison/Time 
Point Analysis Type
Swollen Joint 
Count (SJC)Time-to SJC >1 (loss 
of response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who had a SJC ≤1 
at time of randomizationAssessed during Period 3 Secondary analysis
Time-to SJC Achieve 
≤1Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who had 
a SJC >1 at time of relapseAssessed during Relapse 
PeriodSeconda ry analy sis
Patient’s 
Assessment of 
Pain Visual 
Analog Scale 
(VAS)Time-to Pain VAS 
score >15 (loss of 
response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who had a Pain 
VAS score ≤15at time of 
randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve Pain 
VAS score ≤15Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who had 
a Pain VAS score >15 at time 
of relapseAssessed during Relapse 
PeriodSecondary analysis
Patient’s 
Global Visual 
Analog Scale 
(VAS)Time-to patient global 
disease activity VAS 
score >20 (loss of 
response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who had a global 
disease a ctivity VAS score 
≤20 at time of randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve 
patient global disease 
activity  VAS score 
≤20Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who had 
a global disease activity scale 
VAS score >20 at time of 
relapseAssessed during Relapse 
PeriodSecondary analysis
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 45
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1)Comparison/Time 
Point Analysis Type
Patient’s 
Assessment of 
Physical 
Function 
Health 
Assessment
Questionnaire –
Disability 
Index (HAQ -
DI)Change f rom baseline 
in HAQ -DI total score
Percent improvement 
in HAQ -DI total scoreDescriptive statistics Initial open -label treatment 
period populationAssessed during Period 2 Secondary analysis
Relapse population Assessed during Relapse 
PeriodSecondary analy sis
Ixekizumab -treated patients: 
nonrandomized population 
and randomized withdrawal 
ITT populationAssessed during Period 2 
and Period 3 combinedSecondary analysis
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 
through 40 Weeks of 
Randomized TreatmentSecondary analysis
HAQ -DI total score 
improvement ≥0.35Descriptive statistics Initial open -label treatment 
period population -  Patients 
with baseline HAQ -DI ≥0.35Assessed during Period 2 Secondary analy sis
Relapse population -  Patients 
with baseline HAQ -DI ≥0.35Assessed during Relapse 
PeriodSecondary analysis
Ixekizumab -treated patients: 
nonrandomized population 
and randomized withdrawal 
ITT population -  Patients 
with baseline HAQ -DI ≥0.35Assessed during Period 2 
and Period 3 combinedSecondary analysis
Logistic regression analysis 
with NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n Assess during Period 3 
through 40 weeks of 
Randomized TreatmentSecondary analy sis
Time-to HAQ -DI 
score >0.5 (loss of 
response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who had a HAQ -
DI score ≤0.5 at time of 
randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve 
HAQ -DI score ≤0.5Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who had 
a HAQ -DI score >0.5 at time 
of relapseAssessed during Relapse 
PeriodSecondary analysis
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 46
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1)Comparison/Time 
Point Analysis Type
American 
College of 
Rheumatology
Responder 
Index (ACR)Time-to achieve 
ACR20
Time-to achieve 
ACR50
Time-to achieve 
ACR70Descriptive Statistics for 
ixekizumab 80 mg Q2W 
(including Kaplan Meier 
estimates of the survival 
curve)Initial open -label treatment 
period populationAssessed durin g Period 2 Secondary analysis
Ixekizumab -treated patients: 
nonrandomized population 
and  randomized withdrawal 
ITT populationAssessed during Period 2 
and Period 3 combinedSecondary analysis
Proportio n of patients 
achieving ACR20
Proportio n of patients 
achieving ACR50
Proportio n of patients 
achieving ACR70Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment 
populatio n Assessed during Period 2 Secondary analysis
Ixekizumab -treated patients 
nonrandomized population  
and randomized withdrawal 
ITT population Assessed during Period 2 
and Period 3 combinedSecondary analysis
Logistic regression analysis 
with NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n Assess during Period 3 
through 40weeks of 
Randomized TreatmentSecondary analysis
C-Reactive 
Protein (CRP)CRP (mg/L)
Change f rom baseline
in CRP (mg/L)
% improvement in 
CRP (mg/L)Descriptive statistics Initial open -label treatment 
period populationAssessed during Period 2 Secondary analysis
Relapse population Assessed during Relapse 
PeriodSecondary analysis
Ixekizumab -treated patients: 
nonrandomized population 
and randomized withdrawal 
ITT populationAssessed during Period 2 
and Period 3 combinedSecondary analysis
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 
through 40 weeks of 
Randomized TreatmentSecondary analysis
Static 
Physician’s 
Global 
Assessment Time-to sPGA ≥2 
(loss of response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who were sPGA 
(0,1) at time of 
randomizationAssessed during Period 3 Secondary analysis
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 47
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1)Comparison/Time 
Point Analysis Type
(sPGA) Time-to Achieve 
sPGA (0,1)Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who were 
sPGA ≥2at time of relapseAssessed during Relapse 
PeriodSecondary analysis
Psoriasis Area 
and Severity 
Index (PASI)Time-to PASI total 
score >1 (loss of 
response)Log-Rank Test.  Kaplan -
Meier product limit met hodRandomized withdrawal ITT 
populatio n who were PASI 
total score ≤1 at time of 
randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve PASI 
total score ≤1Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who were 
PASI total score >1at time of 
relapseAssessed during Relapse 
PeriodSecondary analysis
Percentage of 
Body Surface 
Area (BSA)Time-to -BSA >3% 
(loss of response)Log-Rank Test.  Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who were BSA 
≤3% at time of 
randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve BSA 
≤3%Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who wer e 
BSA >3% at time of relapseAssessed during Relapse 
PeriodSecondary analysis
Tender 
Entheseal 
Points (defined 
using the 18 
entheseal 
points )Time-to tender 
entheseal points >1 
(loss of response)Log-Rank Test. Kaplan -
Meier product limit methodRandomized withdrawal ITT 
populatio n who had a tender 
entheseal points ≤1 at time of 
randomizationAssessed during Period 3 Secondary analysis
Time-to Achieve 
tender entheseal points 
≤1Descriptive statistics 
(including Kaplan Meier 
estimates of the survival 
curve)Relapse population who had 
a tender entheseal points >1 
at time of relapseAssessed during Relapse 
PeriodSecondary analysis
Abbreviations:  ACR20/50/70 = 20%, 50%, or 70% improvement in American College of Rheumatology criteria; ANCOVA = analysis of covariance; ITT = 
intent -to-treat; IXE80Q2W = ixekizumab 80 mg ever y 2 weeks; mBOCF = modified baseline observation carried forwar d; MMRM = mixed -effects model of 
repeated measures; NRI = nonresponder imputation; PPS = per -protocol set; Q2W = ever y 2 weeks.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 48 
LY2439821 6.11.1. Primary Outcome and Methodology 
The primary analysis is the time-to relapse (no longer meeting Coates criteria for MDA) for the 
randomized withdrawal ITT population.  Time-to re lapse will be calculated in weeks as follows: 
ሺ݁ݏ݌݈ܴܽ݁	݂݋	݁ݐܽܦെ	݀݋݅ݎ݁ܲ	݊݅	ݐ݊݁݉ݐܽ݁ݎݐ	ݕ݀ݑݐݏ	݀݁ݖ݅݉݋ܴ݀݊ܽ	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݅ܨ	݂݋	݁ݐܽܦ 3 ሻ൅1
7 
If the date of first injection is missing, the date of randomization will be used.  Patients 
completing Period 3 without relapsing will be censored  at the date of completion (that is, the date 
of the last visit in the period).  Patients without a date of completion or discontinuation for Period 
3 will be censored at the latest non-missing date out of the following dates:  date of last dose and 
date of last attended visit in Period 3.   
Treatment comparison between ixekizumab 80 mg  Q2W and placebo in time-to relapse for the 
randomized withdrawal ITT population and the PPS will be analyzed using a log-rank test with 
treatment, geographic region, and cDMARD use (past use, current use) at the time of 
randomization in Period 3, in the model.  The Kaplan-Meier product limit method will be used to 
estimate the survival curves for time-to relaps e.  Time-to relapse will also be summarized 
graphically by treatment group using Kaplan-Meier techniques. 
6.11.2. Secondary Efficacy Analyses 
There will be no adjustment for multiple comparisons for other secondary analyses.  The 
secondary analyses are detailed in Table RHBF.6.3  and Table RHBF.6.4 . 
6.11.3. Sensitivity Analyses 
Sensitivity analyses will be performed for the primar y analysis using the modified Coates criteria 
for MDA.  For the modified criteria for MDA, sPGA “skin clear” or “skin almost clear” (as MDA-sPGA [0,1]) is substituted for PASI ≤1 (Mease et al. 2013).  The modified Coates criteria 
for MDA is described in Table RHBF.6.3  and the sensitivity analyses are detailed in 
Table RHBF.6.4 . 
6.12. Bioanalytical and Pharmaco kinetic/Pharmacodynamic Methods 
Pharmacokinetic, PD, and biomarker analyses to address secondary and exploratory objectives of 
this study will be described by Lilly in sepa rate PK/PD and biomarker analysis plans. 
6.13. Safety Analyses 
Safety will be assessed by summarizing and an alyzing SAEs, AEs, AESIs, QIDS-SR16, vital 
signs, other measures of cardi ovascular function, laboratory ev aluations (including chemistry, 
calculated creatinine clea rance, hematology [including (WBC) count and differential], urinalysis 
[dipstick and microscopic], thyroid-stimula ting hormone and free T4, and immunogenicity 
testing [TE-ADAs]).   
Primary safety analyses will focus on comparis on of ixekizumab 80 mg Q2W to placebo for the 
randomized withdrawal safety population in Pe riod 3.  Treatment group comparisons will be 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 49 
LY2439821 analyzed using the methods described in Section 6.1.2. the Period 2 (initial open-label treatment 
population), Period 2 and Period 3 combined (ixeki zumab-treated patients within the randomized 
withdrawal safety population and nonrandomized population), and for Relapse Period (relapse 
population), the above safety variables will be summarized as described in Sections 6.1.1, 6.1.2, 
and 6.1.3, respectively. 
Summaries of safety data collected during the Period 4 (post-treatment follow-up period) will be 
presented separately. 
For safety analyses, the follo wing baselines will be used: 
 Treatment-emergent adverse events:  baseline  will be all result s recorded during the 
baseline period (see Section 6.1 for definitions of the baseline period). 
 Treatment-emergent abnormal laboratory and vital signs:  baseline will be all results 
recorded during the base line period (see Section 6.1 for definitions of the baseline 
period). 
 Change from baseline to mini mum and maximum:  baseline will be all results recorded 
during the baseline period (see Section 6.1 for definitions of the baseline period). 
6.13.1. Extent of Exposure 
Duration of exposure to study drug will be su mmarized by treatment group for Period 2, 
Period 3, and the Period 2 and Period 3 co mbined using descriptive statistics. 
A by-patient listing of exposure duration with number of active injections and total dose will be 
provided. 
The duration of exposure for Period 2 (initial open-label treatment pe riod population) will be 
calculated: 
 For randomized patients: 
	݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑܦ ሺݏݕܽ݀ሻ
ൌ ሺ	݊݋݅ݐܽݖ݅݉݋݀݊ܽݎ	݂݋	݁ݐܽܦ
െ	ܾܽ݉ݑݖ݅݇݁ݔ݅	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ80	ܳ	݃݉2	݀݋݅ݎ݁ܲ	݊݅	ܹ2ሻ൅1  
 For nonrandomized patients: 
	݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑܦ ሺݏݕܽ݀ሻ
ൌ ሺ	ݐ݅ݏ݅ݒ	ݐݏ݈ܽ	݂݋	݁ݐܽܦ ሺ݈݀݁ݑ݄݀݁ܿݏ݊ݑ	ݎ݋	݈݀݁ݑ݄݀݁ܿݏ ሻ	ݐ݅ݏܸ݅	݋ݐ	ݎ݋݅ݎ݌	ݎ݋	݊݋19ሻ	
െ	ܾܽ݉ݑݖ݅݇݁ݔ݅	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ80	ܳ	݃݉2	݀݋݅ݎ݁ܲ	݊݅	ܹ2ሻ൅1 
The duration of exposure for Period 3 (randomized  withdrawal safety population) will be 
calculated for the randomized patients as: 
	݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑܦ ሺݏݕܽ݀ሻ
ൌ ሺ	ݐ݅ݏ݅ݒ	ݐݏ݈ܽ	݂݋	݁ݐܽܦ ሺ݈݀݁ݑ݄݀݁ܿݏ݊ݑ	ݎ݋	݈݀݁ݑ݄݀݁ܿݏ ሻ			݀݋݅ݎ݁ܲ	݊݅	݁ݏ݌݈ܽ݁ݎ	ݎ݋3	
െ	݀݋݅ݎ݁ܲ	݊݅	݊݋݅ݐܽݖ݅݉݋݀݊ܽݎ	ݎ݁ݐ݂ܽ	ݐ݊݁݉ݐܽ݁ݎݐ	ݕ݀ݑݐݏ	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ 3ሻ൅1  
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 50 
LY2439821 Note that patients who experience a relapse during Period 3 will only have their Period 3 
exposure calculated up until the date of relapse. 
The duration of exposure for Relapse Period (r elapse population) will  be calculated as: 
	݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑܦ ሺݏݕܽ݀ሻ
ൌ ሺ	ݐ݅ݏ݅ݒ	ݐݏ݈ܽ	݂݋	݁ݐܽܦ ሺ݈݀݁ݑ݄݀݁ܿݏ݊ݑ	ݎ݋	݈݀݁ݑ݄݀݁ܿݏ ሻ		݀݋݅ݎ݁ܲ	݊݅3
െ	ܾܽ݉ݑݖ݅݇݁ݔ݅	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ80	ܳ	݃݉2	݀݋݅ݎ݁ܲ	݊݅	ܹ3	݁ݏ݌݈ܽ݁ݎ	݃݊݅ݓ݋݈݈݋݂ ሻ൅1  
The duration of exposure for Period 2 and Period  3 combined (ixekizumab 80 mg Q2W-treated 
patients from the randomized withdrawal safety population) will be calculated for randomized 
patients as:  
	݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑܦ ሺݏݕܽ݀ሻ
ൌ ሺ	ݐ݅ݏ݅ݒ	ݐݏ݈ܽ	݂݋	݁ݐܽܦ ሺ݈݀݁ݑ݄݀݁ܿݏ݊ݑ	ݎ݋	݈݀݁ݑ݄݀݁ܿݏ ሻ		݀݋݅ݎ݁ܲ	݊݅	݁ݏ݌݈ܽ݁ݎ	ݎ݋3
െ	ܾܽ݉ݑݖ݅݇݁ݔ݅	݈ܽݐ݅݊݅	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ80	ܳ	݃݉2	݀݋݅ݎ݁ܲ	݊݅	ݐ݊݁݉ݐܽ݁ݎݐ	ܹ 2ሻ൅1  
The duration of exposure for Period 2 and Period  3 combined (nonrandomized safety population) 
will be calculated for nonrandomized patients as:  
	݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑܦ ሺݏݕܽ݀ሻ
ൌ ሺ	ݐ݅ݏ݅ݒ	ݐݏ݈ܽ	݂݋	݁ݐܽܦ ሺ݈݀݁ݑ݄݀݁ܿݏ݊ݑ	ݎ݋	݈݀݁ݑ݄݀݁ܿݏ ሻ		ݏ݀݋݅ݎ݁݌	݊݅2		ݎ݋3	
െ	ܾܽ݉ݑݖ݅݇݁ݔ݅	݈ܽݐ݅݊݅	݂݋	݊݋݅ݐ݆ܿ݁݊݅	ݐݏݎ݂݅	݂݋	݁ݐܽܦ80	ܳ	݃݉2	݀݋݅ݎ݁ܲ	݊݅	ݐ݊݁݉ݐܽ݁ݎݐ	ܹ 2ሻ൅1  
The number and percentage of patients in each of the following categories will be included in the 
summaries (as applicable for the treatment period summarized):   
 >0, ≥ 7 days, ≥14 days, ≥ 30 days, ≥ 60 days, ≥ 90 days, ≥ 120 days, ≥ 183 days, and 
≥365 days, ≥548, and ≥ 730.  Note that patients may be included in more than 1 
category. 
 >0 to <7 days, ≥7 to <14 days, ≥14 to <30 days, ≥30 to <60 days, ≥60 days to <90 
days, ≥90 to <120 days, ≥120 to <183 days, ≥ 183 to <365 days, and ≥ 365 days. 
The summaries will also incl ude the following information: 
 Total exposure in patient years, calculated as: 
ൌ	݌ݑ݋ݎ݃	ݐ݊݁݉ݐܽ݁ݎݐ	݄݁ݐ	݊݅	݀݋݅ݎ݁݌	ݕ݀ݑݐݏ	݄݁ݐ	݊݅	ݏݐ݊݁݅ݐܽ݌	݈݈ܽ	ݎ݋݂	ݏ݁ݎݑݏ݋݌ݔ݁	݂݋	݊݋݅ݐܽݎݑ݀	݂݋	݉ݑܵ 
365.25 
 Number of active injections taken; deri ved using the response to the question 
“Was dose administered?” on the Expos ure eCRF page and the actual dose 
description from IWRS study drug dispense dataset. 
 Total dose (in mg); calculated by the numb er of active injections taken multiplied 
by a dose of 80 mg.   
6.13.2. Adverse Events 
Adverse events will be classified based upon th e latest version of Me dical Dictionary for 
Regulatory Activities (MedDRA).  Adverse events  will be recorded at every study visit.  
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 51
LY2439821Condi tion starti ng on or after the date of informed consent will be considered an AE.  A 
preexist ing condit ion that worsens in severit y on or after the date of informed consent will be 
considered and recorded as an AE on the AE eCRF page from the date of worsening onwards .  
A TEAE i s defined as an event that first occurred or worsened in severit y after baseline and on or 
prior to the date of the last visit wit hin the defined treatment period.  Both the date/time of the 
event and the date/time of the dose (that is, inject ion) are consi dered when determining TEAEs.  
Treatment -emergent adverse events will be assigned to the study period to which it’s considered 
treatm ent-emergent.
The MedDRA Lowest Level Term (LLT) will be used when classifying AEs as 
treatm ent-emergent.  
The maximum  severi ty recorded for each LLT prior to the first dose date/time in 
the treatment period will be used as the pretreatment severit y for that LLT.  If an 
event during the baseline period has missing severity , and the event persists 
during the treat ment period, then i t will be considered as treatment -emergent, 
regardl ess of the post -baseline level of severit y.  Events wi th a missing severit y 
during the treatment period will be considered treatment -emergent.  
Adverse events with a particular LLT will be classified as treatment -emergent if 
they first start on or after the first dose date/time in the treatment period (that is, a 
patient has no preexisting condit ions with that LLT), or if the severit y is greater 
than the pretreatment severit y for that LL T.  
A follow-up emergent adverse event (FEAE) is defined as an event that first occurred or 
worsened in severit y after the date of Vi sit 29 (that is, Week 104) or the ETV:
The MedDRA LLT will be used when classifying AEs as fo llow-up emergent.
For AEs tha t are ongoi ng at the date of Visit 29 (Week 104) or ETV, the 
maximum severit y recorded for each LLT on or prior to the date of Visit 29 
(Week 104) or ETV will be used as the fo llow-up baseline severit y for that LLT.
If a partial or completely missing AE st art date/time or end date/time is present the fo llowing 
imputati on rul es will  be utilized in the analysis: 
For the start date: 
oIf year, m onth, and day  are missing, then use the consent date.
oIf eit her m onth or m onth and day  are missing, then use January 1.
oIf only  day is missing, impute the first day  of the m onth.
For the start time:
oImpute as 23:59
For the end date: 
oIf year, m onth, and day  are missing, then use the patient’s last visit date.
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 52
LY2439821oIf eit her m onth or m onth and day  are missing, then use December 31.
oIf only  day is missing, then use the last day  of the m onth.
oThe imputed date will not be beyo nd the patient’s last visit date in the fo llow-
up period.
If there is any doubt, the event will be flagged as treatment -emergent or fo llow-up 
emergent according the corresponding study perio d.  If a fo llow-up em ergent 
event was already counted as treatment -emergent during the prior treatment 
period, it will  not be coun ted as a follow -up emergent event.
Adverse events and TEAEs will be listed for all ent ered patients and summarized for the 
following periods:
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomized wit hdrawal safety  popul ation) 
Relapse Period (relapse population )
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m 
the randomized withdrawal safet y popul ation and nonrando mized population).
Adverse events and TEAEs for Period 3 will be compared between treatment groups using a 
Fisher’s exact test for the rando mized withdrawal safet y popul ation.
The following summaries/analyses will be performed:
An overall summary o f AEs including the number and percentage of patients who 
experienced TEAE, TEAE by  maximum severit y, death, SAE, TEAE rel ated to 
study  drug, discont inuat ions from the treatm ent due to a n AE, and TEAEs of 
special interest.
treatm ent-emergent adve rse event by  System  Organ Class (SOC) and PT
treatm ent-emergent adve rse event by  maximum severit y, SOC, and PT
Follow-up em ergent adverse events will be summarized for the fo llow-up popul ation forthe 
post-treatm ent follow-up peri od (Peri od 4):
Follow-up em ergent adverse event by  SOC and PT
In general, for all AE related summaries, the number and percentage of patients experiencing the 
events will be presented by  treatm ent group.  The events will b e ordered by  decreasing frequency  
in the ixekizumab treatment group, within SOC and/or PT for sorting.  For events that are 
gender -specific (as defined by  MedDRA), the denominator and computation of the percentage 
will include only  patients from the given gender.
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 53
LY24398216.13.3. Deaths, Other Serious Adverse Events, and Other Notable 
Adverse Events
6.13.3.1 .Deaths
A listing of deaths will be provided for all entered patients.  All deaths will be included, 
regardl ess of the Invest igator’s or the Sponsor’s judgment about c ausalit y, including (1) any  
deaths occurring during participat ion in the study , (2) any  deaths occurring after a patient leaves 
(is discont inued fro m the study  or com pletes the study ) any of the studi es in the database for 
which data are being presented if the death i s (a) the resul t of a process init iated during the study , 
regardl ess of when i t actually  occurs, or (b) occurs during the post -treatm ent follow-up peri od 
after di scontinuati on of  study  drug.  The actual rule used for including deaths will be pr ovided in 
a footnote to the table.  Any discrepancies between what is in the Lilly Safety System (LSS) and 
what i s in the clinical study  report (CSR) for individual studies will be explained in the footnote.  
The informat ion from the LSS list ing is used to create a hand -generated list ing.  Each list ing will 
include study  ID, invest igator ID, patient ID, treatment group, baseline age, sex, associated AE, 
whether or not the death and Lilly’s assessment of whether the process leading to death (NOT 
the death it self) began:
“On study  Drug”:  on study  drug or wi thin 14 days after study  drug 
discontinuat ion
“During the post -treatm ent follow-up peri od”:  >14 day s after study  drug 
discontinuat ion through the end of the post- treatm ent fo llow-up peri od
“After the post -treatm ent follow-up period”:  any  time after the end of the post -
treatm ent follow-up peri od.  
6.13.3.2. Serious Adverse Event Analyses
An SAE is any  AE that resul ts in 1 of the fo llowing outcom es:  death, life -threatening, init ial or 
prolonged hospi talizati on, disabilit y or perm anent dam age, congenital ano maly or bi rth defect, or 
any other serious/important medical events that may jeopardize the patient or may require 
intervent ion to prevent 1 of the other outcomes listed in the definit ion above.
Exposure -adjusted incidence rates (per 100 patient years) for SAEs will be presented by  
treatm ent group using MedDRA PT nested within SOC.
Serious adverse events will be listed for all entered patients and summarized for the fo llowing 
periods:
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomized wit hdrawal safety  popul ation)
Relapse Period (relapse population) 
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m 
the randomized withdrawal safet y popul ation and nonrando mized population).
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 54
LY2439821Serious adverse events for Period 3 will be compared between treatment groups using the 
Fisher’s exact test for the rando mized withdrawal safet y popul ation.
A summary  table of SAEs by SOC and PT will be provided.
A follow-up emerge nt serious adverse event (FESAE) is defined as an SAE that first occurred or 
worsened in severit y after the date of Vi sit 29 (that is, Week 104) or the ETV.  The baseline 
severit y for SAEs occurri ng during the post -treatment fo llow-up peri od will be the m aximum 
severit y from the preceding visit before entering the post -treatment follow up period .  A 
summary table of FESAEs by SOC and PT will be provided for the fo llow-up popul ation for 
Period 4. 
The events will be ordered by  decreasing frequency  in the ixe kizumab treatm ent group, wi thin 
SOC and/or PT for sorting.  For events that are gender -specific, the deno minator and 
computati on of  the percentage will include only  patients fro m the given gender.
6.13.3.3. Other Significant Adverse Events
Adverse events that lead t o treatm ent di scontinuation (including death) will be listed for all 
entered pati ents and summarized for the fo llowing peri ods:
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomized wit hdrawal safety  popul ation) 
Relapse Period (re lapse population)
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m 
the randomized withdrawal safet y popul ation and nonrando mized population).
Adverse events that lead to treatment discontinuation (including death) for Period 3 wil l be 
compared between treatment groups using the Fisher’s exact test for the randomized withdrawal 
safet y popul ation.
A summary  table of AEs that l ead to treatm ent discontinuat ion (including death) by SOC and PT 
will be provided:
A summary  table of FEAEs that lead to study  discontinuat ion (including death) by SOC and PT 
will be provided for Period 4: 
Events will be ordered by  decreasing frequency in the combined ixekizumab group within SOC.  
For events that are gender -specific, th e deno minator and computation of the percentage will 
include only  patients from the given gender.  
6.13.4. Depression and Suicide -Related Patient Reported Outcomes
The QIDS -SR16, the C -SSRS, and the Self -Harm  Suppl ement Form  will be administered to 
patients at ba seline and post -baseline to assess depressio n and the risk o f suicide.
The QIDS -SR16 is a self -administered 16 -item instrum ent intended to assess the existence and 
severit y of symptom s of depressio n as listed in the American Psychiatric Associat ion’s (APA’ s) 
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 55
LY2439821Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM -IV)(APA 1994).  
Refer to Table RHBF. 6.11 and Table RHBF. 6.12for further details.
The C -SSRS (Posner et al. 2007; Columbia Universit y Medical  Center [WWW]) is a scale that 
captures the occurrence, severit y, and frequency  of suicide-related i deati ons and behaviors 
during the assessment period.  
The C -SSRS was added after study  enrollment had been init iated.  Given that few or no suicidal 
ideat ion or behaviors are ant icipated, C -SSRS will be listed by pat ient and visit.  Only patients 
that show suicidal ideat ion/behavior or self -injuri ous behavior without suicidal intent will be 
displayed (that is, if a patient answers are all ‘no’ for the C -SSRS, then that patient will not be 
displayed).  However, if a pat ient reported any  suicidal ideat ion/ behavior or self -injuri ous 
behavior without suicidal intent at any  time point then all their ideation and behavior will be 
displayed, even if not posit ive.
The Self -Harm  Supplement Form is a 1 -question form  that is completed, at any  visit, including 
baseline visits, that asks for the number of suicidal or nonsuicidal self -injuri ous behaviors the 
patient has experienced since the last assessment.  For each uni que event i dentified, a 
questionnaire (Self -Harm  Follow-up Form ) which collects supplemental informat ion on the self -
injuri ous behavi or is to be com pleted.  Suppl emental  informat ion collected will be listed by 
patient and visit for only  the pat ients that h ave a number of suici dal or nonsuicidal  self-injuri ous 
behaviors greater than 0 at any  visit.
6.13.5. Clinical Laboratory Evaluation
Clinical laboratory  assessments include hematology , serum  chemistry , urinalysis, and safet y
-
related immune markers such as neutrophil counts.  
By-patient listing of laboratory  test val ues will be provi ded for all entered patients.  List ing of 
laboratory  tests reference ranges (both large clinical trial population based reference limit s and 
Covance reference ranges) will be provided. By-patient list ing of abnormal laboratory  test 
resul ts (cri teria defined in the shift tables excluding the normal category ) for param eters of 
special interest (hepatic, immunoglobulins, leukocytes and platelets) will be provided.
Laboratory  resul ts will b e summarized for (unless otherwise noted) :
Period 2 (init ial open -label treatm ent peri od populati on);
Period 3 (randomized wit hdrawal safety  popul ation); 
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m the 
rando mized withdrawal safety popul ation and nonrando mized populat ion) 
Continuous laboratory  tests will be summarized as changes from baseline for patients who have 
both baseline and at least 1 post- baseline result.
The scheduled visits/measurements will be included.  The unsch eduled visit s and 
the repeat measurements will be excluded.  
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 56
LY2439821Both international system o f unit (SI) and convent ional unit will be summarized 
when different.  
Data will be analyzed based on original scale.
Change from minimum value during the baseline per iod to the minimum value during the 
treatm ent peri od, as well as change fro m the maximum  value during the baseline period to the 
maximum value during the treatment period will be summarized for patients who have both a 
baseline and at least 1 post -baseline resul t.
For the randomized wit hdrawal safet y popul ation for Period 3, the comparisons between 
treatm ent groups will be conducted using an ANCOVA wit h treatment group and baseline value 
in the model.  
The number and percentage of patients with a treatment -emergent or fo llow-up em ergent 
abnorm al, high, or l ow for laboratory  tests will be summarized by  treatm ent group.  These will 
be displayed for (unless otherwise noted): 
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomized wit hdrawal safety  popul ation) 
Relapse Period (relapse population)
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m the 
rando mized withdrawal safet y popul ation and nonrando mized populat ion); and Period 4 
(post -treatment follow -up peri odpopul ation)  
Period 4 (post -treatm ent follow-up peri od popul ation)
The comparisons between treatment groups will be conducted using the Fisher’s exact test for 
the randomized withdrawal safet y popul ation for Peri od 3.  
All scheduled, unscheduled, and r epeated m easurements will be included.
In general, large clinical trial populat ion based reference limit s (that is, Lilly  
reference ranges) will be used to define the low and high limit s since it i s 
generally desirable for limits used for analyses to have greater specificit y (identify  
fewer false posit ive cases) than reference limits used for individual subject 
management.  In the case when the reference limit s based on the large clinical 
trial popul ation is not available for a laboratory measure, Covance reference 
ranges will be used.  Alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), total  bilirubin, and alkaline phosphatase (ALP) will not be included in the 
treatm ent-emergent abnormal, high, or low summary  as a separate analysis 
addressing the risk of liver injury is described in Section 6.13.7 in which Covance 
Reference Ranges are used.  
Note that the ranges are defined by  a lower l imit of normal (LLN) and an upper 
limit of normal (ULN).  A result that is greater than or equal to the LLN and less 
than or equal to the ULN is considered to be within the normal ranges.
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 57
LY2439821For categorical laboratory  tests:  
oTreatment -emergent abnormal value is defined as a change from normal at 
all baseline visits to abnormal at any  time post -baseline during the treatment 
period.
oFollow-up em ergent abnormal resul t is defined as a change from normal at 
baseline to abnormal at any  time during the fo llow-up pe riod.  
For continuous laboratory  tests:  
oTreatment -emergent high value is defined as a change fro m a value less than 
or equal to the ULN at all baseline visits to a value greater than the ULN at 
any time post -baseline during the treatment period.
oTreatme nt-emergent lowvalue is defined as a change fro m a value greater 
than or equal to the LLN at all baseline visits to a value less than the LLN at 
any time post -baseline during the treatment period.
oFollow-up em ergent high value is defined as a change fro m a value less than 
or equal to the ULN at baseline to a value greater than the ULN at any  time 
post-baseline during the follow -up peri od.
oFollow-up em ergent lowvalue is defined as a change fro m a value greater 
than or equal to the LLN at baseline to a valu e less than the LLN at any  time 
post-baseline during the follow -up peri od.
Shift tables will be produced using the fo llowing categori es:
Neutrophils:  ≥1 × LLN (Norm al), < LLN to ≥1.5 × 10^9/L (Grade 1) , <1.5 × 10^9/L to 
≥1.0 × 10^9/L (Grade 2) , <1.0 × 10^ 9/L to ≥0.5 × 10^9/L (Grade 3) , and <0.5 × 10^9/L
(Grade 4)
Leukocy tes:  ≥1 × LLN (Norm al), < LLN to ≥3.0 × 10^9/L (Grade 1) , <3.0 × 10^9/L to 
≥2.0 × 10^9/L (Grade 2) , <2.0 ×10^9/L to ≥1.0 × 10^9/L (Grade 3) , and <1.0 × 10^9/L
(Grade 4)
Platelets:  >1 × LLN (Norm al), < LLN to >75.0 × 10^9/L (Grade 1) , <75.0 × 10^9/L to 
>50.0 × 10^9/L (Grade 2) , <50.0 × 10^9/L to > 25.0 × 10^9/L (Grade 3) , and <25.0 × 
10^9/L (Grade 4)
Lymphocy tes:  ≥1 × LLN (Norm al), < LLN to ≥0.8 × 10^9/L (Grade 1) , <0.8 × 10^9/L to 
≥0.5 × 10^9/L (Grade 2) , <0.5 × 10^9/L to ≥0.2 × 10^9/L (Grade 3) , and <0.2 × 10^9/L
(Grade 4)
The fo llowing LLN will be defined for analyses :
Leukocy tes:  LLN=4.0 ×10^9/L
Neutrophils:  LLN=2.0×10^9/L
Lymphocy tes:  LLN=1.1×10^9/L
Platelets: LLN=150×10^9/ L
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 58
LY2439821In addition, for the above parameters (neutrophils, leukocy tes, pl atelets and lymphocy tes), the 
number and percentage of patients with minimum post -baseline results will be presented overall 
and by  treatm ent group wi thin the fo llowing groups using the categor ies as defined above:
Decreased; post-baseline category < baseline category
Increased; post -baseline category > baseline category
Same; post -baseline category  = baseline category
The number and percentages of pat ients with treatment -emergent l ow laboratory resul ts at any 
time will be summarized for these 4 measures by treatment group for each treatment period.   
Shift tables will be produced showing the number and percentage of patients with a minimum 
post-baseline result for these 4 measures and will be sum marized overall, and by treatment group 
and baseline result.
6.13.5.1. Leukocytes (WBC) and Platelets
Leukocy tes (WBC) and platelets results will be summarized for (unless otherwise noted) :
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomiz ed wi thdrawal  safety  popul ation) 
Relapse period (relapse populat ion)
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m the 
rando mized withdrawal safet y popul ation and nonrando mized populat ion).
Change from minimum value and maximu m value for total  leukocy tes, neutrophils, pl atelets, 
lymphocy tes, m onocy tes, eosinophils, and basophils will be included in summaries described in 
Secti on 6.13.5 . Unless otherwise specified, neutrophils will be summarized for abso lute 
neutrophils (defined as the sum o f segmented neutrophil count and the band neutrophil count).  
Laboratory  values at e ach visit (starting at baseline) and change fro m baseline to each scheduled 
visit for these laboratory  tests will  be included in box plots (with outliers displayed) described in 
Secti on 6.13.5 .
6.13.5.2. Neutrophil Follow -Up
Neutrophil counts will be fo llowed throughout the study .  Pati ents will cont inue in Period 4 until 
their neutrophil counts have recovered.
The neutrophil fo llow-up analysis will be conducte d on the neutrophil fo llow-up popul ation 
defined as pat ients who have an abso lute neutrophil count <1500 cells/µL (SI units:  <1.5× 
10^9/L) at the last scheduled visit or early terminatio n visit pri or to entering the post -treatm ent 
follow-up period (Period 4) and less than the patient’s baseline abso lute neutrophil count (that is, 
prior to fi rst inject ion at Week 0).  These patients are monitored during the Period 4 until 
neutrophil recovery .  
Neutrophil clinical recovery  is defined as an absolute neutroph il count ≥1500 cells/µL (SI units:  
≥1.5× 10^9/L) or greater than or equal to a patient’s absolute neutrophil count prior to first study  
drug inject ion at Week 0.
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 59
LY2439821If a patient’s neutrophil count has not recovered, wit hin 12 weeks after entering the fo llow-up 
period (Vi sit 802), the pati ent will return for Visit 803 (12 weeks after Visit 802).  Addit ional 
visits may be requi red for appropri ate pati ent m anagem ent depending upon the degree of 
neutropeni a.  If at Vi sit 802, a pati ent has met the cri teria for ne utrophil recovery , the pati ent’s 
participat ion in the study will be considered complete unless the invest igator deems addit ional 
follow-up m ay be necessary .  
The number and percentage of patients achieving neutrophil clinical recovery will be presented 
bytreatm ent group and week interval for neutrophil fo llow-up popul ation for post -treatm ent 
follow-up period (Period 4).  The number and percentage of patients with an abso lute neutrophil 
cell count that is at least 25%, 50%, 75%, or 100% of the patient’s ba seline absol ute neutrophil 
count (that is, prior to first inject ion at Week 0), irrespect ive of abso lute neutrophil minimum, 
will be included in the summary .
The time to neutrophil recovery  will be calculated (for patients entering the Post -Treatment 
Follow-up Peri od) as foll ows:
Time to neutrophil recovery (in weeks) = (Date of neutrophil recovery –Date of last visit prior 
to entering the follow -up period) / 7 .
Kaplan -Meier estimates of the proportion of pat ients not y et experiencing absolute neutrophil 
recovery  at selected time points will be provided by  treatm ent group.  A Kaplan -Meier pl ot of  
the time to neutrophil recovery will be presented by treatment group.
If a patient has not experienced neutrophil recovery, he/she will be censored at the date of the 
last neutrophil count assessment.  If they  did not have a neutrophil count assessment, they  will be 
censored at the date of last fo llow-up visit.
6.13.6. Vital Signs and Other Physical Findings
Analyses will be conducted on vital signs and physical characteri stics including systolic blood 
pressure (mmHg), diastolic blood pressure (mmHg), pulse (bpm), weight (kg), and BMI (kg/m 2).  
By-patient listing of vital signs and physical characterist ics will be provided.
Vital signs and other physical finding results wil l be summarized for (unless otherwise noted) :
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomized wit hdrawal safety  popul ation)
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W- treated pati ents fro m the 
rando mized withdrawal safety popul ation and nonrando mized populat ion).
Change from baseline for vital signs and other physical findings will be summarized for patients 
who have both baseline and at least one post -baseline result.
The scheduled visits/measurements will be includ ed.  The unscheduled visit s and 
the repeat measurements will be excluded.  
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 60
LY2439821For the randomized wit hdrawal safet y popul ation for Period 3, the comparisons 
between treatment groups will be conducted using an ANCOVA wit h treatment 
group and baseline value in the model.  
Data will be analyzed based on original scale.
Change from minimum value during the baseline period to the minimum value during the 
treatm ent peri od, as well as change fro m the maximum  value during the baseline period to the 
maximum value duri ng the treatment period will be summarized for patients who have both a 
baseline and at least 1 post -baseline result.
The number and percentage of patients with treatment -emergent or fo llow-up em ergent hi gh or 
low vital sign and weight at any  time will be summarized.  These will be displayed for (unless 
otherwi se noted): 
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (randomized wit hdrawal safety  popul ation) 
Relapse Period (relapse population)
Combined Period 2 and Period 3 (ixekizumab 80 mg Q2W -treated pati ents fro m the 
rando mized withdrawal safet y popul ation and nonrando mized populat ion) 
Period 4 (post -treatm ent follow-up peri od popul ation)  
The comparisons between treatment groups will be conducted using the Fisher’s exact test for
the randomized withdrawal safet y popul ation for Peri od 3.  
Table RHBF. 6.5defines the high and low baseline values as well as the limits that are 
specified as treatment -emergent and fo llow
-up emergent.  Note that weight does not have 
an abnormal baseline; therefore , the treatment -emergent and follow -up emergent val ues 
are determined by  change fro m baseline.
All post -baseline scheduled, unscheduled and repeated measurements will be 
included.
To assess increases, change fro m the maximum  value during the baseline period 
or baseline to the maximum value during each study period will be used.
To assess decreases, change from the minimum value during the baseline period 
or baseline to the minimum value during each study period will be used.
For treatm ent-emergent high and low:
oA treatment -emergent high resul t is defined as a change fro m a value less than 
or equal to the high limit at baseline to a value greater than the high limit at 
any time that meets the specified change criteria during the treatment period.
oA treat ment-emergent lowresul t is defined as a change from a value greater 
than or equal to the low limit at baseline to a value less than the low limit at 
any time that meets the specified change criteria during the treatment period.
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 61
LY2439821For follow -up emergent hi ghand l ow:
oA follow-up emergent high resul t is defined as a change from a value less 
than or equal to the high limit at baseline to a value greater than the high limit 
at any  time that m eets the specified change criteria during the follow-up 
period.
oA follow-up emergent lowresul t is defined as a change fro m a value greater 
than or equal to the low limit at baseline to a value less than the low limit at 
any time that meets the specified change criteria during the fo llow-up peri od.
Table RHBF. 6.5. Categorical Criteria for A bnormal Treatment -Emergent Blood 
Pressures and Pulse Measurement, and Categorical Criteria for 
Weight Changes for A dults
Parameter Low High
Systolic BP (mm Hg) a
(supine or sitting –
forearm at heart level)≤90 and decrease from
baseline ≥20≥140 and increase from
baseline ≥20
Diastolic BP (mm Hg) a
(supine or sitting –
forearm at heart level)≤50 and decrease from
baseline ≥10≥90 and increase from
baseline ≥10
Pulse (bpm) a
(supine or sitting)<50 and decrease from
baseline ≥15>100 and increase from
baseline ≥15
Weight (kg) (Loss) decrease from
baseline ≥7%(Gain) increase from
baseline ≥7%
Abbreviations:  BP = blood pressure; bpm = beats per minute; kg = kilogram; mm Hg = millimeter s of mercury.
aBaseline abnormal values are defined by the value presented.
To assess the effect of administration of study  drug on vi tal signs (bl ood pressures and pulse 
rate) among pat ients, at Week 0, vital signs will be measured before the first inje ction and 1 hour 
after the inject ion.  The box plots will be produced for pre- dose and post -dose vital signs at 
Week 0 (Visit 2) for the init ial open -label treatm ent peri od popul ation.  
6.13.7. Special Safety Topics including Adverse Events of Special 
Interest
Safety informat ion on special topics including AESIs will be presented by  treatm ent group and 
by study peri od.  Table RHBF. 6.6provides the definit ions/derivat ions and analyses methods 
(including analyses, summaries and by -patient listings) of special safety topics including AESIs.
Potenti al AESIs will be i dentified by a standardized MedDRA query (SMQ) or a Lilly -defined 
MedDRA P T list ing.  Preferred terms within an SMQ will be classified as broad and narrow.  In 
the Lilly -defined MedDRA PT list ings, Lilly has provided the broad and narrow classificat ion.  
The Lilly -defined broad term s are for a more sensitive search of potential events of interest and 
the Lilly -defined narrow term s are for a more specific search.   
Therefore, the summaries will 
include the classificat ions of broad term (same as pooling narrow and broad terms together) and 
narrow term .  In the event that the list ingof term s or analysis changes for a special safet y topic, 
I1F-MC-RHBF Statistical Analysis P lan Version 3 Page 62
LY2439821it will be documented in the program safet y analysis plan (PSAP) which will supersede this 
docum ent; i t will  not warrant an amendment to the individual study  SAP.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 63
LY2439821Table RHBF. 6.6. Definitions and A nalyses of Special Safety Topics Including Adverse Events of Special Interest
Special Safety 
Topic Definition / Derivation Analysis / Summ ary / Listing
Hepatic Hepatic AE analysis will include events that are potentially drug -related hepatic disorders by 
using the MedDRA PTs contained in any of the following SMQs or sub -SMQs as defined in 
MedDRA:
Broad and narrow terms in the Liver related investigations, signs and symptoms (20000008)
Broad and narrow terms in the Cholestasis and jaundice of hepatic origin (20000009)
Broad and narrow terms in the Hepatitis, non -infectious (20000010) 
Broad and narrow terms in the Hepatic failure, fibrosis and cirrhosis and other liver damage 
(20000013) 
Narrow terms in the Liver -related coagulation and bleeding disturbances (20000015)Period 2, Period 3, and Combined 
Periods 2 and 3 (Summary):
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT within SMQ or sub -SMQ, 
SAE by  PT within SMQ or sub -SMQ, AE 
leading to treatment discontinuation by PT 
within SMQ or sub -SMQ
Listing:  
TEAE
Elevations in hepatic laboratory tests (ALT, AST, ALP, total bilirubin) using Performing lab 
ULN during the treatment period are defined as:
Include scheduled visits, unscheduled visits, and repeat measurements.
ALT or AST:  maximum post -baseline measureme nt ≥3 times (3×), 5×, 10×, and 20× the 
Covance ULN for all patients with a post -baseline value.
oThe analy sis of 3×ULN will contain 4 subsets:  patients w hose non -missing maximum 
baseline value is ≤1×ULN, >1×ULN to <3×ULN, ≥3×ULN, or missing.
oThe analy sis of 5×ULN will contain 5 subsets:  patients w hose non -missing maximum 
baseline value is ≤1×ULN, >1×ULN to <3×ULN, ≥3×ULN to <5×ULN, ≥5×ULN, or 
missing.
oThe analy sis of 10×ULN will contain 6 subsets:  patients whose non -missing maximum 
baseline value is ≤1×ULN, >1×ULN to <3×ULN, ≥3×ULN to <5×ULN, ≥5×ULN to 
<10×ULN, ≥10×ULN, or missing.
oThe analy sis of 20×ULN will contain 7 subsets:  patients whose non -missing maximum 
baseline value is ≤1×ULN, >1×ULN to <3×ULN, ≥3×ULN to <5×ULN, ≥5×ULN to 
<10×ULN, ≥10×ULN to <20×ULN, ≥20×ULN, or missing.
Total bilirubin:  maximum post -baseline measurement greater ≥2× the Performing lab ULN 
for all patients with a post -baseline value, and divided into 4 subsets:  patients whose non -
missing maximum baseline value is ≤1×ULN, >1×ULN to < 1.5×ULN, ≥1.5×ULN to 
<2×ULN , ≥2×ULN ,or missing.
ALP:  maximum post -baseline measurement >1.5× the Covance ULN for all patients with a Period 2, Period 3, and Combined 
Periods 2 and 3 (Summary) :
Elevations in hepatic laboratory tests:  
maximum baseline category to abnormal 
maximum post -baseline category
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 64
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summ ary / Listing
post-baseline value, and divided into 4 subsets:  patients whose non -missing maximum 
baseline value is ≤1×ULN, >1×ULN to ≤1.5×ULN, >1.5×ULN, or missing.
Shift for ALT, AST, and total bilirubin from maximum baseline to maximum post -baseline will 
be produced with the requirements using Performing lab ULN during the treatment period :
Include scheduled visits, unscheduled visits, and repeat measurements.
Use the maximum non -missing value in the baseline period.
Use the maximum non -missing post -baseline value within each study period.
Categories are:
oALT:  ≤1×ULN, >1 to <3×ULN, ≥3 to <5×ULN, ≥5 to <10×ULN, ≥10  to <20×ULN, 
and ≥20×ULN
oAST:  ≤1×ULN, >1 to <3×ULN, ≥3 to <5×ULN, ≥5 to <10×ULN, ≥10× to <20×ULN 
and ≥20×ULN
oTotal bilirubin:  ≤1×ULN, >1 to <1.5×ULN, ≥1.5 to <2×ULN, ≥2×ULN
oALP; ≤1× ULN, >1 to ≤1.5× ULN, >1.5× ULN.
With additional categories:
oDecreased:  post -baseline category < baseline category
oIncreased:  post -baseline category > baseline category
oSame:  post -baseline category = baseline categoryPeriod 2, Period 3, and Combined 
Periods 2 and 3 (Summary) :
Shifts f rom maximum baseline to 
maximum post -baseline category
Elevated hepatic criteria:  maximum ALT ≥3×ULN and maximum total bilirubin ≥2×ULN, 
using Performing lab Reference Ranges .
Listing of patients w ho meet any  of the following criteria:
Elevated hepatic criteria:  defined as maximum ALT ≥3×ULN and maximum tota l bilirubin 
≥2×ULN
An ALT or AST ≥3×ULN 
An alkaline phosphatase (ALP) ≥1.5×ULN 
A total bilirubin ≥2×ULN 
The listing will include:  patient demographics, concomitant medications, ALT/AST/ALP/total 
bilirubin/gamma -glutamyl transferase ( GGT) by visit, trea tment start and stop dates, and reason 
for treatment discontinuation.  Listing:
Elevations in hepatic laboratory tests
eDISH plot:  use maximum ALT measurement and maximum total bilirubin measurement after 
the first injection of study treatment with patients having at least one post -baseline ALT and 
total bilirubin, which contributes one point to the plot.  The measurements do not need to be 
taken at the same blood draw.   Period 2, 3, and 4 combined :  eDISH plot
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 65
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summ ary / Listing
Cytopenias Cytopenias are defined using the PTs from the following 2 sub -SMQs of the Haematopoietic 
cytopenias SMQ (20000027) as specified in MedDRA:  
Broad and narrow terms in the Haematopoietic leukopenia (20000030)
Broad and narrow terms in the Haematopoietic thr ombocytopenia (20000031)Period 2, Period 3, and Combined 
Periods 2 and 3 (Summary) :
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT within sub -SMQ, 
SAE by  PT within sub -SMQ, 
AE leading to treatment discontinuation by 
PT within sub -SMQ
Listing:  
TEAE
Infections Infections are events including all infections (defined using all the MedDRA PTs from the 
Infections and infestations SOC) , serious infections, potential OIs, and infections resulting in 
anti-infective medicat ion adminstration (i.e., antibacterial, antiviral, antifungal, antiparasitic 
treatment .) .  Period 2, Period 3, and Combined 
Periods 2 and 3 (Summary) :
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT, 
TEAE by  maximum se verity  by PT, 
SAE by  PT, 
AE leading to treatment discontinuation by 
PT
Listing:  
TEAE
Anti-infective medications are defined in Appendix 7 including antibacterial, antiviral, 
antifungal, and antiparasitic treatment .
Listing of patients experiencing a TEAE of infections will be provided including the following 
additional information:  anti -infective medications use (if treated) with medication start/end 
dates, indication for use, and route; minimum post -baseline value within treatment Period 2 for 
leukocytes, platelets, lymphocytes, and absolute neutrophils.Listing:  
TEAE with anti -infect ive medications
The list of MedDRA terms used to identify infections that are defined as potential O Is are 
found in Appendix 12 .  This list conta ins PTs with Categories (narrow or broad) from the 
Infections and Infestations SOC and from the Investigations SOC which can assist in 
indentifying potential O Is.  The narrow terms are considered O Is unless medical review Period 2, Period 3, and Combined 
Periods 2 and 3 (Summary) :
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 66
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summ ary / Listing
determines that the reported term is not consistent with the patient’s clinical 
history /presentation/course.  Medical review of broad terms is needed for final 
determination of patients meeting the program definitionof O Is.
Listing of patients experiencing a TEAE of potential OIs will be p rovided including the 
following additional information: source of identification (CRF or Lilly -defined list), 
primary /secondary  site of infection, primary/secondary infection type, primary/secondary 
identified by a laboratory diagnostic test (Yes/No), acqu ired in a health care setting (Yes/No).TEAE of OIs by maximum severity by PT
Listing:  
TEAE of OIs
The duration of each common (≥1% of total ixekizumab) TEAE PT of Infections is defined as: 
Duration of treatment -emergent AE Infections (in weeks) = (End date of AE –Start date of AE 
+ 1) / 7.  Only TEAEs of infections beginning during treatment Period 3 will be included in the 
summary.  If an AE has not ended by the date of completion of the treatment Period 3, or date of 
early  discontinuation, it will be censored as of that date (last visit within the treatment Period 3, 
or date of early discontinuation).  If a patient has multiple episodes of the same TEAE, the 
episode with the greatest severity will be used for the duration of event calculation.  If a patient 
has multiple episodes of the same TEAE with the same severity, the episode with the longest 
duration will be us ed for the duration of event calculation.Period 2, Period 3, and Combined 
Periods 2 and 3 (Summary) :
Period 3 randomized withdrawal safety 
population (Summary) :
Duration of Common TEAE –Infections
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 67
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Allergic 
Reactions/
Hypersensitiv -
itiesAllergic reactions/hypersensitivity events will be categorized as either potential anaphylaxis 
or non-anaphylaxis events (these will refer to events that are not localized to the site of 
injection) and summarized separately.  Medical reviews are needed for final determination 
of patients with allergic  reactions/hypersensitivities.
Allergic Reactions/Hypersensitivity Events, Potential Anaphylaxis :  Anaphy laxis has been 
broadly defined as “a serious allergic reaction that is rapid in onset and may cause dea th” 
(Sampson et al. 2006).  Identification of cases of potential anaphylaxis from the clinical trial 
data involves 2 criteria:
1)designed to specifically identify cases (following Criterion 1) based on narrow terms 
from the MedDRA SMQ for anaphylactic reaction (20000021).  Criterion 1 for 
anaphy laxis is defined by the presence of a TEAE based on the following MedDRA 
PTs from the anaphylacti c reaction SMQ:
Anaphy lactic reaction
Anaphy lactic shock
Anaphy lactoid reaction
Anaphy lactoid shock
Anaphy lactic treatment
Kounis Syndrome
2)to identify possible cases, following Criterion 2 as defined by Sampson et al. (2006).  
Criterio n 2 for anaphy laxis r equires having TEAEs from 2 or more of 4 categories of 
AEs as described by Sampson et al. (2006).  Occurrence of these events should be 
nearly  coincident and develop rapidly after exposure to the most recent injection; based 
on recording of events on CRFs, all qualifying events must be within 1 day of study 
drug injection.  
The 4 categories to be considered in Criterion 2 are:
Category  A:  Involvement of the skin -mucosal tissue
Category  B:  Respiratory compromise
Category  C:  Reduced blood pressure or associated symptoms
Category  D:  Persistent gastrointestinal symptoms
The specific MedDRA PTs covered by each of these Criterion 2 categories are shown in 
Appendix 8 .Period 2, Period 3, and Combined Periods 
2 and 3:
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT within Category, 
TEAE by maximum severity by PT within 
Category ,
SAE by  PT within Category, 
AE leading to treatment discontinuation by 
PT within Category
Listing:  
TEAE
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 68
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Summaries of Criterion 2 anaphylactic TEAEs will be provided by the specific 
combinatio n of categories as follows:
AB:  events based on meeting Category A and Category B (but no other category)
AC:  events based on meeting Category A and Category C (but no other category)
AD:  events based on meeting Category A and Category D (but no other category)
BC:  events based on meeting Category B and Category C  (but no other category)
BD:  events based on meeting Category B and Category D (but no other category)
CD:  events based on meeting Category C and Category D (but no other category)
ABC:  events based on meeting Category A, Category B and Category C (but no 
other category)
ABD:  events based on meeting Category A, Category B and Category D (but no 
other cate gory)
ACD:  events based on meeting Category A, Category C and Category D (but no 
other category)
BCD:  events based on meeting Category B, Category C and Category D (but no 
other category)
ABCD:  events based on meeting each of the 4 Criterion 2 categorie s
Summaries of treatment -emergent anaphylactic AEs will be provided for patients meeting 
each of the 2 criteria and for patients who meet either criteria overall.  Severity of treatment -
emergent Criterion 2 anaphylactic AEs will be based on the maximum sev erity of the 
specific events met by the patient.  Maximum severity of an (or overall) treatment -emergent 
anaphy lactic AE will be based on the maximum severity within Criterion 1 and/or Criterion 
2.
Allergic Reactions/Hypersensitivity Events, Non-Anaphy laxis :  TEAEs of allergic 
reaction/hy persensitivity categorized as non -anaphylaxis events are defined by the narrow 
terms within Hypersensitivity SMQ (20000214) excluding the PTs noted in Appendix 9 and 
excluding the anaphylactic events as defined above. 
A by -patient listing will be provided for all patients experiencing TEAE of allergic 
reactions/hypersen sitivities at any time, including status/criterion of anaphylaxis or non -
anaphy laxis, and the associated information collected on Allergic/Hypersensitivity Reaction 
Follow-Up eCRF page if identified by the investigator.Listing:  
TEAE including informatio n collected on 
Allergic/Hypersensitivity Reaction Follow -
UpeCRF page
Injection Site Injection site reaction is defined using the PTs from the MedDRA HLT of Injection site Period 2, Period 3, and Combined Periods 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 69
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Reactions reactions as specified by MedDRA excluding the following 10 PTs:
1)Embolia cutis medicamentosa
2)Injection site joint discomfort
3)Injection site joint effusion
4)Injection site joint inflammation
5)Injection site joint movement impairment
6)Injection site joint pain
7)Injection site joint redness
8)Injection site joint swelling
9)Injection site joint warmth
10) Injection site joint infection
TheInjection Site Reaction eCRF page captures the injection site reactions identified by the 
investigator.  These TEAEs will be summarized within the MedDRA HLT by maximum
severity  or category .  If mo re than 1 TEAE of injection site reaction occurs, the event with 
the worst value (within the individual categories:  redness, swelling and pain) will be used.
Redness (Scored 0 -4)
[0] Subject’s normal skin color, no increased r edness
[1] Noticeable, but very mild redness
[2] Clearly red
[3] Bright red
[4] Dark with some scar formation 
Swelling (Scored 0 -4 after running a finger over injected area)
[0] No bump
[1] Barely noticeable
[2] Clear bump but very thin
[3] Clear bump 1 mm thick
[4] Clear bump 2 mm thick or more 
Pain (including burning) (Scored 0 -3)
[0] None
[1] Mild 
[2] Moderate 
[3] Severe 2 and 3: (Summary):
Period 3 randomized withdrawal safety 
population (Fisher’s exact tes t):
TEAE by  maximum severity by PT within 
HLT,
SAE by  PT within HLT,
AE leading to treatment discontinuation by 
PT within HLT
TEAE identified by the investigator PT 
within HLT:
bymaximum severity, 
by maximum redness category,
by maximum swelling categor y, 
by maximum pain category
Listing:  
TEAE including information collected on 
Injection Site Reaction eCRF page
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 70
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Cerebro -
cardiovascular 
EventsCerebro -cardiovascular events will be externally adjudicated by the CEC at the Cleveland 
Clinic, as outlined in the Manual of Operations.  The CEC will adjudicate investigator -
reported events selected for adjudication and render an assessment as to whether the event 
represents a confirmed event (meeting the event definition with all necessary 
documentation), a non -event (does not meet the event definition and likely represents an 
alternative or nonevent diagnosis), or lacks sufficient documentation for conf irmation of an 
event.  All events which qualify for CEC adjudication will be used for the analysis of 
cerebro -cardiovascular events.  The categories and subcategories of adjudicated events used 
for the analysis will include the following:
Cardiovascular 
oDeath (Cardiovascular)
oCardiac Ischemic Event:  Myocardial Infarction and Hospitalization for Unstable 
Angina
oSerious Arrhythmia 
oHospitalization for Heart Failure
oHospitalization for Hypertension
oResuscitated Sudden Death 
oCardiogenic Shock 
oCoronary  Revas cularizatio n
Neurologic 
oCerebrovascular Event:  Transient Ischemic Attack or Stroke (Haemorrhagic, 
Ischemic and Undetermined) 
Peripheral Vascular Events
oPeripheral Arterial Event
oPeripheral Revascularization
Events will be analyzed using MedDRA PT nested within the CEC assessment (confirmed 
event, no event, or insufficient documentation for event determination) and the subcategor y.  
Subtypes of stroke (Hemorrhagic Stroke, Ischemic Stroke, and Undetermined Stroke Type) 
will be displayed in the analyses nested within Cerebrovascular Event.  Subtypes of Serious 
Arrhy thmia (Atrial Arrhythmia, Ventricular Arrhythmia, Heart Block, Other, Unknown) 
will be displayed nested within Serious Arrhythmia.  Period 2, Period 3, and Combined Periods 
2 and 3 (Summary):
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT within Subcategory,
Listing:  
TEAE
Major
Adverse MACE (requiring adjudication as defined above) is defined as:
Vascular Death (including cardiovascular and cerebro -vascular causes excluding Period 2, Period 3, and Combined Periods 
2 and 3 (Summary):
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 71
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Cerebro -
Cardiovascular 
Events 
(MACE)hemo rrhagic deaths outside of the central nervous system)
Non-fatal myocardial infarction 
Non-fatal stroke (subtypes:  hemorrhagic stroke, ischemic strok e, undetermined stroke 
type) 
Where,
Vascular death should be captured as an Event on Adjudication -Death eCRF page with 
Adjudication Death Type = ‘Cardiovascular’.  
Non-
fatal myocardial infarction should be captured as an Event on Adjudication -
Cardiac Ischemic Event eCRF page with Type of Ischemic Event = “Myocardial 
Infarctio n” and the Event is NOT on Adjudication -Death eCRF page.
Non-fatal strokes (ischemic, hemorrhagic) should be captured as an Event on 
Adjudication -Cerebrovascular Event eCRF pa ge with Stroke Cerebrovascular Event 
Subtype in one of the following categories:  hemorrhagic stroke, ischemic stroke, 
undetermined stroke type, and the Event is NOT on Adjudication -Death eCRF page.  
Subcategories of non -
fatal stroke (Hemorrhagic Stroke, Ischemic Stroke, and 
Undetermined Stroke Type) will be displayed nested within non -fatal stroke category.Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  maximum severity by PT within 
Category
Listing:  
TEAE
Malignancies Malignancy is defined using PTs from the Malignant or unspecified tumors SMQ as 
specified in MedDRA (SMQ:  20000091, which includes the sub -SMQs:  
20000195 [Tumors of unspecified malignancy] , including sub -SMQs of 20000229 
[Haematological tumours of unspecified malignancy ] and 20000230 [Non -
haematological tumours of unspecified malignancy ]and 
20000194 [Malignant tumors] , including sub -SMQs of 20000227 [Haemat ological 
malignant tumours] and 20000228 [Non -haematological malignant tumours ]).  
Events will be summarize by the following categories:
Nonmelanoma Skin Cancer (NMSC)
oBasal Cell Carcinoma, PTs include:  
Basal cell carcinoma 
Basosquamous carcinoma
Basosquamous carcinoma of skin
oSquamo us Cell Carcinoma, PTs include:
Squamous cell carcinoma of skin
Bowen’s disease
Lip squamous cell carcinomaPeriod 2, Period 3, and Combined Periods 
2 and 3 (Summary):
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT within Category, 
SAE by  PT within Category, 
AE leading to treatment discontinuation by
PT within Category
Listing:  
TEAE
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 72
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Skin squamous cell carcinoma metastatic
Keratoacanthoma
Malignancies excluding NMSC:  all PTs in the Malignant or unspecified tumors SMQ 
excluding t he 8 defined NMSC PTs.  
Depression and
Suicide/self -
injuryDepression and suicide/self -injury  is defined using the PTs from the Depression and 
suicide/self -injury  SMQ as specified in MedDRA ( SMQ: 20000035, which includes the sub -
SMQs: 20000 037 [Suicide/self -injury ] and 20000167 [Depression (excluding suicide and 
self injury)]).Period 2, Period 3, and Combined Periods 
2 and 3 (Summary):
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT within SMQ and sub -SMQ, 
SAE by  PT within SMQ and sub -SMQ, 
AE leading to treatment discontinuation by 
PT within SMQ and sub -SMQ
Listing:  
TEAE (including QIDS -SR16 total scores)
The Quick Inventory of Depressive Symptomology -Self Report 16 items (QIDS -SR16) is a
self-administered 16-item instrument intended to assess the existence and severity of
symptoms of depression as listed in the American Psychiatric Association’s (APA’s)
Diagnostic and Statistical Manual of Mental Disorders, 4th Editi on (DSM -IV) (APA 1994).
Refer to Table RHBF. 6.11and Table RHBF. 6.12 for further details.
The following groups are based upon the maximum post -
baseline QIDS -SR16 total score
category (none, mild, moderate, severe, very severe) score:
Improved; maximum post -baseline < baseline
Worsened; post -baseline > baseline
Same; post -baseline = baselinePeriod 2, Period 3, and Combined Periods 
2 and 3
Period 3 randomized withdrawal safety 
population
Shift in QIDS -SR16 total score categories
Inflammato ry 
Bowel DiseaseInflammato ry Bowel Disease (IBD) will be identified by medical review using the following  
Category  and MedDRA PTs . The narrow terms are considered IBD. Medical reviews of 
patients with identified broad terms are needed for final determination of patients with IBD.
IBD Specific Terms (Narrow terms)
Inflammato ry Bowel Disease:  Inflammatory bowel disease
Crohn’s Disease:  Crohn’s disease
Ulcerative Colitis:  Acute haemorrhagic ulcerative colitis; Colitis ulcerative; 
Proctitis ulcerative
IBD Non-Specific Terms :  The PTs in this category are listed in Appendix 11Period 2, Period 3, and Combined Perio ds 
2 and 3 (Summary):
Period 3 randomized withdrawal safety 
population (Fisher’s exact test) :
TEAE by  PT by  maximum severity by PT 
within Category
Listing:  
TEAE
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 73
LY2439821Special Safety 
Topic Definition / Derivation Analysis / Summary / Listing
Interstitial 
Lung DiseaseInterstitial lung disease is defined using the following terms:  
Narrow terms in the interstitial lung disease SMQ (20000042) 
The following 6 PTs from eosinophilic pneumonia SMQ (20000157):  
oAngioly mphoid hy perplasia with eosinophilia (Narrow)
oEosinophilic bronchitis (Narrow)
oHypereosinophilic syndrome (Narrow)
oLoef fler’s syndrome (Narrow)
oPulmonary eosinophilia (Narrow)
oPulmonary vasculitis (Narrow)Listing:
TEAE
Abbreviations:  AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CEC = Central Events Committee; eCRF = electronic 
case report form; eDISH = Evaluatio n of Drug -Induced Serious Hepatotoxicity; HLT = High Level Term; MedDRA = Medical Dictionary for Regulatory 
Activities; OI = opportunistic infection; PT = preferred term; SAE = serious adverse event; SMQ = standardized MedDRA query; SOC = System Organ 
Class; TB = tuberculosis; TEAE = treatment -emergent adverse event; ULN = upper limit of normal.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 74
LY24398216.13.8. Immunogenicity
6.13.8.1. Definitions and Terms
The fo llowing sample -and pat ient-related definit ions and parameters will be used to describe the 
immunogenicit y data.  
6.13.8.1.1. Sample Category Definitions
Samples are classified into the fo llowing categori es:
Unevaluable sample:   Sam ple coul d not be teste d for ant i-drug antibody  (ADA) 
due to sam ple loss, mishandling, or errors in collection, processing, storage, etc.  
Antidrug antibody (ADA) Positive sample:   The presences of ADA is detected 
and confirmed.  The samples are reported as posit ive.  If the sa mple is posit ive, a 
titer val ue is reported.
Neutralizing anti -drug antibody (NAb) Positive sample:   NAb are reported as 
detected.
Antidrug antibody (ADA) Negative sample:   The presence of ADA is not 
detected and the assay  drug tol erance level is not excee ded.
Neutralizing anti -drug antibody (Nab) Negative sample:   The presence of NAb 
is not detected and the assay drug tolerance level is not exceeded.
Inconclusive sample:   when ADA/NAb is not detected in a sample but drug is 
present in the same sample at a level that can cause interference in the ADA/NAb 
detection method.  The negat ive ADA/NAb result cannot be confirmed and the 
sample was considered inconclusive.
oConfirmation o f a negat ive ADA result was based on ixekizumab 
concentrations.
Figure RHBF. 6.1illustrates the relat ionship of some of the above terms.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 75
LY2439821Abbreviation:  ADA = anti -drug antibody.
Figure RHBF. 6.1. Sample definitions.
6.13.8.1.2. Patient Category Definitions
The fo llowing categori es are applied to pati ents based on the classificat ion of their samples:
Unevaluable patient:   
a) a patient with no evaluable baseline sample and/or no 
evaluable postbaseline samples; b) a patient with an evaluable baseline sample but 
no evaluable postbaseline sample; c) a patient with no evaluable baseline sample, 
but whose evaluable postbaseline values are all ADA positive or a mix of posit ive 
and negat ive.  (Note:  If all post -baseline samples are negat ive, the patient is 
considered ‘evaluable’ and will be classified as ADA -negat ive.)
Evaluable patient: a) Patient with an evaluable baseline sample and at least 1 
evaluable post- baseline sample (that is, sample aft er administration of study  
drug); b) patient with no evaluable baseline sample whose evaluable post -baseline 
samples are all ADA negat ive.
Figure RHBF. 6
.2illustrates the relat ionship of the above terms.

I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 76
LY2439821Abbreviation:  ADA = anti -drug antibody.
Figure RHBF. 6.2. Patient categories (evaluable/unevaluable) based on sample status 
at baseline and post -baseline.
6.13.8.1.3. Definitions for Clinical Interpretation of Assay Results
Baseline: For immunogenicit y analyses during Period 2, Period 3, and Period 4
,
baseline is the last nonmissing observat ion on, or pri or to ,the date of the first 
inject ion of study  treatment of ixekizumab ( Week 0). 
Baseline ADA positive (preexisting antibody):   ADA detected in a sample 
collected at baseline.
Treatment -emergent antidrug antibody positive:   
a) a patient with a 4-fold 
increase over a positive baseline antibody t iter (Ti er 3); or b) for a negative 
baseline titer, a patient with an increase from the baseline to a level o f 1:10.
Baseline ADA- negative: ADA is not detected in a sample co llected at baseline.
Treatment -emergent antidrug antibody inconclusive patient:   A patie nt 
without a TE -ADA posit ive sample and with at least one sample for which drug 
levels may interfere with the ADA assay.  
Treatment -emergent antidrug antibody negative patient:   A patient who is 
evaluable for TE -ADA and is not either TE -ADA posit ive or TE- ADA 
inconclusive.  
Figure RHBF. 6.3illustrates the relat ionship of some of these terms.

I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 77
LY2439821Abbreviation:  ADA = anti -drug antibody.
Figure RHBF. 6.3. Relationship of terms for clinical interpretation of assay results for 
evaluable patients.
Incidence of TE
-ADA:   Patients with TE -ADA as a proportion of the evaluable 
pati
ent popul ation during the treatment period.  This excludes unevaluable 
patients.
All ADA posi tive samples will be evaluated for NAb.  Definit ions for NAb patient status will be 
defined as fo llows:
Neutralizing anti -drug antibody -positive patient:   A patient where a NAb 
positive result is detected for ≥1TE-ADA posit ive samples.
Neutralizing anti -drug antibody -inconclusive patient:   A patient without a 
NAb posi tive sample and with at least one sampl e for which drug levels may  
interfere wi th the NAb assay .
Neutralizing anti -drug antibody -negative patient:   A patient who is evaluable 
for NAb and is not either NAb posit ive or NAb inconclusive.
A flow chart that reflects the connect ion between the analyt ical test results and the clinical 
interpretati on based on the definit ions is shown in Figure RHBF. 6.4.

I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 78
LY2439821Abbreviation:  ADA = anti -drug antibody; NAb = neutralizing anti -drug antibody; PK 
= pharmacokinetic.
Figure RHBF. 6.4. Flow chart of A DA assessment with clinical interpretation of the 
various result possibilities.
6.13.8.2. Immunogenicity Analyses
Immunogenici tywill be summarized for evaluable patients for (unless otherwise noted):
Period 2 (init ial open -label treatment period population)
Period 3 (randomized wit hdrawal safety populat ion)
Relapse period (relapse populat ion)

I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 79
LY2439821Combined Period 2 and Period 3 (ixekiz umab 80 mg Q2W -treated pati ents fro m the 
rando mized withdrawal safet y popul ation and nonrando mized populat ion)
Period 4 (post -treatm ent follow-up peri od popul ation).
Immunogenicit y evaluable pat ients will be ident ified as TE -ADA positive, TE -ADA negative, or 
TE-ADA inconclusive, according to the definit ions provided in Sect ion 6.13.8.1.2 and fur ther 
grouped into TE -ADA status groups and time- varying TE -ADA status groups :
TE-ADA Status Groups:
Treatment -emergent antidrug antibody status (posit ive, negative, or 
inconclusive);
Neutralizing anti -drug ant ibody  status (posi tive, negative, or inconclusi ve) for 
TE-ADA posit ive patients
Treatment -emergent antidrug antibody titer groups for TE -ADA positive 
patients:
oLow Ti ter:  TE -ADA titer value (LOCF) < 1:160
oModerate Ti ter: TE -ADA titer value (LOCF) ≥1:160 and < 1:1,280
oHigh Ti ter:  TE -ADA titer value (LOCF) ≥1:1,280
Time -varying TE -ADA Status Groups:
Individual ADA samples will be ascribed into 3 different dichotomous variables as explained in 
Table RHBF. 6.7.  Each variable has possible values of a ‘greater- TE-ADA status’ or a ‘lesser -
TE-ADA status,’ in the sense that the level o f TE-ADA detected in the greater -TE-ADA 
category  is higher than in the lesser -TE-ADA category .
Table RHBF. 6.7. TE-ADA Status Dichotomous Variables for AE analysis
TE-ADA Status Dichotomous 
VariableGreater -TE-ADA Status Lesser- TE-ADA Status
TE-ADA positive TE-ADA positive not TE -ADA positive
TE-ADA moderate -to-high TE-ADA positive with moderate titer 
or high titernot TE -ADA positive, or TE -
ADA positive with low titer
TE-ADA high status TE-ADA positive with high titer not TE -ADA positive, or TE -
ADA positive with low or 
moderate titer
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 80
LY2439821TE-ADA Status Dichotomous Variables for AE analysis (Abbreviations and Footnotes)
Abbreviations:  AE = adverse events; ADA = antidrug antibody; TE -ADA = t reatment -emergent antidrug antibody .
Note:  For purpose of this analysis, TE -ADA Inconclusive is taken to be “not TE -ADA positive.”
Note:   A TE -ADA low is defined as a TE -ADA positive with a titer value < 1:160; a TE -ADA moderate is defined 
as a TE -ADA positive with a titer value ≥1:160 and < 1:1,280; and a TE -ADA high is defined as a TE -ADA 
positive with a titer value ≥1:1,280.
For each TE- ADA status dichotomous variable, a time -varying TE -ADA status will be 
computed.  At time tthe TE -ADA status is taken to be the highest of the TE -ADA values 
bracket ing time t.  More form ally, the TE -ADA status at time tis given by the greater of (a) the
TE-ADA status at the most -recent postbaseline measurement prior to t, and (b) the TE -ADA 
status at the first TE -ADA postbaseline measurement at or after time t.  In thi s computation, 
‘greater’ is given by the greater -TE-ADA status of Table RHBF. 6.7.  If  there i s no val ue 
satisfying criterion (a), then the value (b) is used.  Similarly, if there is no value (b), then the 
value (a) i s used. 
For each TE -ADA status dichotomous variable, patients will be categorized according to 
whether they  were (i ) always in lesser
-TE-ADA status postbaseline or (ii) at some po int 
postbaseline, were in greater -TE-ADA status.  
6.13.8.2.1. Analyses of Characteristics of ADA Immune Response 
The analyses of characteristics of ADA response will be conducted on all immunogenicit y 
evaluable pat ients within the Init ial Open -Label  Treatm ent, Randomized Double -Blind 
Withdrawal Period, Combined Open -Label  Treatment Peri od and Random ized Double -Blind 
Withdrawal Periods, Relapse Period, and the Post -Treatment Follow -up Peri od.  Pati ents will be 
analyzed according to the treatment to which they were assigned.
The overall frequency and percentage (incidence) of patients will be summarize d for the TE -
ADA status groups and the time -varying TE -ADA status groups.  Scheduled visits, unscheduled 
visits, and repeat measurements will be included.    
The time to the development of TE- ADAs (TE -ADA posit ive, low titer, moderate titer, high titer, 
and NAb posi tive) will be calculated as follows:
Time to development of TE -ADAs/NAb (in w eeks) = (Date of development of TE -ADAs/NAb –
Date of first injection of study treatment + 1) / 7.
If a patient has not developed TE -ADAs/NAbs, they will be censored at the date of the last 
immunogenicit y assessment.  If a patient does not have any postbaseline assessments for 
immunogenicit y, they  will be censored at the date of randomizat ion.
Descript ive statistics, including 25th percent ile, 50th percentile (median), 7 5th percent ile, and 
corresponding 95% CIs as well as probabilit y of TE-ADA/NAb posit ive by endpoint 
summarized by  treatm ent group, will also be provided if sufficient data is present.  A Kaplan -
Meier pl ot of the time to development of treatment -emergent AD A/NAb will be presented by 
treatm ent group, al so if sufficient data is present.  The log -rank test will be used to test the null 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 81
LY2439821hypothesis against the alternate hypothesis that the time to TE -ADA/NAb is not equal between 
ixekizumab and placebo.  Caution s hould be exercised in the interpretation of time -to event 
analyses, and related statist ics, given the limited sampling scheme for immunogenicit y testing.
For each TE -ADA status dichotomous variable (as defined in Table RHBF. 6.7), summaries will 
be provided o f the total postbaseline time in the greater -TE-ADA status for patients who were at 
some point postbaseline in the greater
-TE-ADA status group.  Post baseline time in greater -TE-
ADA status for each patient will be aggregated.  
A by-patient listing to include treatment, visit date, visit, ADA result, TE -ADA result, NAb 
resul t, ADA t iter value, ixekizumab concentration, ADA and NAb inconclusive results w ill also 
be provided, for patients with any  one sam ple of  ADA (or NAb) posit ive or inconclusive.
6.13.8.2.2. Analyses of Treatment -Emergent ADA Effects on Efficacy
Analyses will be performed to examine how patient TE -ADA effects time -to rel apse in the 
rando mized withd rawal ITT popul ation by the TE -ADA status groups.  The Kaplan -Meier 
product limit method will be used to estimate the survival curves for time -to relapse.  A Cox-
proporti onal hazards model with treatm ent group, TE -ADA status group and the interaction of 
treatment group -by-TE-ADA status group included as factors in the model will be used to test 
the interaction of treatment group -by-TE-ADA status group.  Addit ionally , the Kaplan -Meier 
product limit method will be used to estimate the survival curves for time -to relapse.
Analyses will also be performed to examine how patient TE -ADA effects the proportion of 
patients who rel apse by40 weeks of randomized treatment in the randomized withdrawal ITT 
popul ation by the TE -ADA status groups.  A logistic regressio n model with treatm ent group, TE -
ADA status group and the interaction of treatment group -by-TE-ADA status group included as 
factors i n the m odel will be used to test the interactio n of treatment group -by-TE-ADA status 
group.
Analyses will also be performed to examine how patient TE -ADA effects the proportion of 
patients wi th 20% and 50% improvement in American Co llege o f Rheumatology  criteria 
(ACR20 and ACR50) at the l ast observat ion in the init ial open -label treatment period populat ion 
and at40 weeks of rando mized treatment in the rando mized wit hdrawal ITT populat ion by the 
TE-ADA status groups.  For the init ial open -label treatment period population, the TE -ADA 
status groups will be summarized for the ixekizumab 80 mg Q2W treatment group.  For the 
rando mized withdrawal ITT popul ation, a logist ic regression model with treatment group, TE -
ADA status group and the interaction of treatment group -by-TE-ADA status group included as 
factors i n the m odel will be used to test the interactio n of treatment group -by-TE-ADA status 
group.
The p -value associated with the interaction terms will be used to assess if the treatment group 
effect is consistent across TE -ADA status group.  When the interaction term is statist ically 
significant, the associ ation between responder status and the treatment group depends, in so me 
manner, on the status group.  The interaction will be tested at the 10% significance level.  If any 
group within the subgroup (for example, y es, no) is <10% of the total populat ion, only 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 82
LY2439821descript ive statistics wi ll be provi ded for that subgroup (that is, no inferential testing).  Treatment 
group differences will be evaluated within each subgroup regardless of whether the interaction is 
statist ically significant.
6.13.8.2.3. Analyses of Treatment -Emergent ADA on Specific Adver se Events
The analyses of TE -ADA effects on safet y will be conducted on all immunogenicit y evaluable 
patients wi thin the Init ial Open -Label  Treatm ent Peri od, Randomized Double -Blind Wit hdrawal 
Period, and the Combined Open -Label Treatment and Rando mized Do uble-Blind Wit hdrawal 
Periods.  Pati ents will be analyzed according to the treatment to which they  were assigned.
Adverse events of special interest of allergic react ion/hypersensit ivity (anaphylaxis and 
nonanaphylaxis) and of inject ion-site reacti ons will be included in an assessment of AE to TE -
ADA over time.  See Table RHBF. 6.6for the definit ions of the AESIs.  Timing of an AE will be 
taken to be the reported AE start date.  
For each TE -ADA status dichotomous variable (as defined in Table RHBF. 6.7), pati ents will  be 
categori zed according to whether they  were (i ) always in lesser -TE
-ADA status postbaseline or 
(ii) at som e point postbaseline, were in greater -TE-ADA status.  For each AESI, within the time -
varying TE -ADA status groups, a summary will be provided of the number of pat ients who had 
no event, events only  while in lesser -TE-ADA status for group (i), or – for group (ii) –at least 
one event while in greate r-TE-ADA status.
Addit ionally , summaries will  be provi ded of  the total  number of AESI events (with unique start 
dates) by  time -varying TE -ADA status groups at the event date.  The summaries will aggregate 
time respect ively in greater -TE-ADA status and in lesser -TE-ADA status , alongwith the event 
rates (rates per 100 patient -years) relat ive to those aggregate times.
By-patient listings will be provided of pat ients with TE-ADA who experience a treatment -
emergent allergi c react ion/hypersensit ivity react ion oran inject ion site react ion.
6.14. Subgroup Analyses
6.14.1. Efficacy Subgroup Analysis
Subgroup analyses will be conducted for time -to relapse and the proportion of patients who 
relapse by 40 weeks of rando mized treatment in therandomized withdrawal ITT populat ion 
during Period 3.
For the time -to-relapse, the Kaplan -Meier product limit method will be used to estimate the 
survival curves for time -to rel apse.  Analyses will be performed using a Cox-proporti onal 
hazards model with treatm ent group, subgroup, and the interaction of treatment group -by-
subgroup included as factors in the model.  
For the proportion of patients who relapse, a logistic regressio n model with treatm ent, subgroup, 
and the interaction of treatment group -by-subgroup included as factors will be used.    
The treatment group -by-subgroup interactions will be tested at the significance level o f 0.10.  If 
any group within the subgroup (for example, y es, no) i s <10% of the total populat ion, only 
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 83
LY2439821descript ive stat istics will be provided for that subgroup (that is, no inferential testing).  Treatment 
group differences will be evaluated within each category  of the subgroup using log -rank test
without stratificat ionsor Fi sher’s exact test , regardless of whether the i nteracti on is statistically  
significant.  
Subgroups to be evaluated include: 
Dem ographic subgroups:
oAge group:  <65 y ears, ≥65 years to <75 years, ≥75 years
oAge group:  <40 y ears, ≥40 years 
oGender (male, female)
oRace:  AI, AS, BL, NH, WH, MU
oEthnicit y: Hispanic or Latino, Not Hispanic or Latino
oWeight category :  <100 kg, ≥100 kg
oWeight category :  <80 kg, ≥80 kg to <100 kg, ≥100 kg
oBMI category :  underweight (<18.5 kg/m 2); norm al (≥18.5 to 
<25kg/m 2); overwei ght ( ≥25 to <30 kg/m 2); obese ( ≥30 to 40 kg/m 2); 
extrem e obese ( ≥40 kg/m 2)
Geographic region subgroups:
oGeographic region:  US, Europe, Rest of the World
Baseline severit y subgroups:
oC-reactive protein (mg/dL):  ≤6, >6
oDurati on of  PsA (y ears):  0 to <5, ≥5
oBaseline psoriat ic lesion(s) invo lving BSA ≥3%: yes or no)
oModerate to severe psoriasis (defined as PASI ≥12, sPGA ≥3, and 
BSA ≥10%):  yes, no
oEnthesit is (LEI score >0 or SPARCC >0): y es or no
oDactylit is (LDI -B score >0): y es or no
Psori atic arthritis therapy subgroups:
oPrevious cDMARD use at the tim e of rando mizat ion (past use, current 
use) for the rando mized withdrawal ITT populat ion
oMethotrexate use at the time of randomizat ion (none, past use, current 
use) for the rando mized withdrawal ITT populat ion
Addit ional subgroup analyses on efficacy may  beperform ed as deemed appropriate and 
necessary .
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 84
LY24398216.14.2. Safety Subgroup Analysis
Subgroup analyses will be conducted for common TEAEs and AESIs of allergy/hypersensit ivity, 
infect ions, and inject ion site reactions for the init ial open -label treatm ent peri od popul ation 
during Peri od 2 and the randomized withdrawal safet y popul ation during Period 3.
The m ost comm on TEAEs and AESIs will be presented by  MedDRA PT nested wi thin SOC 
(SMQ or Hi gh Level Term where specifie d in Secti on 6.13. 7).  A logist ic regressio n model will 
be used to test the treatment group -
by-subgroup interaction for the rando mized withdrawal s afety 
popul ation.  The model will include explanatory  variables o f treatm ent group, subgroup, and 
treatm ent group by -subgroup interaction.  The interaction test will be evaluated at the 0.10 
significance level.  If any  group wi thin the subgroup (for exampl e, yes, no) i s <10% of the total 
popul ation, only  descriptive statist ics will be provided for that subgroup (that is, no inferent ial 
testing).  Treatment group differences will be evaluated within each category of the subgroup, 
regardl ess of whether the in teracti on is stati stically significant.  Treatment differences will be 
assessed wit hin the subgroups using the Fisher’s exact test.
Subgroups to be evaluated include: 
Dem ographic subgroups:
oAge group:  <65 y ears, ≥65 years to <75 years, ≥75 years
oAge grou p:  <40 y ears, ≥40 years 
oGender (male, female)
oRace:  AI, AS, BL, NH, WH, MU
oEthnicit y:  Hispanic or Latino, Not Hispanic or Latino
oWeight category :  <100 kg, ≥100 kg
oWeight category :  <80 kg, ≥80 kg to <100 kg, ≥100 kg
oBody  mass index category:  underwei ght (<18.5 kg/m 2); norm al (≥18.5 
and <25 kg/m 2); overweight ( ≥25 to <30 kg/m 2); obese ( ≥30 to 40 kg/m 2); 
extrem e obese ( ≥40 kg/m 2)
Geographic region subgroups:
oGeographic region at baseline for the init ial open -label treatm ent peri od 
popul ation:  Europe, U S, Rest of the World
Psori atic arthritis therapy  subgroups:
oPrevious cDMARD use at the time o f rando mizat ion (past use, current 
use) for the rando mized withdrawal safet y popul ation
oMethotrexate use at the time of randomizat ion (none, past use, current use)
for the randomized wit hdrawal safet y popul ation.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 85
LY24398216.15. Anal ysis for Australian Submission
Efficacy analysis may be conducted if needed to meet the Pharmaceut ical Benefi ts Advisory  
Commissio n (PBAC) criteria for a regulatory  submissi on or request.  The time -to relapse and 
proporti on of  patients with relapse will be analyzed using a PBAC randomized withdrawal ITT 
popul ation for Peri od 3.  Data will be analyzed using the analysis methods defined in Sect ion 
6.1.2.1 for the time -to analysis and categorical analyses.  
The PBAC rando mized wit hdrawal ITT populat ion is a subset of the randomized wit hdrawal 
popul ation and i s defined as all randomized patient s in Peri od 3 wi th:
1.An elevated CRP >15 mg/L 
2.An act ive joint count of at least 20 active (swollen and tender) jo ints or at least 4majo r 
active jo ints:  elbow, wri st, knee, ankle, shoulder and/or hip 
3.Psori atic arthritis that has not responded to adequate trials o f at least 2 cDMARDs, 
administered either individually  or in combinat ion for a minimum o f 3 months  
6.16. Anal ysis for United Kingdom National Institute for Health and 
Care Excellence Submission
Efficacy analysis will be conducted to meet the UK’s Nat ional Inst itute for Heal th and Care 
Excellence (NICE) criteria.  The time -to rel apse and proporti on of  patients wi th relapse will be 
analyzed using a NICE randomized withdrawal ITT populat ion for Peri od 3.  Data will be 
analyzed using the analysis methods defined in Section 6.1.2.1 for the time -to analysis and 
categori cal analyses.  
The NICE rando mized wit hdrawal ITT populat ion is a subset of the randomized withdrawal 
popul ation and i s defined as all randomized patients in Period 3 with:
1.Peripheral  arthri tis with ≥3 tender j oints and ≥3 swollen jo ints
2.Psori atic arthritis that has not responded to a dequate trials o f at least 2 cDMARDs, 
administered either individually  or in combinat ion.  
6.17. Protocol Deviations
Protocol  deviat ionswill be ident ified throughout the study.  Important protocol deviat ionsare 
defined as those deviat ionsfrom the protocol  likely to have a significant impact on the 
completeness, accuracy , and/or reliabili ty of the study  data or that m ay significantly affect a 
subject’s rights, safety , or well -being.  All important protocol deviat ions identified are reviewed 
by the study  team  prior to database l ock.
Table RHBF. 6.8includes the categories and subcategories of important protocol deviat ions, the 
source of ident ificat ion for the deviat ion, and the statist ical programming gui dance for the CSR.  
A by
-patient listing of important protocol deviations will be provided for all entered patients.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 86
LY2439821The number and percentage of patients having important protocol deviat ion(s) will be 
summari zed wi thin category  and subcategory  of deviat ions by treatm ent group for:
Period 2 (init ial open -label treatm ent peri od populati on)
Period 3 (random ized wit hdrawal ITT populat ion).
In addit ion, other protocol deviat ions considered important for reporting p urposes derived from 
manual review of study  records as recorded via mo nitoring reports or other site compliance 
monitoring will be summarized.  These may include  
Ethics review board (ERB) approval not obtained
Follicle -stimulating horm one (FSH) not asses sed
Good Clinical Pract ice guidelines not fo llowed by principal investigator (PI)
Hepati tis monitoring not done
Improper consent/re -consent (not timely, wrong version, not signed)
Physical examinat ion not performed
Postbaseline pregnancy  test not performed
Quick Inventory  of Depressive Symptom atology not assessed
Serious adverse events not reported on time
Tuberculosis test collected late
Tuberculosis test not performed
Temperature excursion at site
Unqualified study  personnel performing procedures
One hour post-dose vitals not performed at Visit 2
Assessment not performed by  Independent Assessor
Unauthori zed use of electronic patient reported outcomes (ePRO) device 
credent ials
Vital signs not performed.
This list is not conclusive and addit ional other impor tant protocol deviat ions may be identified.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 87
LY2439821Table RHBF. 6.8. Identification and A ction of Important Protocol Deviations
Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
Patient did not give written consent
Informed consent form must be signed before any
protocol procedures begin (Proper order of 
informed consent signature, randomization, and 
therapy  start dates).Monitor and Stats Either from monitor’s list, or,
If patient informed consent date is after Visit 1 dateYes
Failed to meet study inclusion criteria but was enrolled into the study
[1] Age <18 years Monitor and Stats From monitor’s list.  Stats may program preliminarily based on 
data for age <18 at Visit 1, but deviation must be confirmed 
and sourced by monitor.  This is because only birth year is 
collected, and age is calculated by imputation.Yes
[1a]Male patients did not use a reliable method 
of birth controlMonitor From monitor’s list.  Yes
[1b] Lack of confirmation of non -pregnant status 
prior to randomization at visit 2   Monitor From monitor’s list.Yes
[2] No confirmed diagnosis of PsA of at least 6 
months prior to baseline or did not meet 
CASPAR criteriaMonitor and Stats Review monitor’s list.
Check time since PsA diagnosis and CASPAR criteria.Yes
[3] <3 tender or <3 swollen joints at  Visit 1 or 
Visit 2Monitor and Stats Review monitor’s list.
Check if TJC68 <3 or SJC66 <3 either at Visit 1 or at Visit 2Yes
[4] Never been treated with a cDMARD or has 
been treated with a cDMARD and no 
documentation of inadequate resp onse with a 
minimum of 12 weeks or intoleranceMonitor From monitor’s list . Yes
[5] No active or history of plaque psoriasis Monitor and Stats Review monitor’s list .
Check if the answer to current Psoriasis is No AND patient 
contains no record in medical history where:
1.(the reported term for medical history = “PSORIASIS 
DISEASE” and category for medical history = 
“PRIMARY DIAGNOSIS”) or
2.(the dictionary derived term = “PSORIASIS” and 
category for medical history  = “PRE -EXISTING Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 88
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
CONDITION”) or
3.(repo rted term for medical history =“PLAQUE 
PSORIASIS” and category for medical history = 
“PRE -EXISTING CONDITION”)]
Met study exclusion criteria but was enrolled into the study
[7] Prio r or current use of bDMARDs or biologics Monitor Monitor’s list Yes
[8] Previous or current medication exposure at 
Visit 1 to LY2439821 or IL -17 antagonists or 
previous participation in the current study.
(Note: See protocol for patients who may be 
allow ed to re -screen.)Monitor Monitor’s list Yes
[9] Have history of dru g-induced Ps Monitor Monitor’s list Yes
[10] Inadequate response to ≥4 cDMARDs 
prescribed alone or in combination for 3 monthsMonitor and Stats Either from monitor’s list, or,
If a patient used for least 90 days any 4 or more of the 
following previous therapies category or non-biologic systemic 
agent subcategory:
MTX, Leflunomide, Azathioprine, Cyclosporine, 
Hydroxychloroquine, Gold Salts, SulfasalazineYes
[11] & [12] Use of cDMARDs within the 
washout periods or using >1 at entry into the 
study, or us ing DMARDs at doses outside of 
specified rangeMonitor Monitor’s list Yes
[13] Have discontinued leflunomide within 4 
weeks prior to baseline or from 4 to 12 weeks 
prior without drug elimination procedureMonitor and Stats Monitor’s list, or,
If the diffe rence between Visit 2 date and medication end date 
<28 day s for previous therapy, LeflunomideYes
[14] Use of oral corticosteroids >10 mg/day of 
prednisone or equivalent, use of variable doses 
within 4 weeks prior to baselineMonitor Monitor’s list Yes
[15] Have received parenteral glucocorticoids 
within 6 weeks prior to baseline or if use is 
anticipated during  initial open -label treatment 
period (Period 2) of the studyMonitor and Stats Monitor’s list, or,
If a patient has a reported previous therapy of parenteral 
glucocorticoids with and end date <42 days prior to the Visit 2 
dateYes
[16] Concomitant use of NSAIDs or Monitor Monitor’s list Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 89
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
cyclooxygenase -2 inhibitors unless on a stable 
dose for at least 2 weeks prior to baseline
[17] Use of opi ate analgesics >30 mg/day of 
morphine or equivalent or variable doses within 6 
weeks prior to baselineMonitor and Status Monitor’s list, or,
If a patient has either a reported previous therapy of opiate 
analgesics or a concomitant medication with ATC code s of 
N02AA with a start or end date of <42 days prior to Visit 2 
date.Yes
[18] Received systemic non -biologic psoriasis 
therapy  (including, but not limited to, oral 
psoralens and ultraviolet A [PUVA] light therapy; 
cyclosporine; corticosteroids; MTX; oral 
retinoids; mycophenolate mofetil; thioguanine; 
hydroxy urea; sirolimus; azathioprine; fumaric 
acid derivatives; or 1, 25 dihydroxy  vitamin D3 
and analogues) or phototherapy (including either 
oral and topical PUVA light therapy, ultraviolet B 
[UVB] or s elf-treatment with tanning beds or 
therapeutic sunbathing) within 4 weeks prior to 
baseline (Visit 2).
or had topical psoriasis treatment (including, but 
not limited to, corticosteroids, anthralin, 
calcipotriene, topical vitamin D derivatives, 
retinoids, t azarotene, emollients and other non -
prescription topical products containing urea, 
>3% salicylic acid, or alpha -or beta -hydroxy l 
acids, and medicated shampoos [for example 
those that contain >3% salicylic acid, 
corticosteroids, coal tar, or vitamin D3 
analogues]) within the previous 2 weeks prior to 
baseline (Week 0; Visit 2).  Note WHO Group 
1weak potency (such as hydrocortisone) topical 
TRT are allowed.Monitor and Stats Monitor’s list, or,
If the patient has any record with an end date ≤28 days of the 
Visit 2 date for Phototherapy for previous therapy
If the patient has any concomitant medications with an end 
date that is on or prior to Visit 2 date, and ≤28 days prior to the 
Visit 2 date for oral medications with the following ATC 
codes: D05B, D05BA, D0 5BB, D05BX).
If the patient has any concomitant medications with an end 
date that is on or prior to Visit 2 date, and ≤14 days prior to the 
Visit 2 date for topical medications with the following ATC 
codes: D07AC, D07AD, D07BC, D07BD, D07CC, D07CD, 
D07XC, D07XD, A11CC, D05AA, D05AC, D05AD, D05AX, 
D05BB, L04AD, D11AC, D07AB, D02AF, D02BB.Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 90
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
[19] Use of tanning beds/booths for at least 4 
weeks (or 28 days) prior to Visit 2 for patients 
with plaque psoriasis.Monitor Monitor’s list Yes
[20] Have a known allergy  or hy persensitivity to 
any biologic therapy  that would pose an 
unacceptable risk to the patient if participating in 
this study.Monitor Monitor’s list Yes
[21] Ever received natalizumab or other agents 
that target alpha -4-integrinMonitor Monitor’ s list Yes
[22] Have been exposed to a live vaccine within 
12 weeks prior to Visit 2 or intend to have a live 
vaccination during the course of the study, or 
participated in a BCG (12 months prior to 
baseline) orother vaccine clinical study within 
12 weeks prior to Visit 2Monitor Monitor’s list Yes
[23] Had a BCG (12 months prior to baseline), or 
intent to have this vaccine during the study or 
within 12 months of completion of the studyMonitor Monitor’s list Yes
[24] Have diagnosis of other inflammatory 
arthritic syndromeMonitor Monitor’s list Yes
[25 ] Have active Crohn's disease or active 
ulcerative colitisMonitor Monitor’s list Yes
[26] Have current diagnosis of  fibromyalgia Monitor Monitor’s list Yes
[27] Have  a chronic pain condition what would 
confound evaluation of the patientMonitor Monitor’s list Yes
[28] Evidence of active vasculitis or uveitis Monitor Monitor’s list Yes
[29] Surgical treatment of joint within 8 weeks 
prior to baseline or wi ll require such up to Week 
24Monitor Monitor’s list Yes
[30] Had any major surgery within 8 weeks prior 
to baseline (Week 0; Visit 2), or will require such 
during the study that, in the opinion of the Monitor Monitor’s list Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 91
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
investigator in consultation with Lilly or its 
designee, would pose an unacceptable risk to the 
patient.
[31] Have current or a history of 
lymphoproliferative diseaseMonitor Monitor’s list Yes
[32] Have active or history of malignant disease 
within the 5 years prior to bas eline (Visit 2).  
Patients with successfully treated basal -cell 
carcinoma [no more than 3], squamous -cell 
carcinoma of the skin (no more than 2), within the 
5 years prior to Visit 2 may participate in the 
study.Monitor Monitor’s list Yes
[33] Presence of significant uncontrolled cerebro -
cardiovascular (for example, MI, unstable angina, 
unstable arterial hypertension, moderate -to-severe 
NYHA class III/IV heart failure, or 
cerebrovascular accident [CVA]), respiratory, 
hepatic, renal, gastrointestinal, endoc rine, 
hematologic, neurologic or neuropsychiatric 
disorders, or abnormal laboratory values at 
screening that, in the opinion of the investigator, 
pose an unacceptable risk to the patient if 
participating in the study or of interfering with the 
interpretati on of data.Monitor Monitor’s list Yes
[34] Have had fluid overload, MI, or new -onset 
ischemic heart disease, uncompensated heart 
failure, o r in the opinion of the investigator other 
serious cardiac disease within 12 weeks prior to 
Visit 2.Monitor Monitor’s list Yes
[35] Have history of a suicide attempt, have a 
score of 3 on Item 12 (Thoughts of Death or 
Suicide) of the QIDS -SR16 at screening (Visit 1) Monitor and Stats Monitor’s list, or,
If a patient has a score of 3 for the ‘thoughts of death or 
suicide’ on the QIDS -SR16 at Visits 1 or 2.Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 92
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
or baseline (Week 0; Visit 2), or are clinically 
judged by the investigator to be at risk for su icide.
[36] Have serious infection (for example, 
pneumonia, cellulitis), been hospitalized, received 
IV antib iotics for an infection within 12 weeks of 
Visit 2, or had a serious bone or joint infection 
within 24 weeks prior to baseline, or have ever 
had an infection of an artificial joint, or are 
immunocompromised to an extent such that 
participation in the study would pose an 
unacceptable risk to the patient.Monitor Monitor’s list Yes
[37] have or had an opportunistic infection 
characteristic of an immunocompromised host 
and/o r that occurs with increased incidence in an 
immunocompromised host (including but not
limited to Pneumocystis jirovecii pneumonia, 
histoplasmosis, coccidioidomycosis, or 
cryptococcosis) or have a known 
immunodeficiencyMonitor Monitor’s list Yes
[38] have or had a herpes zoster or any other 
clinically apparent varicella -zoster virus infection 
within 12 weeks of baseline (Week 0, Visit 2)Monitor Monitor’s list Yes
[39] Evidence or suspicion of active or latent TB 
(refer to Protocol Section 10.3.2.2 f or details o n 
determining full TB exclusion criteria).Monitor Monitor’s list Yes
[40] within 4 weeks of baseline (Week 0, Visit 2), 
have any active or recent infection other than 
those mentioned in exclusion criteria 36 -39 that, 
in the opinion of the inv estigator, would pose an 
unacceptable risk to the patient if participating in 
the study ; these patients may be rescreened once 
≥4 weeks after documented resolution of Monitor Monitor Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 93
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
symptoms
[41] Body temperature ≥38 degrees Celsius 
(100.5°F) at Visit 2 or at rescreen (1 time) 
≥4weeks after documented resolution of elevated 
temperatureMonitor and Stats Monitor’s list, or,
If a patient’s temperature is ≥38 digress Celsius at Visit 2Yes
Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
[42] Have uncontrolled arterial hypertension 
characterized by a systolic blood pressure (BP) 
>160 mm Hg or diastolic BP >100 mm Hg.  
Determined by 2 consecutive elevated readingsMonitor and Stats Monitor’s list, or,
If a patients SBP >160 or DBP >100 mmHg at Visit 1Yes
[43] Are positive for human immunodeficiency 
virus (HIV) serology (positive for HIV antibody)Monitor and Stats Monitor’s list, or,
If a patients laboratory tests at Visit 1 indicate they are positive 
for HIV antibodyYes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 94
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
[44] Have evidence of or test positive for hepatitis 
B by any of the following criteria:  
1) positive for hepatitis B surface antigen 
(HBsAg+); 
2) positive fo r anti -hepatitis B core antibody 
(HBcAb+) and negative for anti -hepatitis B 
surface antibody (HBsAb –); 
3) positive for anti -hepatitis B core antibody 
(HBcAb+) and positive for anti -hepatitis B 
surface antibody (HBsAb+) with a concentration 
of HBsAb < 200 mIU/mL; or 
4) HBcAb+, HBsAb+ (regardless of HBsAb 
level), and positive for serum hepatitis B virus 
(HBV) DNA.
(Note: Patients who are negative for hepatitis B 
surface antigen (HBsAg -
), HBcAb+, HBsAb+ 
with a concentration of HBsAb >200 mIU/mL, 
and negative for serum HBV DNA may 
participate in the study.  Patients who meet these 
criteria at screening will be identified by the 
central laboratory and monitored during the 
study as detailed in Section 10.3.3.3 of the RHBF 
protocol).Monitor and Stats Mon itor’s list, or,
If a patients laboratory tests at Visit 1 indicate they are positive 
for hepatitis BYes
[45] Have evidence of or test positive for hepatitis 
C virus (HCV).  A positive test for HCV is 
defined as:  
1) positive for hepatitis C antibody (a nti-HCV 
Ab), and 
2) positive via a confirmatory test for HCV (for 
example, HCV polymerase chain reaction).Monitor and Stats Monitor’s list, or,
If a patient’s laboratory tests at Visit 1 indicate they are 
positive for hepatitis C virusYes
[46] Have cli nical laboratory test results at 
screening that are outside the normal reference 
range for the population and are considered 
clinically significant, and/or have any of the 
following specific abnormalities:Monitor and Stats Monitor’s list, or,
If a patients laboratory tests at Visit 1 indicate any of the 
following:
1.Neutrophil count <1500 cells/µL
2.Lymphocy te count <800 cells/ µLYes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 95
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
[46a] Neutrophil count <1500 cells/μL
[46b]Lymphocyte count <800 cells/μL
[46c] Platelet count <100,000 cells/μL
[46d]Aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >2.5 times the upper 
limit of normal (ULN)
[46e] Total white blood cell (WBC) count <3000 
cells/μL
[46f] Hemo globin <8.5 g/dL (85.0 g/L) for male 
patients and <8.0 g/dL (80 g/L) for female 
patients
[46g]Serum creatinine >2.0 mg/dL.3.Platelet count <100,000 cells/ µL
4.AST or ALT >2.5 times the ULN
5.Total WBC <3000 cells/ µL
6.Hemoglobin <8.5 g/dL for male patients and <8 g/dL for 
female patients
7.Serum creatinine >2 mg/dL
[47] Have electrocardiogram (ECG) 
abnormalities that are considered clinically 
significant and would pose an unacceptable risk 
to the patient if participating in the studyMonitor Monitor’s list Yes
[48] Have any other condition that precludes the 
patient from foll owing and completing the 
protocol.Monitor Monitor’s list Yes
[49] have donated blood of more than 1 unit 
(approximately 500 mL) within the last 4 weeks 
or intend to donate blood during the course of the 
studyMonitor Monitor’s list Yes
[50] Are women who are lactating or 
breastfeedingMonitor Monitor’s list Yes
[51] are investigator site personnel directly 
affiliated with this study and/or their immediate 
families.  Immediate family is defined as a 
spouse, parent, child, or sibling, whether
biological or legally adopted.Monitor Monitor’s list Yes
[52] are employees of Lilly or its designee or are 
employees of third-party organizations (TPOs) Monitor Monitor’s list Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 96
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
involved in the study
[53] are currently enrolled in a clinical trial 
involving an investigational product or 
nonapproved use of a drug or device (other than 
the investigational product used in this study) or 
concurrently enrolled in any other type of medical 
research judged not to be scientifically or 
medically compatible w ith this studyMonitor Monitor’s list Yes
[54] have been discontinued from a clinical trial 
involving an investigational product or 
nonapproved use of a drug or device within the 
last 4 weeks or a period of at least 5 half -lives of 
the last administration of the drug, whichever is 
longerMonitor Monitor’s list Yes
Met study discontinuation criteria but continued to receive study medication
[D1] Neutrophil (segmented) counts:
<500 cells/µL; or  ≥500 and <1000 cells/µL (from 
2 test results; the second test must be performed 
within 1 week from knowledge of the initial 
result); or ≥1000 and <1500 cells/µL (from 3 test 
results) and an infection that is not fully resolvedMonitor and Stats Monitor’s list, or,
Ifapatient still receives study treatment afte r 10 day s with 
confirmed segmented neutrophil counts <500 cells/µL;  ≥500 
and <1000 cells/µL (from a test and a re -test result; the re -test 
must be performed within 1 week from knowledge of the 
initial result); or ≥1000 and <1500 cells/µL (from a test and 2 
re-test results) and an infection that is not fully resolved
If there are missing re -test results, use the non -missing resultsYes
[D2] Total WBC count <2000 cells/µL Monitor and Stats Monitor’s list, or,
Ifapatient still receives study treatment afte r 10 day s with 
confirmed total WBC count <2000 cells/µL (defined as a test 
and a retest within 10 days); 
If no retest, use the test resultsYes
[D3] Lymphocyte count <500 cells/μL Monitor and Stats Monitor’s list, or,
Ifapatient still receives study treatment after 10 days with 
confirmed lymphocy te count <500 cells/μL (defined as a test 
and a retest within 10 days )Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 97
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
If no retest, use the test results
[D4] Platelet count <50,000 cells/μL Monitor and Stats Monitor’s li st, or,
Ifapatient still receives study treatment after 10 days with 
confirmed platelet count <50,000 cells/μL (defined as a test 
and a re -test within 10 days )
If no retest, use the test resultsYes
[D5] Patient has a clinically significant systemic 
hypersensitivity reaction after subcutaneous (SC) 
administration of investigational productMonitor Monitor’s list Yes
[D6] Patient becomes pregnant Monitor Monitor’s list Yes
[D7] The patient develops a malignancy.  (No 
more than 2 nonmelanoma skin cancers over any 
12-month period during the study.)Monitor Monitor’s list Yes
[D8] The result of the TB test is positive at Week 
52 (Visit 16) or later AND the patient is 
diagnosed with active infectionMonitor Monitor’s list Yes
[D9] Patient develops s ymptoms suggestive of a 
lupus -like syndrome or is positive for antibodies 
against double -stranded DNAMonitor Monitor’s list Yes
[D10] If the patient for any reason requires 
treatment with another therapeutic agent that has 
been demonstrated to be effective for the 
treatment of PsA or psoriasis before the post -
treatment follow -up period.Monitor Monitor’s list Yes
[D11] Enrollment in any other clinical trial 
involving an investigational product or enrollment 
in any  other ty pe of medical research judged not 
to be scientifically or medically compatible with 
this studyMonitor Monitor’s list Yes
[D12] The patient scores a 3 for Item 12 
(Thoughts of Death or Suicide) on the QIDS -
SR16 at any time in the study.  Monitor and Stats Monitor’s list, or,
If patient still receives study treatment on the same day or after 
the date with a score of 3 for Item 12 on the QIDS -SR16Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 98
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
[D13] Failure to demonstrate at least a 20% 
improvement from baseline in both TJC and SJC 
at Week 24 or at any subsequent visit thr ough 
Week 104 except from the point of randomization 
until the visit after relapse for those patients who 
are randomized in Period 3Monitor and Stats Monitor’s list, or,
If a patients has <20% improvement from baseline in both TJC 
and SJC at either Week 24 or any  other subsequent visit 
through Week 104, with the exception of randomization 
through the following visit after relapse for those patients who 
are randomized.Yes
[D14] Lilly or its designee stops the patient’s 
participation in the study or Lilly stops the study 
for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and 
GCPMonitor Monitor’s list Yes
[D15] The patient becomes HBV DNA positive. Monitor Monitor’s list Yes
Missing Data /Assessments not Done
MDA missing due to missing values of MDA 
components at baseline or any visit.Stats If missing any individual component of MDA at baseline or 
any visit from Weeks 24 through 104.No
Missing ECG: missing baseline Monitor Monitor listing No
Missing C -SSRS while on study medication Monitor If missing C-SSRS at any Visit From Week 2 through Week 
104 after Amendment A implemented at siteNo
Patient was inadvertently randomized.   Due to 
a discrepancy in recorded ePRO data versus the 
IWRS data for meeting Coate s Criteria for MDA.Monitor Monitor listing Yes
Patient started on ixekizumab 80 mg Q2W 
after randomization to placebo and prior to 
experiencing a relapse (no longer meeting 
Coates criteria for MDA in Period 3 ).Monitor and Stats Monitor listing, or, programming for exposure to ixekizumab 
80 mg Q2W after randomization and exposure to placebo in 
period 3 and prior to relapse.Yes
Patient took incorrect medication Monitor and Stats Monitor’s list, or,
If patient randomized and expos ure data shows the patient took 
incorrect study medicationNo
Patient did not take any study medication Monitor and Stats Monitor’s list, or,
If patient randomized and exposure data shows the patient took 
no study  medicationYes
Patient non -compliant wit h study medication Monitor and Stats Monitor’s list, or, Yes
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 99
LY2439821Important Protocol Deviation
Category/SubcategorySource to Identify Protocol 
DeviationStatistical Programming Guidance for Clinical Study 
ReportExclude 
from the 
PPS?
regimen.   Patient missing 2 consecutive doses or 
take 2 doses of study medication on the same day 
(i.e. double -dosing) are considered to be non -
compliant .Study drug exposure is reported as missing more than 20% of 
expected doses for a study period or is missing 2 consecutive 
doses.
Patient took prohibited concomitant 
medicationMonitor and Stats Monitor’s list, or,
If patient takes prohibited concomitant medication.
(Note:  Prohibited concomita nt medication will be provided by 
medical in a separate file.)Yes
Unblinding is considered unjustified if the 
unblinding occurred on a patient where the 
patient’s wellbeing was not dependent upon 
knowing their treatment assignment.Monitor Monitor’s list Yes
Abbreviations:  ATC = anatomical therapeutic chemical; BCG = Bacille de Calmette et Guérin; bDMARD = biologic disease -modifying antirheumatic drug; 
bHCG = beta human chorionic gonadotropin; ; CASPAR = classification for psoriatic arthritis; cDMARD = conventional disease -modifying antirheumatic 
drug; DBP = diastolic blood pressure; ePRO = electro nic patient reported outcomes; GCP = good clinical practice; IV = intravenous; IWRS = interactive web -
response system; MDA = minimal disease activity; MI = myocardial infarction; MTX = methotrexate; NSAID = nonsteroidal anti -inflammatory drug; NYHA 
= New Y ork Heart Association; PPS = per protocol set; PsA = psoriatic arthritis; QIDS -SR16 = quick inventory of depressive symptomatology –self-report 16 
items; SBP = systolic blood pressure; SJC = swollen joint count; TB = tuberculosis; TJC = tender joint count; WHO = World Health Organization.
The term “Monitor” indicates the protocol deviation will be identified by site monitors and entered into monitor’s list using a spreadsheet.  The spreadsheet will 
be exported as Study Data Tabulation Model (SDTM) DV domain.
The term “Stats” indicates the protocol deviatio nwill be programmed based on data in clinical database by statistical programmers with the statistical 
programming guidance provided as the last column.  The detailed programming specification will be docum ented in Analysis Data Model (ADaM) 
specification.
The terms “Monitor and Stats” indicates the protocol deviation will be a combination of monitor’s list (SDTM.DV domain) and s tatistical programming from 
clinical database, the deviation will show if either source identifies.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 100
LY24398216.18. Interim Analyses and Data Monitoring 
The study  will have approximately  2 interim and 1 final database locks.  The first interim 
database lock may occur onc e all pat ients com plete or di scont inue in the open -label treatment 
period the visit of rando mization or Week 64 for patients who do not meet the randomization 
criteria); only data fro m the open -label treatment period will be summarized.  The second interim
database lock may occur when all patients complete Week 104 or discont inue study  treatm ent 
prior to the end of the rando mized double -blind withdrawal period.  The final database lock will 
occur when all pat ients com plete or di scont inue the study.  The sec ond interim lock and final 
database lock may be combined depending upon the timing of last patient visit.  Addit ional 
analyses and snapshots of study  data m ay be perform ed to fulfill the need for regulatory  
interact ion or publication purposes
Inform ation that may unblind the study during the analyses will not be reported to study  sites or 
the blinded study  team  until the study  has been unblinded.  All invest igators and patients will 
remain blinded to treatment assignments unt il the last patient completes th e randomized double -
blind withdrawal period and the final database lock occurs.
6.19. Planned Exploratory Analyses
6.19.1. Planned Exploratory Efficacy Analysis
Table RHBF. 6.9includes the descript ion and derivation of the exploratory  outcom es.
Table RHBF. 6.10 provides the detailed analyses including analysis t ype, method and imputation, 
popul ation, time point, and comparisons for exploratory
 analyses.
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 101
LY2439821Table RHBF. 6.9. Description and Derivation of Additional Exploratory Outcomes
Measure Description Variable Derivation / CommentImputation Approach if 
with Missing 
Components
Physician’s 
Global 
Assessment of 
Disease 
Activity  Visual 
Analog Scale
(VAS)Physician Global VAS:  overall 
assessment of the severity of the patient’s 
current PsA activity using a 100 -mm 
horizo ntal VAS.  The investigator making 
the assessment must be a rheumatologist 
or medically qualified physician.Change f rom baseline in
Physician Global VAS
Percent improvement in 
Physician Global VASRange: 0 to 100 mm
0 represents no disease activity
100 represents extremely active 
disease activitysingle measure, missing if 
missing
missing if baseline or 
observed value are missing
Leeds 
Enthesitis 
Index (LEI)LEI:  For patients with enthesitis, an 
assessment that consists of 18 entheseal 
points is performed by site personnel.  
The LEI has been developed specifically 
for use in PsA and measures enthesitis at 
6 sites (lateral epicondyl e [left and right], 
medial femoral condyle [left and right], 
and Achilles tendon insertion [left and 
right] ) (Healy and Helliwell 2008).  Change f rom baseline in LEI
Percent Improvement in LEIEach site is assigned a score of 
0 (absent) or 1 (present ); the 
results from each site are then 
added to produce a total score 
(range:  0 to 6).if one or more sites are 
missing, then set to 
missing
missing if baseline or 
observed value are missing
Proportio n of patients with 
resolution in enthesitis (LEI 
score = 0)For patients with baseline 
enthesitis (LEI ≥1), number of 
patients LEI score of 0if one or more sites are 
missing, then set to 
missing
missing if baseline or 
observed value are missing
Leeds 
Dactylitis 
Index -Basic 
(LDI -B)LDI-B:  measure of severity of dactylitis 
for patients with dactylitis.  Each dactylic 
digit is defined by a minimum increase of 
10% in circumference over the 
contralateral digit.  If the same digits on 
both hands or feet are thought to be 
involved, the cl inician will refer to a table 
of normative values (provided to 
investigative sites) for a value that will be 
used to provide the comparison.  Change f rom baseline in LDI -B
Percent improvement in LDI -BOnce the presence of dactylitis 
is established in eac h digit, the 
ratio of the circumference of the 
affected digit to the 
circumference of the same digit 
on the patient’s other hand or 
foot is measured (Helliwell et 
al. 2005).  If the circumference 
of the affected digit ratio is 10% 
greater than the contra d igit, the 
calculated ratio is  minus 1 and 
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 102
LY2439821Measure Description Variable Derivation / CommentImputation Approach if 
with Missing 
Components
then multiplied 100 and then 
multiplied by a tenderness score 
of 0 (not tender) or 1 (tender).  
Tenderness is assessed in the 
area between the joints.  The 
results of each digit are then 
added to produce a total s core 
(Healy and Helliwell 2007).
Proportio n of patients with 
resolution of dactylitis (LDI -B 
score =0)For patients with baseline 
dacty litis (LDI -B score >0), 
number of patients with 
resolution of dactylitis (LDI -B 
score = 0)NA
Spondyloarthri
tis Research 
Consortium of 
Canada 
(SPARCC)SPARCC:  For patients with enthesitis, an 
assessment that consists of 18 entheseal 
points is performed by site personnel.  
From this assessment the SPARCC index 
evaluates tenderness in a total of 16 
enthesitis sites: the greater trochanter 
(right and left), quadriceps tendon 
insertion into the patella (right and left), 
patellar ligament insertion into the patella 
and tibial tuberosity (right and left), 
Achilles tendon insertion (right and left), 
plantar fascia inserti on (right and left), 
medial epicondyles (right and left), lateral 
epicondy les (right and left), and the 
supraspinatus insertion (right and left) 
(Mease 2011).  Change f rom baseline in 
SPARCC
Percent improvement in 
SPARCC
Proportio n of patients with 
resolution of enthesitis 
(SPARCC >0)Tenderness at each site is 
quantified on a dichotomous 
basis:  0 = nontender and 1 = 
tender.  The results from each 
site are then added to produce a 
total score (range, 0 to 16).if one or more sites are 
missing, then s et to 
missing.  
missing if baseline or 
observed value are missing
Disease 
Activity  Score DAS28 -CRP:  is a measure of disease 
activity  in 28 joints that consists of a Change f rom baseline in 
DAS28 -CRPThe following equation will be 
used to calculate the DAS28-if one or more component 
are missing, then set to 
I1F-MC-RHBF Statistical Analysis Plan Version 3  Page 103 
LY2439821 Measure Description Variable Derivation / Comment Imputation Approach if 
with Missing 
Components 
(28 diathrodial 
joint count) based on C-reactive 
protein 
(DAS28-CRP) composite numerical score using the following measures: TJC, SJC, C-reactive protein (mg/L), and patient’s global assessment of disease activity recorded by 
patients in a 100-mm VAS. 
The 28 joints to be examined and assessed as tender or not tender and as swollen or not swollen are a subset of those assessed for the TJC and SJC and include 14 joints on each side of the 
patient’s body:  the 2 shoulders, the 2 
elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees (Smolen et al. 1995).    Percent improvement in DAS-CRP CRP (Vander Cruyssen et al. 2005) See Appendix 3  for further 
details on calculating joint 
counts. 
Sum of the following: 
1. 
28 56 . 0TJC 
2. 28 28 . 0SJC  
3.   1 ln 36 . 0 CRP 
4.   balVAS PatientGlo 014 . 0  
5. 96 . 0 
Higher DAS28-CRP scores indicate more severe symptoms and greater functional impairment. missing.   
 
missing if baseline or 
observed value are missing 
Psoriatic 
Arthritis Disease 
Activity Score 
(PASDAS) PASDAS is a weighted index comprising assessments of joints, function, acute phase response, quality of life, and patient 
and physician global assessment of 
disease by VAS (0 mm to 10 mm).   The TJC is 68 joints, the SJC is 66 joints.  Worse disease activity is represented by higher scores (Helliwell et al. 2013). PASDAS Sum the following: 
1. 
  lobalVAS PhysicianG 18 . 0  
2.   balVAS PatientGlo 159 . 0  
3.  PCS 253 . 0  
4. 1 ln * 101 . 0SJC  
5. 1 ln * 048 . 0TJC  
6.  1 ln * 23 . 0LEI  
7.  1 ln * 377 . 0 TDC  
8.   2 1 ln * 102 . 0 CRP  
Then multiply by 1.5 if one or more components 
are missing, then set to 
missing.   
Composite 
Psoriatic Disease Activity Index CPDAI is a validated instrument to assess composite psoriatic disease activity and response to therapy (Mumtaz et al. 2011).  This instrument assesses individual Change from baseline in CPDAI  Percent improvement in CPDAI Each domain is scored from 0–3.  Individual domain scores are summed to give  an overall 
composite score (range 0–12).  if one or more domains are 
missing, then set to missing.   
 
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 104
LY2439821Measure Description Variable Derivation / CommentImputation Approach if 
with Missing 
Components
(CPDAI) domains:
peripheral arthritis as assessed by the 
number of tender and swollen joints 
and the HAQ -DI, 
skin as assessed by the PASI and the 
DLQI, 
enthesitis as assessed by the number 
of sites with enthesitis and the HAQ -
DI, and 
dacty litis as assessed by the number 
of digits affected and the HAQ -DI. 
A modified version that does not include 
the axial domain is being used in this 
study.  Scores range from 0 to 12; a 
higher score indicates higher disease 
activity .The composit e scores range 
from 0 to 12 for assessment 
excluding spinal disease, with a 
higher score indicating higher 
disease activity.
See Appendix 10 for further 
details.missing if baseline or 
observed value are missing
Psoriasis Area 
and Severity 
Index (PASI)PASI improvement from baseline PASI 75 Flag
PASI 90 Flag
PASI 100 FlagDefined as at least a 75%, 90%, 
or 100% improvement from 
baseline in PASI score
See Table RHBF. 6.3for details 
on the calculation of PASISingle item, missing if 
missing
Psoriatic 
Arthritis 
Response 
Criteria 
(PsARC)PsARC is a composite criteria reported in 
terms of the percentage of patients 
achieving response according to the 
following criteria:
1.Physician Global Assessment of 
Disease Activity,
2.Patient Global Assessment o f Disease 
Activity ,
3.TJC, and PsARC responder Flag Response is defined by 
improvement from baseline 
assessment in 2 of the 4 criteria, 
1 in which must be a joint 
count; and there must not be 
worsening of any of the 4 
criteria:
1.≥30% reduction in TJC,
2.≥30% reduction in SJC,If one or more criteria are 
missing then missing
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 105
LY2439821Measure Description Variable Derivation / CommentImputation Approach if 
with Missing 
Components
4.SJC 3.≥20 mm reduction in the 
physician’s assessment 
(VAS), and
4.≥20 mm reduction in the 
patient’s assessment (VAS)
(Clegg et al. 1996)
Static 
Physician’s 
Global 
Assessment 
(sPGA) (0,1) 
and (0)sPGA (0,1) sPGA (0,1) Flag Defined as plaques that are 
either clear or minimal (0,1)Single item, missing if 
missing
sPGA (0) PGA (0) Flag Defined as plaques that are clear 
(0)Single item, missing if 
missing
Disease 
Activity  index 
for PSoriatic 
Arthritis 
(DAPSA)Composite score that includes at least one 
variable from each factor to cover all 
important domains of the multifaceted 
systemic disease with a main focus on the 
musculoskeletal system and excludes the 
skin domain (Smolen et al. 2015) .Change f rom baseline in 
DAPSA score
Percent improvement in DAPSA 
scoreSum of the following:
1.SJC
2. TJC
3.patient pain VAS score
4.patient global VAS score
5.CRP (mg/L)If any item is missing, then 
missing
DAPSA Low Disease Activity 
(LDA)4 <DAPSA ≤14 If DAPSA is missing, 
missing
DAPSA Remission DAPSA ≤4 If DAPSA is missing, 
missing
DAPSA ≤14 DAPSA ≤14 If DAPSA is missing, 
missing
Abbreviations:  NA = not applicable; PsA = psoriatic arthritis; SJC = swollen joint count; TJC = tender joint count.
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 106
LY2439821Table RHBF. 6.10. Description of Planned Exploratory Efficacy Analyses
Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Coates criteria for 
minimal disease 
activity  (MDA)Time-to achieve 
sustained Coates Criteria 
for MDA (MDA for 12 
consecutive months)Descriptive Statistics for 
ixekizu mab 80 mg Q2W 
(including Kaplan Meier 
estimates of the survival curve)Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Period 2 and 3 
combined
Disease Activity 
Score (28 
arthrodial joint 
count) based on 
CRP (DAS28 -
CRP)Time-to achieve DAS28 -
CRP low disease activity 
(score ≤2.8)
(Helliwell et al. 2014)Descriptive Statistics for 
ixekizumab 80 mg Q2W 
(including Kaplan Meier 
estimates of the survival curve)Initial open -label treatment perio d 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
Change f rom baseline in 
DAS28 -CRP
Percent improvement in 
DAS28 -CRPDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3, patients 
with 40 Weeks of Randomized 
Treatment
Psoriatic Arthritis 
Disease Activity 
Score (PASDAS)Time-to achieve 
PASDAS low disease 
activity  (score ≤3.2)
(Helliwell et al. 2014)Descriptive Statistics for 
ixekizumab 80 mg Q2W 
(including Kaplan Meier 
estimates of the survival curve)Initial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
Change f rom baseline in 
PASDASDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 107
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Percent improvement in 
PASDASIxekizumab -treated patients: 
nonrandomized population  and  
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 Weeks of Randomized 
Treatment
Composite 
Psoriatic Disease 
Active Index 
(CPDAI)Time-to achieve 
modified CPDAI low 
disease activity (score 
≤3)Descriptive Statistics for 
ixekizumab 80 mg Q2W 
(including Kaplan Meier 
estimates of the survival curve)Initial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
Change f rom baseline in 
CPDAI domain scores
Change f rom baseline in 
CPDAI composite scoresDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 Weeks of Randomized 
Treatment
Psoriatic Arthritis 
Response Criteria 
(PsARC)PsARC responder Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and  
randomized withdrawal ITT populationAssessed during Periods 2 and 
3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 Weeks of Randomized 
Treatment
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 108
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Psoriasis Area and 
Severity  Index 
(PASI) 75, 90, and 
100Proportio nof patients 
with PASI 75
Proportio n of patients 
with PASI 90
Proportio n of patients 
with PASI 100Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment population 
with baseline psoriatic lesions 
involving BSA ≥3%Assessed during P eriod 2
Ixekizumab -treated patients with 
baseline psoriatic lesions involving 
BSA ≥3%: no nrandomized population  
and randomized withdrawal ITT 
populatio n Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n with baseline psoriatic 
lesions involving BSA ≥3%Assess during Period 3 through 
40 Weeks of Randomized 
Treatment
Change f rom baseline in 
PASI Total Score
Percent Improvement in 
Total ScoreDescr iptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment population 
with baseline psoriatic lesions 
involving BSA ≥3%Assessed during Period 2
Ixekizumab -treated patients with 
baseline psoriatic lesions involving 
BSA ≥3%: no nrandomized population 
and  randomized withdrawal ITT 
populatio n Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio n with baseline psoriatic 
lesions involving BSA ≥3%Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Static Physician’s 
Global Assessment 
sPGA of Psoriasis 
(0,1) and (0)Proportio n of patients 
with sPGA (0,1)
Proportio n of patient s 
with sPGA(0)Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment population 
with sPGA ≥3 at baselineAssessed during Period 2
Ixekizumab -treated patients with sPGA 
≥3 at baseline:  nonrandomized 
populatio n and randomized withdrawal 
ITT population Assessed during Period 2 and 
Period 3 combined
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 109
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n with sPGA ≥3 at baselineAssess during Period 3 through 
40 weeks of Randomized 
Treatment
Body surface area 
(BSA)Change f rom baseline in 
percent involvement of 
BSADescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment population 
with baseline Psoriatic Lesions 
Involving ≥3% BSAAssessed during Period 2
Ixekizumab -treated patients with 
baseline Psoriatic Lesions Involving 
≥3% BSA: nonrandomized population 
and  randomized withdrawal ITT 
populatio n Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio n with baseline Psoriatic 
Lesions Involving ≥3% BSAAssess during Period 3 through 
40 w eeks of Randomized 
Treatment
Patient’s 
Assessment of 
Pain Visual 
Analog Scale 
(VAS)Change in baseline in 
Patient Pain VAS
Percent improvement in 
Patient Pain VASDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 weeks of Randomized 
Treatment
Patient’s Global 
Assessment of 
Disease Activity 
VASChange in baseline in 
patient global VAS
Percent improvement in 
patient global VASDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 weeks of Randomized 
Treatment
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 110
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Physician’s Global 
Assessment of 
Disease Activity 
VASChange in baseline in 
physician global VAS
Percent improvement in 
physician global VASDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populati onAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 weeks of Randomized 
Treatment
Spondyloarthritis 
Research 
Consortium of 
Canada (SPARCC)Change f rom baseline in 
SPARCC
Percent improvement in
SPARCCDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline enthesitis 
(SPARCC >0)Assessed during Period 2
Ixekizumab -treated patients with 
baseline enthesitis (SPARCC >0):  
nonrandomized population and 
randomized withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio n with Baseline Enthesitis 
(SPARCC >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 111
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Proportio n of patients 
with resolution in 
enthesitis (SPARCC =0)Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with Baseline Enthesitis 
(SPARCC >0)Assessed during Period 2
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n with Baseline Enthesitis 
(SPARCC >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Leeds Dactylitis 
Index -Basic 
(LDI -B)Change f rom baseline in 
LDI-B
Percent improvement in 
LDI-BDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline dactylitis 
(LDI -B Score >0)Assessed during Period 2
Ixekizumab -treated patients with 
baseline dactylitis (LDI-B Score >0): 
nonrandomized population and 
randomized withdrawal ITT population Assesse d during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio n with baseline dactylitis 
(LDI -B Score >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Proportio n of patients 
with improvement in 
dacty litis ( ≥1 digit 
resolved)
Proportio n of patients 
with resolution of 
dacty litis (LDI -B = 0)Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline dactylitis 
(LDI -B Score >0)Assessed during Perio d 2
Ixekizumab -treated patients with 
baseline dactylitis (LDI-B Score >0): 
nonrandomized population and 
randomized withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n with baseline dactylitis 
(LDI -B Score >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Leeds Enthesitis 
Index (LEI)Change f rom baseline in 
LEIDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline enthesitis (LEI 
Score >0)Assessed during Period 2
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 112
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
Percent improvement in 
LEIIxekizumab -treated patients with 
baseline enthesitis (LEI Score >0): 
nonrandomized population and 
random ized withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio n with baseline enthesitis (LEI 
Score >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Proportio n of patients 
with resolution in 
enthesitis (LEI =0)Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline enthesitis (LEI 
Score >0)Assessed during Period 2
Ixekizumab -treated patients wi th 
baseline enthesitis (LEI Score >0: 
nonrandomized population and 
randomized withdrawal ITT 
populatio n)Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n with baseline enthesitis (LEI 
Score >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Enthesitis, 18 
entheseal points 
(as measured by a 
combinatio n of the 
LEI and the 
SPARCC)Change f rom baseline in 
Enthesitis, 18 entheseal 
points
Percent improvement in 
Enthesitis, 18 entheseal 
pointsDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline enthesitis (18 
entheseal point score >0)Assessed during Period 2
Ixekizumab -treated patients with 
baseline enthesitis (18 entheseal point 
score >0): nonrandomized population 
and randomized withdrawal ITT 
populatio n Assessed during Period 2 and 
Period 3 combined
MMRM;
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio n with baseline enthesitis (18 
entheseal points score >0)Assess during Period 3 through 
40 weeks of Randomized 
Treatment
Proportio n of patients 
with resolution in 
enthesitis (18 entheseal Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline enthesitis (18 
entheseal points score >0)Assessed during Period 2
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 113
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
points score =0) Ixekizumab -treated patients with 
baseline enthesitis (18 entheseal points 
score >0: nonrandomized population 
and randomized withdra wal ITT 
populatio n)Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n with baseline enthesitis (18 
entheseal points score >0)Assess during Period 3 through 
40 Weeks of Randomized 
Treatment
Swollen joint 
count (SJC)Change f rom baseline in 
SJC
Percent improvement in 
SJCDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and  
randomized withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 weeks of Randomized 
Treatment
Tender joint count 
(TJC)Change f rom baseline in 
TJC
Percent improvement in 
TJCDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 weeks of Randomized 
Treatment
Disease Activity 
index for PSoriatic 
Arthritis (DAPSA)Change f rom baseline in 
DAPSA score
Percent improvement in 
DAPSA scoreDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and 
randomized withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
I1F-MC-RHBF Statistical Analysis Plan Versio n 3 Page 114
LY2439821Measure VariableAnalysis Method
(Section 6.1)Population
(Section 6.6.1) Comparison/Time Point
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT 
populatio nAssess during Period 3 through 
40 weeks of Randomized 
Treatment
Proportio n of patients 
with DAPSA LDA 
(DAPSA >4 and DAPSA 
≤14)Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients 
(nonrandomized population and 
randomized withdrawal ITT 
populatio n)Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n Assess during Period 3 through 
40 Weeks of Randomized 
Treatment
Proportio n of patients 
with DAPSA remission 
(DAPSA ≤4)Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients 
(nonrandomized population and 
randomized withdrawal ITT 
populatio n)Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n Assess during Period 3 through 
40 Weeks of Randomized 
Treatment
Proportio n of patients 
with DAPSA ≤14Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients 
(nonrandomized population and 
randomized withdrawal ITT 
populatio n)Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI;
Fisher’s exact test with NRIRandomized withdrawal ITT 
populatio n Assess during Period 3 through 
40 Weeks of Randomized 
Treatment
Abbreviations:  ANCOVA = analysis of covariance; ITT = intent -to-treat; mBOCF = modified baseline observation carried forward; MMRM = mixed -effects 
model of repeated measures; NRI = nonresponder imputation; Q2W = every 2 weeks.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 115
LY24398216.19.2. Planned Exploratory Health Outcomes/Quality -of-Life Analyses
The health outcomes and qualit y of life (QOL) m easures are Itch NRS, Fatigue Severit y NRS, 
DLQI, SF -36 Mental and Physical Co mponent Summary Scores, EQ -5D- 5L, Work Productivit y 
and Act ivity Impairment Questi onnaire -Specific Health Problem, and the QIDS -SR16.  T here 
will be no adjust ment for multiple com parisons.  
Table RHBF. 6.11 includes the descript ion and derivat ion of the health outcomes and QOL 
meas ures.
Table RHBF. 6.12 provides the detailed analyses including analysis t ype, method and imputation, 
popul ation, time point, and comparisons for healt houtcom es and QOL analyses
.
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 116
LY2439821Table RHBF. 6.11. Description and Derivation of Health Outcomes and Quality -of-Life Measures
Measure Description Variable Derivation / Comment Missing Items
Itch Numeric 
Rating Scale 
(NRS)Itch NRS: is a single -item, patient -
reported outcome (PRO) measure 
designed to capture information on the 
overall severity of a patient’s itching 
due to their psoriati c skin condition by 
having the patient selecting the integer 
that best describes the worst level of 
itching in the past 24 hours on an 11-
point NRS anchored at 0 representing 
“no itching” and 10 representing 
“worst itch imaginable.”Itch NRS score Range fr om 0 to 10.  Single item, missing if 
missing
Itch NRS change from baseline Calculated as:  
1.observed Itch NRS –baseline Itch 
NRS 
2.mBOCF Itch NRS1.Missing if baseline or 
observed value is 
missing
2.Missing if baseline is 
missing
Itch NRS ≥3 improvement
from baselineReduced/decreased of ≥3 point from 
baselineMissing if baseline or 
observed value is missing
Itch NRS =0 Defined as a post -baseline Itch NRS 
score of 0Missing if Itch NRS score 
is missing
Fatigue 
Severity  
Numeric 
Rating ScaleFatigue Severity NRS: is a patient -
administered single -item 11 -point 
horizo ntal scale anchored at 0 and 10, 
on which 0 represents “no fatigue” and 
10 represents “as bad as you can 
imagine.”  Patients rate their fatigue 
(feeling tired or worn out ) by selecting 
the single number that describes their 
worst level of fatigue during the past 
24hours.  Fatigue Severity NRS Range from 0 to 10.  Single item, missing if 
missing
Fatigue Severity NRS change 
from baselineCalculated as:  
1.observed Fatigue Severity NRS –
baseline Fatigue Severity NRS
2.mBOCF Fatigue Severity1.Missing if baseline or 
observed value is 
missing
2.Missing if baseline is 
missing
Fatigue Severity NRS = 0 Defined as a post -baseline Fatigue 
Severity  NRS score of 0Missing if Fatigue 
Severity  NRS score is 
missing
Improvement in 2 points and 3 
points in Fatigue Severity NRSDefined as a change from baseline in 
Fatigue Severity NRS score of ≥2; 
and
Defined as a change from baseline in 
Fatigue Severity NRS score of ≥3Missing if Fatigue 
Severity  NRS score is 
missing
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 117
LY2439821Measure Description Variable Derivation / Comment Missing Items
Dermatology 
Life Quality 
Index (DLQI)DLQI: is a validated, dermatology -
specific, patient -reported measure that 
evaluates patient’s health -related 
quality  of life.  This questionnaire has 
10 items that are grouped in 6 domains, 
including symptoms and feelings, daily 
activities, leisure, work and school, 
personal relationships, and treatment.  
The recall period of this scale is over 
the “last week”.  Response categories 
and corresponding scores are:
Very  much = 3
A lot = 2
A little = 1
Not at all = 0
Not relevant = 0DLQI symptoms and feelings 
domainSum of responses of questions #1 
and #2:
#1.  How itchy, sore, painful or 
stinging has your skin been?
#2.  How embarrassed or self -
conscious have you been because of 
your s kin?If one question in a 
domain is missing, that 
domain is missing.
DLQI daily  activities domain Sum of responses of questions #3 
and #4:
#3.  How much has your skin 
interfered with you going shopping 
or looking after your home or 
garden?
#4.  How much has your skin 
influenced the clothes you wear?If one question in a 
domain is missing, that 
domain is missing.
DLQI leisure domain Sum of responses of questions #5 
and #6:
#5.  How much has your skin 
affected any social or leisure 
activities?
#6.  How much has your skin make it 
difficult for you to do any sport?If one question in a 
domain is missing, that 
domain is missing.
DLQI work and school domain Sum of responses of questions 
question #7A and #7B:
#7A.  Has your skin prevented you 
from working or studying?
#7B.  If No: how much has your skin 
been a problem at work or studying?If the answer to question 
#7A is missing, this 
domain is missing.  If 
#7A is No, and #7B is 
missing, this domain is 
missing.
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 118
LY2439821Measure Description Variable Derivation / Comment Missing Items
DLQI personal relationships 
domainSum of responses of questions #8 
and #9:
#8.  How much has your skin created 
problems with your partner or any of 
your close friends or relatives?
#9.  How much has your skin caused 
any sexual difficulties?If one question in a 
domain is missing, that 
domain is missing.
DLQI treatment Response of question #10:
#10.  How much of a problem has 
the treatment for your skin been, for 
example by making your home 
messy, or by taking up time?If one question in a 
domain is missing, that 
domain is missing.
DLQI total score A DLQI total score is calculated by 
summing all 10 question responses, 
and has a range of 0 to 30 (less to 
more impairment) (Finlay and Khan 
1994; Basra et al. 2008).  If two or more questions 
are missing, the total 
score is missing.  (Note: 
#7B could be a valid 
missing w hile #7A is not 
“No.”  That is, #7 should 
be considered as one 
question.)
DLQI (0,1) A DLQI (0,1) response is defined as 
a post -baseline DLQI total score of 0 
or 1.  A DLQI total score of 0 to 1 is 
considered as having no effect on a 
patient’s HRQoL (Khilji et al. 2002; 
Hongbo et al. 2005).Missing if DLQI total 
score is missing
DLQI total score ≥5 
improvement from baselineReduction/decrease of ≥5 points 
from baseline.  A 5 -point change 
from baseline is considered as the 
minimal clinically important 
difference threshold.Missing if baseline or 
observed value is missing
DLQI total score and domain 
scores change from baselineCalculated as: observed DLQI (total 
score or domain scores) –baseline 
DLQI (total score or domain scores)Missing if baseline or 
observed value is missing
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 119
LY2439821Measure Description Variable Derivation / Comment Missing Items
Medical 
Outcomes 
Study 36 -item 
Short -Form 
Health 
Survey (SF -
36)SF-36:  is a 36- item patient -
administered measure designed to be a 
short, multipurpose assessment of 
health in the areas of phy sical 
functioning, role -physical, role -
emotional, bodily pain, vitality, social 
functioning, mental health, and general 
health.  The 2 overarching domains of 
mental well -being and physical well -
being are captured by the Mental 
Component Summary (MCS) and 
Physical Component Summary (PCS) 
scores.  The summary scores range 
from 0 to 100; higher scores indicate 
better levels of function and/or better 
health.  Items are answered on Likert 
scales of varying lengths.  The SF -36 
version 2 (acute version) health sur vey 
will be used, which has a 1 -week recall 
period (B razier et al. 1992; Ware and 
Sherbourne 1992 ).8 associated domain scores:
Physical Functioning, 
Role Physical, 
Bodily Pain, 
General Health,
Vitality, 
Social Functioning, 
Role Emotional, and Mental 
Health
2 component Scores:
MCS Score
PCS ScorePer copyright owner, the 
Quality Metric Health Outcomes™ 
Scoring Software 4.5 will be used to 
derive SF -36 domain and component 
scores.  After data quality -controls, 
the SF -36 software will re -calibrate 
the ite m-level responses for 
calculation of the domain and 
component scores.  These raw scores 
will be transformed into the domain 
scores (t -scores) using the 1 -week 
recall period. The procedure to 
derive the SF -36 scores is described 
in Appendix 6 .  It entails exporting 
the patient data in a CSV or tab -
delimited file for import, generation 
of the SF -36 scores and reports, and 
export of the calculated scores in a 
CSV or tab-de limited file for 
integratio n into SDTM/ADaM 
datasets. The summary scores range 
from 0 to 100.Missing data handling 
offered by SF -36 software 
will not be used.
Work 
Productivity 
and Activity 
Impairment –
Specific 
Health 
ProblemWork Productivity and Activity 
Impairment –Specific Health Problem:  
consists of 6 questions to determine 
employ ment status, hours missed from 
work because of PsA, hours missed 
from work for other reasons, hours 
actually  worked, the degree to which 
PsA affe cted work productivity while 
at work, and the degree to which PsA 
affected activities outside of work.  percentage of absenteeism Percent work time missed due to 
problem: (Q2/(Q2 + Q4))*100if Q2 or Q4 is missing, 
then missing
percentage of presenteeism 
(reduced productivity while at 
work)Percent impairment while working 
due to problem: (Q5/10)*100if Q5 is missing, then 
missing
overall work impairment score 
that combines absenteeism and 
presenteeismPercent overall work impairment due 
to problem: (Q2/(Q2+ Q4) + [(1 -
Q2/(Q2+Q4))*(Q5/10)])*100if Q2, Q4, or Q5 is 
missing, then missing
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 120
LY2439821Measure Description Variable Derivation / Comment Missing Items
Four scores are derived:  percentage of 
absenteeism, percentage of 
presenteeism (reduced productivity 
while at work), an overall work 
impairment score t hat combines 
absenteeism and presenteeism, and 
percentage of impairment in activities 
performed outside of work.  Greater 
scores indicate greater impairment 
(Reilly  et al. 1993; Reilly Associates 
Health Outcomes Research [WWW]).percentage of impairment in 
activities performed outside of 
workPercent activity impairment due to 
problem: (Q6/10)*100if Q6 is missing, then 
missing
European 
Quality  of 
Life – 5 
Dimensions 5 
Level (EQ -
5D-5L)EQ-5D-5L is a standardized measure of 
health status used to provide a simple, 
gene ric measure of health for clinical 
and economic appraisal.  The EQ -5D-
5L consists of 2 components:  a 
descriptive system of the respondent’s 
health and a rating of his/her current 
health state using a 0- to 100 -mm VAS.  
The descriptive system comprises the
following 5 dimensions: 
item 1: mobility
item 2: self -care
item 3: usual activities
item 4: pain/discomfort
item 5: anxiety/depression
The respondent is asked to indicate 
his/her health state by ticking (or 
placing a cross) in the box associated 
with the most appropriate statement in 
each of the 5 dimensions. EQ-5Dmobility, 
EQ-5D self -care,
EQ-5D usual activities, EQ -5D 
pain/ discomfort, 
EQ-5D anxiety/ depressionFive health profile dimensions, each 
dimension has 5 levels: 
1 = no problems
2 = slight problems
3 = moderate problems
4 = severe problems
5 = extreme problems  
It should be noted that the numerals 
1 to 5 have no arithmetic properties 
and should not be used as a primary 
score.Each dimension is a 
single item, missing if 
missing.  (Note: Score of 
9 is missing.)
EQ-5D-5L UKPopulation -
based index scoreUses the concatenation of the value 
of each EQ -5D-5L dimension score 
in the order: item1; item2; item3; 
item4; item5.  Derive EQ-5D-5L UK
Population -based index score
according to the link by using the 
UK algorithm (Szende et al. 2007) to 
produce a patient -level index score 
between -0.59 and 1.0 (continuous 
variable):
http://www.euroqol.org/fileadmin/us
er_upload/Documenten/Excel/CrossIf any of the items is 
missing or equal to 9, the 
index score is missing  
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 121
LY2439821Measure Description Variable Derivation / Comment Missing Items
walk_5L/EQ -5D-
5L_Crosswalk_Value_Sets.xls
The EQ -5D-5L health states, defined 
by the EQ -5D-5L descriptive system, 
may be converted into a single 
summary index by applying a formula 
that essentially attaches values (also 
called weights) to each of the levels in 
each dimension (EuroQol Group 2013 
[WWW]).  The VAS records the 
respondent’s self -rated health on a 
vertical VAS where the endpoints are 
labeled 100 = “best imaginable health 
state” and 0 = “worst imaginable health 
state.”  This information can be used as 
a quantitative measure of health 
outcome. EQ-5DVAS Range from 0 = “worst imaginable 
health state” to 100 = “best 
imaginable health state”.  
(Note: Higher value indicates better 
health state.)Single item, missing if 
missing
Quick 
Inventory of 
Depressive 
Symptoma-
tology -Self 
Report (16 QIDS -SR16  is a self -administered 16 -
item instrument intended to assess the 
existence and severity of symptoms of 
depression as listed in the American 
Psychiatric Association’s Diagnostic 
and Statistical Manual of Mental Sleep disturbance (initial, 
middle, and late insomnia or 
hypersomnia)
Change frombaseline insleep
disturbancethe highest score recorded for the 4 
sleep items:  #1 (falling asleep), #2 
(sleep during the night ), #3 ( waking 
up too early ) and #4 ( sleeping too 
much ).Domain is missing if all 
items are missing.
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 122
LY2439821Measure Description Variable Derivation / Comment Missing Items
Sad mood
Change frombaseline insad
moodScore recorded for item #5 Domain is missing if the 
item is missing.
Decrease/increase in 
appetite/weight
Change frombaseline in
decrease/increase in
appetite/weightthe highest score recorded for the 
appetite/weight items (items #6 to 
#9)Domain is missing if all 
items are mis sing or not 
applicable.
Concentration
Change f rom baseline in 
concentrationScore recorded for item #10 
(concentration/ decision making)Domain is missing if the 
item is missing.
Self-criticism
Change f rom baseline in self -
criticismScore recorded for item #11 ( view of 
myself)Domain is missing if the 
item is missing.
Suicidal ideation
Change f rom baseline in 
suicidal ideationScore recorded for item #12 
(thoughts of death or suicide )Domain is missing if the 
item is missing
Interest
Change from baseline in 
interestScore recorded for item #13 ( general 
interest )Domain is missing if the 
item is missing.
Energy/fatigue
Change f rom baseline in 
energy /fatigueScore recorded for item #14 ( energy 
level)Domain is missing if the 
item is missing.
Psychomotor agitation/ 
retardatio n
Change f rom baseline in The highest score recorded for the 
two psychomotor items:  #15 (feeling 
slowed down ) and #16 (feeling 
restless ).  Domain is missing if all 
items are missing.
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 123
LY2439821Measure Description Variable Derivation / Comment Missing Items
psychomotor agitation/ 
retardatio n
QIDS -SR16 total score
Change frombaseline inQIDS -
SR16 total scoreQIDS -SR16 total score is the sum of 
the domain scores.  The range for 
total score is 0 to 27.The total score will be 
missing if any domain 
score is missing.
Proportio n ofpatients with at 
least a 50% decrease in QIDS -
SR16 total scoreQIDS -SR16 total score at each post -
baseline visit is at least a 50% 
reductio n of the patient’s baseline 
QIDS -SR16 total scoreThe total score will be 
missing if any domain 
score is missing
Abbreviations:  ADaM = Analysis Data Model; mBOCF = modified baseline observation carried forward; PsA = psoriatic arthritis; S DTM = Study Data 
Tabulatio n Model; UK = United Kingdom.
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 124
LY2439821Table RHBF. 6.12. Description of Planned Exploratory Health Outcomes and Quality -of-Life Analyses
Measure Variable Analysis Method ( Section 6.1) Population (Section 6.6.1) Comparison/Time Point
Itch Numeric 
Rating Scale 
(NRS)Itch NRS ≥3 improvement 
from baselineDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline psoriatic lesions 
involving ≥3% BSA and baseline Itch NRS 
score ≥3Assessed during Period 2
Ixekizumab -treated patients with baseline 
psoriatic lesions involving ≥3% BSA and 
baseline Itch NRS score ≥3: no nrandomized 
and Randomized withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI; F isher’s exact test with 
NRIRandomized withdrawal ITT population 
with baseline psoriatic lesions involving 
≥3% BSA and baseline Itch NRS score ≥3Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Itch NRS =0 Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline psoriatic lesions 
involving ≥3% BSA and baseline Itch NRS 
score >0Assessed during Period 2
Ixekizumab -treated patients with baseline 
psoriatic lesions involving ≥3% BSA and 
baseline Itch NRS score >0: nonrandomized 
and Randomized withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI; Fisher’s exact test with 
NRIRandomized withdrawal ITT population 
with baseline psoriatic lesions involving 
≥3% BSA and baseline Itch NRS score >0Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Itch NRS change from 
baselineDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline psoriatic lesions 
involving BSA ≥3%Assessed during Period 2
Ixekizumab -treated patients with baseline 
psoriatic lesions involving BSA ≥3%: 
nonrandomized population and Randomized 
withdrawal ITT population Assessed during Perio d 2 and 
Period 3 combined
MMRM; ANCOVA with 
mBOCFRandomized withdrawal ITT population 
with baseline psoriatic lesions involving 
BSA ≥3%Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 125
LY2439821Measure Variable Analysis Method ( Section 6.1) Population (Section 6.6.1) Comparison/Time Point
Fatigue 
Severity  
NRSFatigue Severity NRS =0 Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and Randomized 
withdrawal ITT populationAssessed during Period 2 and 
Periods 3 combined
Logistic regression analysis with 
NRI; Fisher’s exact test with 
NRIRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Fatigue Severity NRS change 
from baselineDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and Randomized 
withdrawal ITT populationAssessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Dermatology 
Life Quality 
Index 
(DLQI)DLQI (0,1), Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline psoriatic lesions 
involving BSA ≥3%Assessed during Period 2
Ixekizumab -treated patients with baseline 
psoriatic lesions involving BSA ≥3%: 
nonrandomized population and  
Randomized withdrawal ITT population Assessed during Perio d 2 and 
Period 3 combined
Logistic regression analysis with 
NRI; Fisher’s exact test with 
NRI Randomized withdrawal ITT population 
with baseline psoriatic lesions involving 
BSA ≥3%Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
DLQI total score and domain 
scores change from baselineDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline psoriatic lesions 
involving BSA ≥3%Assessed during Period 2
Ixekizumab -treated patients with baseline 
psoriatic lesions involving BSA ≥3%: 
nonrandomized population and Randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 126
LY2439821Measure Variable Analysis Method ( Section 6.1) Population (Section 6.6.1) Comparison/Time Point
MMRM;  
ANCOVA with mBOCFRandomized withdrawal ITT population 
with baseline psoriatic lesions involving 
BSA ≥3%Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
36 item 
Short Form 
Health 
Survey8 associated domain scores:
Physical Functioning
Role Physical
Bodily Pain
General Health,
Vitality 
Social Functioning
Role Emoti onal
Mental HealthDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and Randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
MCS Score Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and Randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
MMRM;
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
PCS Score Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and Randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Work 
Productivity 
and Activity 
Impairment –
Specific Change f rom baseline in the 
following:
percentage of absenteeism
percentage of 
presenteeism (reduced Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 127
LY2439821Measure Variable Analysis Method ( Section 6.1) Population (Section 6.6.1) Comparison/Time Point
Health 
Problemproductivity while at 
work)
overall work impairment 
score that combines 
absenteeism and 
presenteeism
percentage of impairment 
in activities performed 
outside of workMMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
European 
Quality  of 
Life – 5 
dimensions 5 
level (EQ -
5D)EQ-5Dmobility, 
EQ-5D self -care,
EQ-5D usual activities, 
EQ-5D pain/discomfort, 
EQ-5D anxiety/depressionForeach EQ-5Ddimension, the
proportion ofpatients with “no
problems” willbesummarized
using descriptive statistics for
ixekizumab 80mgQ2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
Foreach EQ-5Ddimension, the
proportion ofpatients with “no
problems” willbeanaly zedby:
Logistic regression analysis with 
NRI; Fisher’s exact test with 
NRIRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
EQ-5D-5L UKPopulation -
based index score,
EQ-5DVASDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Quick 
Inventory of 
Depressive 
Symptoma-
tology -Self Observed andchange from
baseline inthefollowing
QIDS -SR16 domains:
(1) sad mood
(2)concentrationDescriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n Assessed during Period 2
Ixekizumab -treated patients : 
nonrandomized population and randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 128
LY2439821Measure Variable Analysis Method ( Section 6.1) Population (Section 6.6.1) Comparison/Time Point
Report 16 
Items 
(QIDS -
SR16)(3)self-criticism
(4)suicidal ideation
(5)intere st
(6)energy/fatigue
(7)sleep disturbance (initial,
middle, andlateinsomnia or
hypersomnia
(8)decrease/increase in
appetite/weight
(9)psychomotor
agitation/retardation
Observed andchange from
baseline inQIDS -SR16 total
scoreMMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
Descriptive Statistics for 
ixekizumab 80 mg Q2WInitial open -label treatment period 
populatio n with baseline QIDS -SR16 total 
score of  ≥11Assessed during Period 2
Ixekizumab -treated patients with baseline 
QIDS -SR16 total score of  ≥11: 
nonrandomized population and randomized 
withdrawal ITT populati on  Assessed during Period 2 and 
Period 3 combined
MMRM; 
ANCOVA with mBOCFRandomized withdrawal ITT population 
with baseline QIDS -SR16 total score of  
≥11Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
QIDS -SR16 total score
categories:
None (nodepression):   
0–5
Mild:   6-10
Moderate: 11
– 15
Severe: 16 – 20
Very severe: 21 – 27.Descriptive Statistics for 
ixekizumab 80 mg Q2W
Shift table from maximum 
baseline for ixekizumab 80 mg 
Q2W 
Descriptive statistics on the 
category based on the maximum 
post-baseline: for ixekizumab 80 
mg Q2W
oImproved; maximum post -
baseline category < 
maximum baseline category.
oWorsened; maximum post -
baseline category > 
maximum baseline category.
oSame; maximum post -
baseline category = 
maximum baseline
category.Initial open -label treatment period 
populatio n All post -baseline visits in 
Period 2
Ixekizumab -treated patients: 
nonrandomized population and randomized 
withdrawal ITT populationAll post -baseline visits in 
Period 2 and Period 3 
combined
Randomized withdrawal ITT population Assessed during Period 3 
through 40 weeks of 
Randomized Treatment
1IF-MC-RHBF Statistical Analysis Plan Version 3 Page 129
LY2439821Measure Variable Analysis Method ( Section 6.1) Population (Section 6.6.1) Comparison/Time Point
Proportio n of patients with at 
least a 50% decrease in 
QIDS -SR16 total scoreDescriptive statistics for
ixekizumab 80mgQ2WInitial open -label treatment period 
populatio nAssessed during Period 2
Ixekizumab -treated patients: 
nonrandomized population and randomized 
withdrawal ITT population Assessed during Period 2 and 
Period 3 combined
Logistic regression analysis with 
NRI; Fisher’s exact test with 
NRIRandomized withdrawal ITT population Assessed during Period 3 
through 40 Weeks of 
Randomized Treatment
Abbreviations:  ANCOVA = analysis of covariance; ITT = intent -to-treat; mBOCF = modified baseline carried forward; MCS = Mental Component Summary; 
MMRM = mixed -effects model of repeated measures; NRI = nonresponder imputation; PCS = Physical Component Summary; Q2W = ever y 2 weeks; UK = 
United Kingdom; VAS = visual analog scale.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 130
LY243982716.20. Annual Report Analyses
Annual report analyses will be documented in a separate document.
6.21. Clinical Trial Registry Analyses
Addit ional analyses will be performed for the purpose of fulfilling the Clinical Trial Registry  
(CTR) re quirements.  
Analyses provided for the CTR requirements include summary o f AEs, provi ded as a dataset 
which will be converted to an XML file.  Both Serious Adverse Events and ‘Other’ Adverse 
Events are summarized:  by treatment group and MedDRA PT.
An AE is considered ‘Serious’ whether or not it is a TEAE.
An AE is considered in the ‘Other’ category  if it is both a TEAE and is not serious.  For 
each Seri ous AE and ‘Other’ AE, for each term and treatment group, the following are 
provi ded:
othe number of part icipants at risk of an event
othe number of participants who experienced each event term
othe number of events experienced.
Consistent with www.ClinicalTrials.gov requirements, ‘Other’ AEs that occur in fewer 
than 5% of patients/subjects in every  treatment g roup may not be included if a 5% 
thresho ld is chosen (5% is the minimum thresho ld).
Adverse event reporting is consistent with other document disclo sures for example, the 
clinical study  report (CSR), m anuscri pts, and so forth.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 131
LY243982717.Unblinding Plan
Refer to the I1F-MC-RHBF Blinding and Unblinding plan.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 132
LY243982718.References
[APA] American Psychiatry  Associ ation. Di agnostic and Statist ical Manual  of Mental  Disorders. 
4th ed. Washington DC: American Psychiatric Associat ion; 1994.
Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Derm atology Life Qualit y Index 
1994- 2007: a comprehensive review of validation data and clinical result s. Br J Dermatol . 
2008;159(5):997 -
1035.
Brazi er JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, West lake L. 
Validat ing the SF -36 he alth survey  questi onnai re: new outcom e measure for primary  care. 
BMJ . 1992;305(6846):160-164.
Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman -Mak E, 
Blackburn WD, Vassey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa 
FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson 
RJ, Ward JR, Henderson WG. Co mpar ison of sulfasalazine and placebo in the treatment of 
psori atic arthrit is. A Depart ment of Veterans Affairs Cooperative Study . Arthritis Rheum . 
1996;39(12):2013 -2020.
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activit y in psoriat ic arthri tis: a 
proposed object ive target for treatment. Ann Rheum Dis . 2010;69(1):48 –53.
Coates LC, Helliwell PS. Validat ion of minimal disease act ivity criteria for psori atic arthrit is 
using interventional trial data. Arthritis Care Res . 2010;62(7):965–969.
Columbia Universit y Medical Center. Columbia –Suicide Severi ty Rating Scale (C -SSRS) web 
site. Available at: http://www.cssrs.columbia.edu. Accessed
April 21, 2011.
[EMA] European Medicines Agency. Committee for Medicinal Products for Human Use 
(CHMP). Guideline on clinical invest igation of medi cinal products indicated for the treatment 
of psori asis. November 2004. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scient ific_guideline/2009/09/WC50
0003329.pdf. Accessed March 17, 2015.
EuroQol  Group. EQ -5D-5L User Guide. Basic information on how to use the EQ-5D- 5L 
instrum ent. Versi on 2.0. October 2013. Available at: 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/EQ -5D-
5L_UserGuide_2015.pdf. Accessed July 28, 2015.
Finlay  AY, Khan GK. Derm atology Life Quali ty Index (DLQI) —a simple pract ical measure for 
routi ne clinical use. Clin Exp Dermatol . 1994;19(3):210 -
216.
Fredri ksson T, Pettersson U. Severe psoriasis —oral  therapy wi th a new retino id. Dermatologica . 
1978;157(4):238 -244.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthrit is. 
Arthritis Rheum . 1980;23(2):137 -145.
Fries JF, Spitz PW, Young DY. The dimensio ns of healt h outcomes: the healt h assessment 
questionnaire, disabilit y and pain scales. J Rheumatol . 1982;9(5):789 -
793.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 133
LY24398271Healy PJ, Helliwell PS. Measuring dact ylitis in clinical trials: which is the best instrumen t to 
use? J Rheumatol. 2007;34:1302 -1306.
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriat ic arthrit is: assessment of exist ing 
measures and development of an instrument specific to psoriat ic arthrit is. Arthritis Rheum.
2008;59(5):686 -691.
Helliwell PS, Firth J, Ibrahim GH, Melso m RD, Shah I, Turner DE. Development of an 
assessment tool for dactylit is in pat ients with psoriati c arthri tis. J Rheumatol.
2005;32:1745 -1750.
Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis -Duffin K, McHugh N, 
Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, 
Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, 
Marzo -Ortega H, Porru G, Moreta EG, Nash P, Raffayo va H, Ranza R, Rayc haudhuri SP, 
Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA. The 
development of candidate composite disease act ivity and responder indices for psoriat ic 
arthri tis (GRACE proj ect). Ann Rheum Dis . 2013;72(6):986 -991.
Helli well PS, Fi tzGeral d O, Fransen J. Composite disease act ivity and responder indices for 
psori atic arthrit is: a report from the GRAPPA 2013 meet ing on development of cutoffs for 
both disease activit y states and response. JRheumatol . 2014;41(6):1212 -1217.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay  AY. Translat ing the science of qualit y 
of life into practice: What do dermatology  life qualit y index scores mean? J Invest Dermatol.
2005;125(4):659 -664.
Khilji FA, Gonzalez M, Finlay  AY. Clinical  meaning o f change in Dermatology  Life Qualit y 
Index scores. Br J Dermatol . 2002;147(suppl 62):50.
Mease PJ. Measures of psoriatic arthrit is: Tender and Swollen Jo int Assessment, Psoriasis Area 
and Severit y Index (PASI), Nail Psoriasis Severit y Index (NAPSI), Modifi ed Nail Psoriasis 
Severit y Index (m NAPSI), Mander/Newcastle Enthesit is Index (MEI), Leeds Enthesit is Index 
(LEI), Spondyloarthrit is Research Consortium o f Canada (SPARCC), Maastricht Ankylosing 
Spondylit is Enthesis Score (MASES), Leeds Dactylit is Index (LDI), Pati ent Gl obal for 
Psori atic Arthri tis, Derm atology Life Qualit y Index (DLQI), Psoriat ic Arthri tis Quali ty of Life 
(PsAQOL), Funct ional Assessment of Chronic Illness Therapy –Fatigue (FACIT -F), Psori atic 
Arthri tis Response Cri teria (PsARC), Psoriatic Ar thritis Joint Activit y Index (PsAJAI), 
Disease Act ivity in Psoriatic Arthrit is (DAPSA), and Co mposite Psoriatic Disease Act ivity 
Index (CPDAI). Arthritis Care Res . 2011;63(S11):S64–S85.
Mease PJ, Heckaman M, Kary S, Kupper H. Application and modificat ions of minimal disease 
activit y measures for patients with psoriat ic arthrit is treated with adalimumab: subanalyses of 
ADEPT. J Rheumatol. 2013;40(5):647 -52. 
Mum taz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, Helliwell P, FitzGerald O. 
Development of a preliminary  com posite disease activit y index in psoriat ic arthrit is. Ann
Rheum Dis. 2011;70(2):272 -277.
[NPF] Nati onal Psori asis Foundat ion. The Psoriasis and Psoriatic Arthrit is Pocket Guide. 
Portl and, OR. 2009.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 134
LY24398271Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA): classificat ion of sui cidal events in the FDA’s pediatric 
suicidal risk analysis of ant idepressants. Am J Pyschiatry. 2007;164(7):1035 -1043 .
Reilly MC, Zbrozek AS, Dukes EM. The validit y and reproducibilit y of a work productivit y and 
activit y impairment instrument. Pharmacoeconomics. 1993;4(5):353 -
365.
Reilly Associates. Work Productivit y and Act ivity Impairment Questi onnaire: Specific Healt h
Problem V2.0 (WPAI:SHP). Available at: http://www.reillyassociates.net/WPAI_SHP.html. 
Accessed 8July 2014.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody  TJ, Arnow B, Kl ein DN, Markowi tz JC, Ninan 
PT, Kornstei n S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item quick inventory  of 
depressive symptomatology  (QIDS), clinician rating (QIDS -C), and self -report (QIDS -SR): a 
psycho metric evaluat ion in pat ients with chronic major depressio n. Biol Psychiatry. 
2003;54(50):573 -583. Erratum in Biol Psychiatry . 2003;5
4(5);585.
Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown 
SG, Camargo CA Jr, Cy dulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, 
Lewis LM, Lieberman PL, Metcalfe DD, O’Connor R, Muraro A, Rudman A, Schmi tt C, 
Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the 
definit ion and management of anaphylaxis: Summary  report -Second National Inst itute of 
Allergy  and Infecti ous Disease/Food Allergy  and Anaphylaxis Network symposium. J Allerg y 
Clin Immunol . 2006;117(2):391 –397.
Saris
-Baglama RN, Dewey  CJ, Chisholm  GB, Pl umb E, King J, Rasicot P, Kosinski M, Bjorner 
JB, Ware JE. Qualit yMetri c Heal th Outcom es™ Scoring Software 4.5 User’s Guide. Lincoln, 
RI: Qualit yMetric Incorporated; 2004.
Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, Kirkpatrick J. Validit y and 
reliabilit y of the twent y-eight-joint count for the assessment of rheumatoid arthritis activit y. 
Arthritis Rheum. 1995;38(1):38 -43.
Smolen JS, Schoel s M, Aletaha D. Dis ease Act ivity and response assessment in psori atic arthritis 
using the Disease Activit y Index for Psoriat ic Arthritis (DAPSA). A brief 
review. Clin Exp 
Rheumatol . 2015;33(93):S48 -S50.
Szende A, Oppe M, Devlin N, eds. EQ -5D Value Sets: Inventory, Comparat ive Review and User 
Guide. Dordrecht, Netherlands: Springer; 2007.
Trivedi MH, Rush AJ, Ibrahim HM, Carmody  TJ, Bi ggs MM, Suppes T, Cri smon ML, 
Shores -Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM. The Inventory o f 
Depressive Symptomatology , Clinician Rating (IDS -C) and Self -Report (IDS -SR), and the 
Quick Inventory  of Depressive Symptom atology, Clinician Rat ing (QIDS -C) and Self -Report 
(QIDS -SR) in public sector patients with mood disorders: a psycho metric evaluat ion. Psychol 
Med. 2004;34(1):73 -82.
Universi ty of Pittsburgh Epi demi ology Data Center. Inventory  of Depressive Symptom atology 
(IDS) and Quick Inventory  of Depressive Symptomatology  (QIDS). Available at: 
http://www.ids -qids.org. Accessed July 08, 2014.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 135
LY24398271Vander Cruyssen B, Van Looy  S, Wyns B, West hovens R, Durez P, Van den Bosch F, Vey s EM, 
Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, 
Boullart L, De Key ser F. DAS28 best reflects the physician’s clinical judgment of response to 
infliximab therapy  in rheumatoi d arthri tis pat ients: validation o f the DAS28 score in patients 
under infliximab treatment. Arthritis Res Ther. 2005;7(5):R1063 -R1071.
Ware JE Jr, Sherbourne CD. The MOS 36- item short -form health survey  (SF-36), I: Conceptual 
framework and item select ion.Med Care. 1992;30(6):473 -483.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 136
LY243982719.Appendices
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 137
LY24398271Appendix 1. Algorithm for Calculating Classification 
for Psoriatic A rthritis (CA SPAR) Total Score
The cl assificat ion for psori atic arthrit is (CASPAR) total score is defined as the summat ion of the 
following 5 categories in pat ients with inflammatory  articular disease (j oint, spine, or entheseal):  
Either:
oEvidence of current psori asis (2 points) or 
oa personal history  of psori asis or a family  history  of psori asis (1 point)
Typical  psori atic nail dystrophy  including ony cholysis, pitting, and 
hyperkeratosis observed on current physical examinat ion (1 point)
A negat ive test result for the presence of rheumatoid factor by any method 
except l atex (1point)
Either current dactylit is, defined as swelling of an ent ire digit, or a hi story  of 
dactylit is recorded by  a rheumatol ogist (1 point)
Radiographic evidence of juxta -articular new bone format ion appearing as ill-
defined ossificat ion near j oint margins (but excluding osteophy te formation) 
on plain radiographs of the hand or foot (1 point)
If any o f the above individual categories have a missing score, then the CASPAR total score will 
be the sum o f the non -missing categories.  If all o f the above categories are missing then the 
CASPAR total  score will equal 0.
Note the fo llowing:
Current psoriasis is defined as psoriat ic skin or scalp disease present today  as 
judged by  a rheumatol ogist or dermatologist. †
A personal history  of psori asis is defined as a history  of psori asis that m ay be 
obtained fro m a pati ent, f amily  physician, dermatologist, rheumatologist, or 
other qualified healt h care provider.  
A family history  of psori asis is defined as a history of psoriasis in a first -or 
second -degree rel ative according to patient report.
Taylor, W, Gladman, D, Helliwell, P, Marchesoni, A, Mease, P, Mielants, H, CASPAR Study  
Group. Classificat ion criteria for psori atic arthrit is: development of new criteria from a large 
internat ional study . Arthritis Rheum. 2006;54(8):2665 –2673.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 138
LY24398271Appendix 2. Algorithm f or Calculating Coates Criteria 
for Minimal Disease A ctivity  (MDA )
Coates criteria for MDA defines a state of disease activit y and not a change in disease and 
includes all attributes of PsA.  Coates criteria for MDA uses a co mposite of 7 key outcome 
measure s.  A pati ent is considered as achieving MDA if they  fulfill 5 of the following 7 outcome 
criterion (Coates et al . 2010; Coates and Helliwell 2010) :
TJC ≤ 1;
SJC ≤ 1;
PASI total  score ≤ 1 or BSA ≤ 3;
Patient pain VAS score of ≤ 15;
Patient gl obal VAS score of ≤ 20;
HAQ -DI score ≤ 0.5;
Tender entheseal points (of 18 entheseal po ints) ≤ 1.
The m odified Coates cri teria for MDA is calculated in the same manner as the Coates criteria for 
MDA subst ituting sPGA for PASI.  Therefore, a patient is considered as achieving modified 
MDA if they fulfill 5 of the fo llowing 7 outcom e criterion (Mease et al . 2013):
TJC ≤ 1;
SJC ≤ 1;
sPGA (0,1) or BSA ≤ 3;
Patient pain VAS score of ≤ 15;
Patient gl obal VAS score of ≤ 20;
HAQ -DI score ≤ 0.5;
Tender entheseal points (of 18 entheseal po ints) ≤ 1.
Note the 18 tender entheseal po ints are measured from combining the unique entheseal sites fro m 
the LEI and the SPARCC.  The LEI consists of 6 entheseal sites and the SPARCC consists of 16 
entheseal sites.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 139
LY24398271Appendix 3. Algorithm for Calculating Joint Counts
Joints are evaluated and recorded as either non -evaluable, or if evaluable, then if tenderness is 
present or absen t, and if swelling is present or absent.  In total, 68 joints are assessed for 
tenderness and 66 are assessed for swelling.  Hips are not assessed for swelling.
The number of tender/swo llen jo ints will be calculated by  summing all jo ints checked to have 
tenderness/swelling present.  If at least half but not all o f the joints are evaluable, then the 
observed prorated jo int count will be calculated instead.  The prorated scores for TJC will be 
adjusted based upon the number of evaluable jo ints:  the counted s core will be mult iplied by  68 
then divided by the number of jo ints evaluated (excluding non -evaluable j oints and any  joints 
with a missing response).  For example:  if only 60 of the 68 joints are assessed to be evaluable 
at a visit, and 32 of those 60 are tender, the prorated jo int count is (32/60)×68=36.27 (not 32) . 
The prorated jo int coun t will be rounded up to the next integer and be used in calculat ing the 
percent change fro m baseline in TJC.  The same algorithm will be applied to the calculat ion of 
percent change fro m baseline in SJC with the exception that the counted score will be mult iplied 
by 66 then divided by the number of jo ints evaluated.  If less than half of the jo ints are evaluable, 
the number of tender/swollen jo ints is missing.
This same algori thm will be used for the calculat ion of TJC and SJC based on 28 jo ints, which is 
part of the 28 diarthrodial joint count, based on C -reactive protein (DAS28 -CRP) score.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 140
LY24398271Appendix 4. Algorithm for Calculating the Health 
Assessment Questionnaire –Disability  Index ( HAQ-DI)
The Health Assessment Questionnaire –Disabilit y Index (HAQ -DI) is a pati ent-reported 
questionnaire to measure disease -associated disabilit y (assessment of physical function).  It 
consists of 24 questions referring to 8 domains:  dressing/grooming, a rising, eating, walking, 
hygiene, reach, grip, and act ivities (Fries et al. 1980, 1982).  
Dressing and grooming (C1.  Dress y ourself, including tying shoelaces and doing 
buttons, C2.  Shampooing y our Hai r)
oIncludes 2 component questions, 1 device checkbox (devices used for dressing), 1 
help checkbox
Arising (C1.  Stand up from straight chair, C2.  Get in and out of bed)
oIncludes 2 component questions, 1 device checkbox (built -up or speci al chair), 1 
help checkbox
Eating (C1.  Cut y our m eat, C2.  Lift a cup or glass to y our m outh, C3.  Open a new 
carton of milk)
oIncludes 3 component questions, 1 device checkbox (build -up or speci al utensils), 
1 help checkbox)
Walking (C1.  Walk outdoors on flat ground, C2.  Climb up 5 steps)
oIncludes 2 component questions, 4 device checkboxes (cane, walker, crutches, 
wheelchair), 1 help checkbox
Hygiene (C1.  Wash and dry  your body , C2.  Take a tub bath, C3.  Gen on and off the 
toilet)
oIncludes 3 component questions, 4 device checkboxes (raised toilet seat, bathtub 
seat, bath tub bar, long -handled appliances in bathroom), 1 help checkbox.
Reach (C1.  Reach and get down a 5 pound object (such as a bag of sugar) from just 
above y our head, C2.  Bend down to pick up clothing from the floor)
oIncludes 2 component questions, 1 device checkbox (l ong-handled appliances for 
reach), 1 help checkbox
Grip (C1.  Open car doors, C2.  Open jars which have been previously  opened, C3.  Turn 
faucets on and off)
oIncludes 3 component questions, 1 device checkbox (jar opener), 1 help checkbox
Activities (C1.  Run errands and shop, C2.  Get in and out of a car, C3.  Do chores such 
as vacuuming or y ard work)
oIncludes 3 component questions, 1 help checkbox
In order to compute the HAQ -DI (Standard Di sabili ty Index) score, the following scores are 
assigned to the responses:
Without any  difficul ty = 0
With some difficult y = 1
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 141
LY24398271With much difficult y = 2
Unable to do = 3.
The disabilit y secti on of  the questi onnaire scores the pat ient’s self -percept ion on the degree of 
difficult y (0 = without any  difficul ty, 1 = with some difficult y, 2 = wi th much difficult y, and 3 = 
unable to do) when dressing and grooming, arising, eating, walking, hygiene, reach, grip, and 
performing other daily  activities.  The reported use of special aids or devices and/or the need for 
assist ance of another person to perform these act ivities is also assessed.  The scores for each of 
the funct ional do mains will be averaged to calculate the funct ional disabilit y index.  
Calculating the HAQ -DI:
The patient must have a score for at least 6 of the 8 categori es.  If there are <6 categories 
completed, a HAQ -DI cannot be computed.
A category  score is determined from the highest score of the subcategories, or 
components, in that category .  (For exam ple, in the category  ARISING there are 3 sub-
category items.  If a patient responds with a 1, 2, and 0, respectively; the category score is 2.)
Adjust for use of aids/devices and/or help fro m another person when indicated:
oWhen there are no aids or devices or help indicated for a category, the category’s 
score is not modified.  
When aids or devices or help ARE indicated by the patient, adjust the score 
for a category by increasing a 0 or a 1 to a 2.  If a patient’s highest score for 
that sub -category is a 2 it remains a 2, and if a 3, it remains a 3.
oSum the 8 category scores
oDivide the sum by the number of categories answered (range 6 -8).
The scale is not truly continuous but has 25 possible values (that i s, 0, 0.125, 0.250, 0.375 … 3).  
The m apping of the aids or devices to the categories is the following:
HAQ-DI Category Companion aids or devices item
Dressing and Grooming Devices used for dressing (button hook, zipper pull, long handled shoe horn, etc.)
Arising Built up or special chair
Eating Built up or special utensils
Walking Cane, walker, crutches, wheelchair
Hygiene Long handled appliances in bathroom; bathtub seat; raised toilet seat;  bathtub bar
Reach Long handled appliances for reach
Grip Jar opener (for jars previously opened)
Abbreviations:  HAQ -DI = Health Assessment Questionnaire –disability index.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 142
LY24398271Appendix 5. Algorithm for Determining A merican 
College of Rheumatology  (ACR) Response
Details presented in this appendix will use “ x” as a generic symbo l, and the appropriate number 
(either 20, 50, or 70) is to be filled in when impleme nting in dataset programming code.  
American Co llege of Rheumatology (ACRx) response is defined as ≥x% improvement from  
baseline in tender jo int count (68 counts) and ≥x% improvement in swo llen jo int count 
(66counts), and ≥x% improvem ent in at l east 3 of the following 5 i tems:
Patient’s gl obal assessment of arthri tis pain
Patient’s gl obal assessment of di sease act ivity
Physician’s global assessment of disease activit y
Health Assessment Questi onnaire –Disabilit y Index (HAQ -DI)
C
-reactive protein (CRP)
The following abbreviat ions will be used throughout this appendix to refer to the items needed in 
the algorithm defini tions:
Parameter Abbreviation for the Parameter
% improvement in tender joint count TJC68
% improvement in swollen joint count SJC66
% impr ovement in patient’s assessment pain PATPAIN
% improvement in patient’s global assessment of disease activity PATGA
% improvement in physician’s global assessment of disease activity PHYGA
% improvement in HAQ -DI HAQ
% improvement in CRP CRP
For all 7 parameters ment ioned above, % improvement at a visit is calculated as:
(baseline value –value at visit) * 100 / baseline value.
To cal culate the observed ACR xresponse at a visit :
Step1:  If the patient discont inued fro m the study  prior to reaching the visit, then STOP –
assign ACR xresponse as blank (that is, missing).  Otherwise, calculate the % 
improvement at the visit for all 7 parameters as described above.  
Step2:  
oIf 68 total jo int count score (TJC68) AND 66 swollen jo int count score (SJC66)
are BOTH ≥x%, then proceed to Step 3.  
oIf both are non -missing but one or both is <x%, then STOP –assign the patient as 
a nonresponder for ACR x.  
oIf eit her or both are missing, proceed as fo llows:
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 143
LY24398271a.If both are missing, then STOP –assign ACR xresponse a s blank (that is, 
missing).
b.If one of TJC68 or SJC66 is missing and the non- missing value is < x%, then 
STOP –assign the patient as a nonresponder for ACR x.
c.If one of TJC68 or SJC66 is missing and the non- missing value is ≥x%, then 
STOP –assign ACR xresponse as blank (that is, missing).
Step3:  Consider the fo llowing 5 variables:  patient’s assessment pain (PATPAIN ), 
patient’s gl obal assessment of di sease act ivity (PATGA ), physician’s global assessment 
of disease activit y (PHYGA ),HAQ, and CRP.
oIf 3 or more items are missing, then STOP –assign ACR xresponse as blank (that 
is, missing).
oIf 3 or more items are non- missing, then proceed with the following order:
d.If at least 3 items are ≥x%, then STOP –assign the patient as a responder for 
ACRx.
e.If at l east 3 i tems are < x%, then STOP –assign the patient as a nonresponder 
for ACRx.
f.If <3 items are ≥x%, then STOP –assign ACR xresponse as blank (that is, 
missing).
To cal culate the ACR xresponse at post-baseline visits up to Week 104 using NRI :
Step 1:  Ca lculate the % improvement at the visit for all 7 parameters as described above.
Step 2:  If all 7 parameters are missing at the visit, or if the pat ient discont inued from the 
study  prior to reaching the visit, then STOP –assign the patient as a nonrespond er for 
ACR x.
Step 3:  If at least 1 of the 7 parameters is non- missing at the visit and the patient is still 
enrolled in the study , then use LOCF to fill in any missing values.
Step 4:  If TJC68 AND SJC66 are BOTH ≥x%, then proceed to Step 5.  If both are non-
missing but one or both is < x%, then STOP –assign the patient as a nonresponder for 
ACR x.  If either or both are missing, then STOP –assign the patient as a nonresponder 
for ACR x.
Step 5:  Consider the fo llowing 5 variables:  PATPAIN, PATGA, PHYGA, H AQ, CRP.
oIf 3 or more of the 5 items are non -missing, then:
If 3 or more of the 5 items are ≥x%, then STOP –assign the patient as a 
responder for ACR x.
If <3 of those 5 items are ≥x%, then STOP –assign the patient as a 
nonresponder for ACR x.
oIf ≥3 of the 5 items are missing, then STOP –assign the patient as a nonresponder 
for ACR x.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 144
LY24398271Appendix 6. Derivation of SF -36v2 ®Health Survey , 
Acute Version Scores
The SF -36v2 ®Health Survey  Scoring Software (Qualit yMetri c Heal th Outcom es™ Scoring 
Software 4.5) will be used to ca lculate the SF -36v2® 8 -domain and 2 -component summary  
scores (Sari s-Baglama et al. 2004) .  The Medical Outcomes Study  36-Item Short -Form  Heal th 
Survey  (SF-36) is a 36 -item, pati ent-completed measure designed to be a short, mult ipurpose 
assessment of healt hin the areas of physical functioning, role -physical, role -emotional, bodily  
pain, vitalit y, social functi oning, m ental  health, and general healt h.  The 2 overarching 
dimensio ns of m ental  well -being and physical well- being are captured by  the Physical  
Com ponent Summary (PCS) and Mental Component Summary  (MCS) scores, respectively.  The 
summary scores range fro m 0to 100, with higher scores indicat ing better levels of funct ion 
and/or better health.  Items are answered on Likert scales o f varying lengths.  In this study , the 
SF-36 acute version will be used, which has a 1 -week recall.
The Scoring Software performs a 4- step process to calculate raw domain scores and t -scores 
consist ing of
1.Data Cl
eaning and Item  recording:  First, data are checked for out of range values, 
convert ing invalid items to missing values.  Next, items (BP01, BP02, GH01, GH03, 
GH05, VT01, VT02, SF01, MH03, MH05) are reverse scored, so that higher scores 
denote bette r health for all SF -36 items.
2.Although current research indicates a linear relat ionship between the SF -36 items and the 
underlying healt h concept, empirical research suggests that items GH01 and BP01 require 
recalibrat ion to satisfy important scaling assumpt ions.  Item  GH01 will be rescored 
according to the fo llowing table: 
Response to GH01 Recommended Value / Recalibrated Value
Excellent 5.0
Very  Good 4.4
Good 3.4
Fair 2.0
Poor 1.0
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 145
LY24398271The BP01 will be rescored with 
Response Choices Final Item Value
None 6.0
Very  mild 5.4
Mild 4.2
Moderate 3.1
Severe 2.2
Very  severe 1.0
Item 08 (BP02) will be rescored if BP01 and BP02 were answered
Response Choices If BP02 Pre -coded 
Item Valueand BP01 Pre -coded 
Item ValueThen Final Item 08 
(BP02) Value
Notat all 1 1 6
Not at all 1 2-6 5
A little bit 2 1-6 4
Moderately 3 1-6 3
Quite a bit 4 1-6 2
Extremely 5 1-6 1
Scoring of BP02 if BP01 is not answered:
Response Choices Final Item Value
Not at all 6.0
A little bit 4.75
Moderately 3.5
Quite a bit 2.25
Extremely 1.0
3.After thi s rescoring, the raw domain scores will be calculated for the scale.  Domain 
scores are the simple algebraic sum of the final values for all items in that scale.
4.All raw do main scores will be transformed to a 0 -100 scale, with 0 being the lowest and 
100 the highest possible score.
5.Finally , the 0 -100 scores will be transformed to t -score based scores.  First, a z -score 
transformation using the mean for the respective recall period, here 1 week recall, of the 
1998 gene ral U.S. populati on will  be used.  Then the distribut ion of z -score i s linearly 
transformed to have a mean of 50 and a SD of 10 by mult iplying each z -score wi th 10 
and adding 50.
The calculat ion of component scores is a 3 -step process using the domain scor es, cal culated as 
described above:
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 146
LY243982711.The standardized scores fro m Step 5, depending on the chosen recall period, are 
calculated.
2.These standardized Physical and Mental component scores are calculated as the weighted 
sums by the factor score coefficients, derived fro m the 1990 general US population, with 
the dom ain scores.  If any do main score is missing then the aggregate Phy sical or Mental  
score will not be calculated.
3.The PCS and MCS are linearly  transformed by mult iplying by 10 and adding 50 to obtain 
the aggregate t -score based scoring.
To run the scoring algorithm, the SF -36 items recorded in the study  database will be exported 
into a comma -or tab -separated values file (*.csv, *.tab).  This file will then be loaded into the 
Scoring Software to perform the calculat ions described above.  The result ing raw domain scores 
and t -scores (domain scores) will then be exported into a comma -or tab -separated values file and 
imported into SAS for storage in the Study  Data Tabulat ion Mode/Analysis Data Model 
(SDTM/ADaM) datasets.
The comma -or tab -separated values file, each row will be one patient record and the first row 
will co mprise the header columns, will have the following column specificat ion:  (to comply  
with the Scori ng Software requirements)
eCRF 
Row 
#Column label 
for export to 
comma -or 
tab-separated 
values file 
[*.csv, *.tab]Annotated SF -36 eCRF 
Variable 
[Format: 
SF36V2RXX_SF36V2F1 ]Item Number, 
Score rangeeCRF q uestion / Specification
1 GH01 [SF36V2R01_SF36V2F1] Item #   1, 
Range 1 -5In general, would you say your health is:
2 HT [SF36V2R02_SF36V2F1] Item #   2, 
Range 1 -5Compared to one week ago, how would 
you rate y our health in general now?
3 PF01 [SF36V2R03_SF36V2F1] Item #  3a, 
Range 1 -3Vigorous activities, such as running, 
lifting heavy objects, participating in 
strenuous sports
4 PF02 [SF36V2R04_SF36V2F1] Item #  3b, 
Range 1 -3Moderate activities, such as moving a 
table, pushing a vacuum clean er, bowling, 
or play ing golf
5 PF03 [SF36V2R05_SF36V2F1] Item #  3c, 
Range 1 -3Lifting or carrying groceries
6 PF04 [SF36V2R06_SF36V2F1] Item #  3d, 
Range 1 -3Climbing several flights of stairs
7 PF05 [SF36V2R07_SF36V2F1] Item #  3e, 
Range 1 -3Climbing one flight of stairs
8 PF06 [SF36V2R08_SF36V2F1] Item #  3f, 
Range 1 -3Bending, kneeling, or stooping
9 PF07 [SF36V2R09_SF36V2F1] Item #  3g, 
Range 1 -3Walking more than a mile
10 PF08 [SF36V2R10_SF36V2F1] Item #  3h, Walking several hundred yards
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 147
LY24398271eCRF 
Row 
#Column label 
for export to 
comma -or 
tab-separated 
values file 
[*.csv, *.tab]Annotated SF -36 eCRF 
Variable 
[Format: 
SF36V2RXX_SF36V2F1 ]Item Number, 
Score rangeeCRF q uestion / Specification
Range 1 -3
11 PF09 [SF36V2R11_SF36V2F1] Item #  3i, 
Range 1 -3Walking one hundred yards
12 PF10 [SF36V2R12_SF36V2F1] Item #  3j, 
Range 1 -3Bathing or dressing yourself
13 RP01 [SF36V2R13_SF36V2F1] Item #  4a, 
Range 1 -5Cut down the amount of time you spent 
on work or other activities
14 RP02 [SF36V2R14_SF36V2F1] Item #  4b, 
Range 1 -5Accomplished less than you would like
15 RP03 [SF36V2R15_SF36V2F1] Item #  4c, 
Range 1 -5Were limited in the kind of work or other 
activities
16 RP04 [SF36V2R16_SF36V2F1] Item #  4d, 
Range 1 -5Had difficulty performing the work or 
other activities (for example, it took extra 
effort)
17 RE01 [SF36V2R17_SF36V2F1] Item #  5a, 
Range 1 -5Cut down the amount of time you spent 
on work or other activities
18 RE02 [SF36V2R18_SF36V 2F1] Item #  5b, 
Range 1 -5Accomplished less than you would like
19 RE03 [SF36V2R19_SF36V2F1] Item #  5c, 
Range 1 -5Did work or other activities less carefully 
than usual
20 SF01 [SF36V2R20_SF36V2F1] Item #   6, 
Range 1 -5During the past week, to what extent has 
your physical health or emotional 
problems interfered with your normal 
social activities with family, friends, 
neighbors, or groups?
21 BP01 [SF36V2R21_SF36V2F1] Item #   7, 
Range 1 -6How much bodily pain have you had 
during the past week?
22 BP02 [SF36V2R22_SF36V2F1] Item #   8, 
Range 1 -5During the past week, how much did pain 
interfere with your normal work 
(including both work outside the home 
and housework)?
23 VT01 [SF36V2R23_SF36V2F1] Item #  9a, 
Range 1 -5Did you feel full of life?
24 MH01 [SF36V2R24_SF36V2F1] Item #  9b, 
Range 1 -5Have you been very nervous?
25 MH02 [SF36V2R25_SF36V2F1] Item #  9c, 
Range 1 -5Have you felt so down in the dumps that 
nothing could cheer you up?
26 MH03 [SF36V2R26_SF36V2F1] Item #  9d, 
Range 1 -5Have you felt calm and peaceful?
27 VT02 [SF36V2R27_SF36V2F1] Item #  9e, 
Range 1 -5Did you have a lot of energy?
28 MH04 [SF36V2R28_SF36V2F1] Item #  9f, 
Range 1 -5Have you felt downhearted and 
depressed?
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 148
LY24398271eCRF 
Row 
#Column label 
for export to 
comma -or 
tab-separated 
values file 
[*.csv, *.tab]Annotated SF -36 eCRF 
Variable 
[Format: 
SF36V2RXX_SF36V2F1 ]Item Number, 
Score rangeeCRF q uestion / Specification
29 VT03 [SF36V2R29_SF36V2F1] Item #  9g, 
Range 1 -5Did you feel worn out?
30 MH05 [SF36V2R30_SF36V2F1] Item #  9h, 
Range 1 -5Have you been happy?
31 VT04 [SF36V2R31_SF36V2F1] Item #  9i, 
Range 1 -5Did you feel tired?
32 SF02 [SF36V2R32_SF36V2F1] Item #  10, 
Range 1 -5During the past week, how much of the
time has your physical health or 
emotional problems interfered with your 
social activities (like visiting with friends, 
relatives, etc.)?
33 GH02 [SF36V2R33_SF36V2F1] Item # 11a, 
Range 1 -5I seem to get sick a little easier than other 
people
34 GH03 [SF36V2R34_SF36V2F1] Item # 11b, 
Range 1 -5I am as healthy as anybody I know
35 GH04 [SF36V2R35_SF36V2F1] Item # 11c, 
Range 1 -5I expect my health to get worse
36 GH05 [SF36V2R36_SF36V2F1] Item # 11d, 
Range 1 -5My health is excellent
SUBJID Subjects ID
VISID Visid ID
Gender Sex coded as: f/m
DateOfBirth Date of birth formatted as: mm/dd/yyyy 
(when scoring software is run in US), or 
dd/mm/yyyy (when scoring software is 
run in no n-US)
RecordID Running number for the exported records
Abbreviations:  eCRF = electronic case report form; SF -36 = Medical Outcomes Study 36 -Item Sho rt-Form Health 
Survey.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 149
LY24398271The SF -36 Scori ng Software will derive raw domain scores and t -scores that can be exported into 
a comma -or tab -separated values file (*.csv, *.tab) with the fo llowing co lumns added:
Column label added to comma -or tab -
separated values file from export 
[*.csv, *.tab]Scoring Software specification
PF Physical Functioning domain score
RP Role Limitations Due To Physical Health domain s core
BP Bodily Pain domain score
GH General Health Perceptions domain score
VT Vitality domain score
SF Social Functioning domain score
RE Role Limitations Due To Emotional Problems domain score
MH Mental Health domain score
PCS Physical Component score
MCS Mental health Component score
For scoring the trial data, the Missing Data Estimator option will not be selected.  If an item is 
missing, there will be no imputation conducted by  the Scoring Software.  Only complete 
questionnaire data will be scored.
The Scoring Software also allows for calculat ing domain and component scores from weights 
derived fro m anoblique factor sol ution for com parative purposes.  This option will notbe used.
The SF -36 scoring using the Scoring Software will be conducte d by a 2 person team  overseeing 
each other in a single scoring sessio n.  In case of relevant observat ions during the scoring, those 
will be documented in pertinent meeting minutes and filed as part of the study  docum entati on.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 150
LY24398271Appendix 7. Anti-infective Medications and Anatomical 
Therapeutic Chemical (A TC) Code List and 
Programming Guide
This appendix provides the code list of Anatomical Therapeutic chemical (ATC) of ant i-infect ive 
medicat ions and the programming guidance.  
ATC 
CodeATC 
Level ATC Description (Based on ATC Dictionary 18Jan2016 )
A01AB 4 ANTIINFECTIVES AND ANTISEPTICS FOR LOCAL ORAL TREA
A02BD 4 COMBINATIONS FOR ERADICATION OF HELICOBACTER PYLOR
A07A 3 INTESTINAL ANTIINFECTIVES
A07AA 4 ANTIBIOTICS
A07AB 4 SULFONAMIDES
A07AC 4 IMIDAZOLE DERIVATIVES
A07AX 4 OTHER INTESTINAL ANTIINFECTIVES
B05CA 4 ANTIINFECTIVES
C05AB 4 ANTIBIOTICS
D01 2 ANTIFUNGALS FOR DERMATOLOGICAL USE
D01A 3 ANTIFUNGALS FOR TOPICAL USE
D01AA 4 ANTIBIOTICS
D01AC 4 IMIDAZOLE AND TRIAZOLE DERIVATIVES
D01AE 4 OTHER ANTIFUNGALS FOR TOPICAL USE
D01B 3 ANTIFUNGALS FOR SYSTEMIC USE
D01BA 4 ANTIFUNGALS FOR SYSTEMIC USE
D06 2 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGIC
D06A 3 ANTIBIOTICS FOR TOPICAL USE
D06AA 4 TETRACYCLINE AND DERIVATIVES
D06AX 4 OTHER ANTIBIOTICS FOR TOPICAL USE
D06B 3 CHEMOTHERAPEUTICS FOR TOPICAL USE
D06BA 4 SULFONAMIDES
D06BB 4 ANTIVIRALS
D06BX 4 OTHER CHEMOTHERAPEUTICS
D06C 3 ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
D07C 3 CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
D07CA 4 CORTICOSTEROIDS, WEAK, COMBINATIONS WITH ANTIBIOTICS
D07CB 4 CORTICOSTEROIDS, MODERATELY POTENT, COMBINATIONS WITH ANTIBIOTICS
D07CC 4 CORTICOSTEROIDS, POTENT, COMBINATIONS WITH ANTIBIOTICS
D07CD 4 CORTICOSTEROIDS, VERY POTENT, COMBINATIONS WITH ANTIBIOTICS
D09AA 4 MEDICATED DRESSINGS WITH ANTIINFECTIVES
D10AF 4 ANTIINFECTIVES FOR TREATMENT OF ACNE
G01AA 4 ANTIBIOTICS
G01AC 4 QUINOLINE DERIVATIVES
G01AE 4 SULFONAMIDES
G01AF 4 IMIDAZOLE DERIVATIVES
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 151
LY24398271ATC 
CodeATC 
Level ATC Description (Based on ATC Dictionary 18Jan2016 )
G01AG 4 TRIAZOLE DERIVATIVES
G01AX 4 OTHER ANTIINFECTIVES AND ANTISEPTICS
G01BA 4 ANTIBIOTICS AND CORTICOSTEROIDS
G01BC 4 QUINOLINE DERIVATIVES AND CORTICOSTEROIDS
G01BE 4 SULFONAMIDES AND CORTICOSTEROIDS
G01BF 4 IMIDAZOLE DERIVATIVES AND CORTICOSTEROIDS
G04AB 4 QUINOLONE DERIVATIVES (EXCL. J01M)
G04AC 4 NITROFURAN DERIVATIVES
G04AG 4 OTHER URINARY ANTISEPTICS AND ANTIINFECT
G04AH 4 SULFONAMIDES IN COMBINATION WITH OTHER DRUGS
G04AK 4 URINARY ANTISEPT&ANTIINF, COMB EXCL SULFONAMIDES
J01 2 ANTIBACTERIALS FOR SYSTEMIC USE
J01A 3 TETRACYCLINES
J01AA 4 TETRACYCLINES
J01B 3 AMPHENICOLS
J01BA 4 AMPHENICOLS
J01C 3 BETA -LACTAM ANTIBACTERIALS, PENICILLINS
J01CA 4 PENICILLINS WITH EXTENDED SPECTRUM
J01CE 4 BETA -LACTAMASE SENSITIVE PENICILLINS
J01CF 4 BETA -LACTAMASE RESISTANT PENICILLINS
J01CG 4 BETA -LACTAMASE INHIBITORS
J01CR 4 COMBINATIONS OF PENICILLINS, INCL. BETA -LACTAMASE
J01D 3 OTHER BETA -LACTAM ANTIBACTERIALS
J01DA 4 CEPHALOSPORINS AND RELATED SUBSTANCES
J01DB 4 FIRST -GENERATION CEPHALOSPORINS
J01DC 4 SECOND -GENERATION CEPHALOSPORINS
J01DD 4 THIRD -GENERATION CEPHALOSPORINS
J01DE 4 FOURTH -GENERATION CEPHALOSPORINS
J01DF 4 MONOBACTAMS
J01DH 4 CARBAPENEMS
J01DI 4 OTHER CEPHALOSPORINS
J01E 3 SULFONAMIDES AND TRIMETHOPRIM
J01EA 4 TRIMETHOPRIM AND DERIVATIVES
J01EB 4 SHORT -ACTING SULFONAMIDES
J01EC 4 INTERMEDIATE -ACTING SULFONAMIDES
J01ED 4 LONG -ACTING SULFONAMIDES
J01EE 4 COMBINATIONS OF SULFONAMIDES AND TRIMETHOPRIM, INC
J01F 3 MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01FA 4 MACROLIDES
J01FF 4 LINCOSAMIDES
J01FG 4 STREPTOGRAMINS
J01G 3 AMINOGLYCOSIDE ANTIBACTERIALS
J01GA 4 STREPTOMYCINS
J01GB 4 OTHER AMINOGLYCOSIDES
J01M 3 QUINOLONE ANTIBACTERIALS
J01MA 4 FLUOROQUINOLONES
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 152
LY24398271ATC 
CodeATC 
Level ATC Description (Based on ATC Dictionary 18Jan2016 )
J01MB 4 OTHER QUINOLONES
J01R 3 COMBINATIONS OF ANTIBACTERIALS
J01RA 4 COMBINATIONS OF ANTIBACTERIALS
J01WA 4 HERBAL ANTIBACTERIALS FOR SYSTEMIC USE
J01WB 4 HERBAL URINARY ANTISEPTICS AND ANTIINFECTIVES
J01X 3 OTHER ANTIBACTERIALS
J01XA 4 GLYCOPEPTIDE ANTIBACTERIALS
J01XB 4 POLYMYXINS
J01XC 4 STEROID ANTIBACTERIALS
J01XD 4 IMIDAZOLE DERIVATIVES
J01XE 4 NITROFURAN DERIVATIVES
J01XX 4 OTHER ANTIBACTERIALS
J02 2 ANTIMYCOTICS FOR SYSTEMIC USE
J02A 3 ANTIMYCOTICS FOR SYSTEMIC USE
J02AA 4 ANTIBIOTICS
J02AB 4 IMIDAZOLE DERIVATIVES
J02AC 4 TRIAZOLE DERIVATIVES
J02AX 4 OTHER ANTIMYCOTICS FOR SYSTEMIC USE
J04AA 4 AMINOSALICYLIC ACID AND DERIVATIVES
J04AB 4 ANTIBIOTICS
J04AC 4 HYDRAZIDES
J04AK 4 OTHER DRUGS FOR TREATMENT OF TUBERCULOSIS
J04AM 4 COMBINATIONS OF DRUGS FOR TREATMENT OF TUBERCULOSI
J04B 3 DRUGS FOR TREATMENT OF LEPRA
J04BA 4 DRUGS FOR TREATMENT OF LEPRA
J05 2 ANTIVIRALS FOR SYSTEMIC USE
J05A 3 DIRECT ACTING ANTIVIRALS
J05AA 4 THIOSEMICARBAZONES
J05AB 4 NUCLEOSIDES AND NUCLEOTIDES EXCL. REVERSE TRANSCRI
J05AC 4 CYCLIC AMINES
J05AD 4 PHOSPHONIC ACID DERIVATIVES
J05AE 4 PROTEASE INHIBITORS
J05AF 4 NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE IN
J05AG 4 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
J05AH 4 NEURAMINIDASE INHIBITORS
J05AR 4 ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBIN
J05AX 4 OTHER ANTIVIRALS
P01A 3 AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISE
P01AA 4 HYDROXYQUINOLINE DERIVATIVES
P01AB 4 NITROIMIDAZOLE DERIVATIVES
P01AC 4 DICHLOROACETAMIDE DERIVATIVES
P01AR 4 ARSENIC COMPOUNDS
P01AX 4 OTHER AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOA
P01BA 4 AMINOQUINOLINES
P01BC 4 METHANOLQUINOLINES
P01BD 4 DIAMINOPYRIMIDINES
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 153
LY24398271ATC 
CodeATC 
Level ATC Description (Based on ATC Dictionary 18Jan2016 )
P01BE 4 ARTEMISININ AND DERIVATIVES, PLAIN
P01BF 4 ARTEMISININ AND DERIVATIVES, COMBINATIONS
P01BX 4 OTHER ANTIMALARIALS
P01C 3 AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
P01CA 4 NITROIMIDAZOLE DERIVATIVES
P01CB 4 ANTIMONY COMPOUNDS
P01CC 4 NITROFURAN DERIVATIVES
P01CD 4 ARSENIC COMPOUNDS
P01CX 4 OTHER AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMI
P02 2 ANTHELMINTICS
P02B 3 ANTITREMATODALS
P02BA 4 QUINOLINE DERIVATIVES AND RELATED SUBSTANCES
P02BB 4 ORGANOPHOSPHOROUS COMPOUNDS
P02BX 4 OTHER ANTITREMATODAL AGENTS
P02C 3 ANTINEMATODAL AGENTS
P02CA 4 BENZIMIDAZOLE DERIVATIVES
P02CB 4 PIPERAZINE AND DERIVATIVES
P02CC 4 TETRAHYDROPYRIMIDINE DERIVATIVES
P02CE 4 IMIDAZOTHIAZOLE DERIVATIVES
P02CF 4 AVERMECTINES
P02CX 4 OTHER ANTINEMATODALS
P02D 3 ANTICESTODALS
P02DA 4 SALICYLIC ACID DERIVATIVES
P02DW 4 HERBAL ANTICESTODALS
P02DX 4 OTHER ANTICESTODALS
P02WA 4 HERBAL ANTHELMINTICS
P03A 3 ECTOPARASITICIDES, INCL. SCABICIDES
P03AA 4 SULFUR CONTAINING PRODUCTS
P03AB 4 CHLORINE CONTAINING PRODUCTS
P03AC 4 PYRETHRINES, INCL. SYNTHETIC COMPOUNDS
P03AX 4 OTHER ECTOPARASITICIDES, INCL. SCABICIDES
P03BA 4 PYRETHRINES
R02AB 4 ANTIBIOTICS
S01A 3 ANTIINFECTIVES
S01AA 4 ANTIBIOTICS
S01AB 4 SULFONAMIDES
S01AD 4 ANTIVIRALS
S01AE 4 FLUOROQUINOLONES
S01AX 4 OTHER ANTIINFECTIVES
S01C 3 ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB
S01CA 4 CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
S01CB 4 CORTICOSTEROIDS/ANTIINFECTIVES/MYDRIATICS IN COMBI
S01CC 4 ANTIINFLAMMATORY AGENTS, NON -STEROIDS AND ANTIINFECTIVES
S02A 3 ANTIINFECTIVES
S02AA 4 ANTIINFECTIVES
S02C 3 CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 154
LY24398271ATC 
CodeATC 
Level ATC Description (Based on ATC Dictionary 18Jan2016 )
S02CA 4 CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
S03A 3 ANTIINFECTIVES
S03AA 4 ANTIINFECTIVES
S03C 3 CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
S03CA 4 CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
Abbreviation:  ATC = World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC) 
Anatomical Therapeutic Chemical (ATC) classification system.
For the above list, the higher level o f ATC includes al l the lower l evels under that l evel, for 
example, level 2 term includes all the level 3 terms under it, level 3 term includes all the level 4 
terms under i t.  Therefore, for programming simplicit y, the table below provides all the required 
ATC codes by  highest l evel.
ATC Level 2 ATC Level 3 ATC Level 4
A01AB
A02BD
A07A
B05CA
C05AB
D01
D06
D07C
D09AA
D10AF
G01AA
G01AC
G01AE
G01AF
G01AG
G01AX
G01BA
G01BC
G01BE
G01BF
G04AB
G04AC
G04AG
G04AH
G04AK
J01
J02
J04AA
J04AB
J04AC
J04AK
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 155
LY24398271ATC Level 2 ATC Level 3 ATC Level 4
J04AM
J04B
J05
P01A
P01BA
P01BC
P01BD
P01BE
P01BF
P01BX
P01C
P02
P03A
P03BA
R02AB
S01A
S01C
S02A
S02C
S03A
S03C
Abbreviation:  ATC = World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC) 
Anatomical Therapeutic Chemical (ATC) classification system.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 156
LY24398271Appendix 8. MedDRA  Preferred Terms for Each 
Category  Associated with Criterion 2 for A naph ylactic 
Allergic Reactions/Hypersensitivity  Events
Preferred Terms (MedDRA Version 21.0)
Category A:  Involvement of the Skin/Mucosal Tissue
Administration site hypersensitivity
Administration site rash
Administration site urticarial
Allergic oedema
Allergic otitis externa
Angioedema
Circumoral oedema
Drug eruption
Erythema
Eye allergy
Eye oedema
Eye pruritus
Eye swelling
Eyelid oedema
Face oedema
Flushing
Generalised erythema
Gingival oedema
Gingival swelling
Idiopathic urticaria
Injection site dermatitis
Injection site hypersensitivity
Injection site rash
Injection site urticaria
Injection site vasculitis
Lip oedema
Lip swellingLocalised oedema
Mouth swelling
Nasal obstruction
Nodular rash
Ocular hy peraemia
Oedema
Oedema mouth
Oedema mucosal
Orbital oedema
Palatal oedema
Palatal swelling
Perineal rash
Periorbital oedema
Pruritus
Pruritus allergic
Pruritus generalised
Rash
Rash erythematous
Rash generalised
Rash pruritic
Skin oedema
Skin swelling
Swelling
Swelling face
Swollen to ngue
Tongue oedema
Urticaria
Urticaria papular
Category B:  Respiratory Compromise
Acute respiratory failure
Allergic cough
Allergic pharyngitis
Asthma
Asthmatic crisis
Bronchial hyperreactivity
Bronchial oedema
Bronchospasm
Cardio -respiratory  distress
Chest discomfort
ChokingLaryngotracheal oedema
Orophary ngeal spasm
Orophary ngeal swelling
Pharyngeal oedema
Respiratory  arrest
Respiratory  distress
Respiratory  failure
Respiratory  tract oedema
Reversible airways obstruction
Sensation of foreign body
Sneezing
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 157
LY24398271Preferred Terms (MedDRA Version 21.0)
Choki ng sensation
Cough
Cyanosis
Dyspnoea
Epiglottic oedema
Hyperventilation
Hypoxia
Laryngeal dy spnoea
Laryngeal obstruction
Laryngeal oedema
Laryngitis allergic
LaryngospasmSpasmodic dysphonia
Status athmaticus
Stridor
Tachy pnea
Throat tightness
Tracheal obstruction
Tracheal oedema
Upper airway obstruction
Wheezing
Category C:  Reduced Blood Pressure or Associated Symptoms
Blood pressure decreased
Blood pressure diastolic decreased
Blood pressure systolic decreased
Cardiac arrest
Cardiopulmonary failure
Cardio -respiratory  arrest
Cardiovascular insufficiency
Circulatory collapse
Diastolic hypotension
Distributive shock
DizzinessHypoperfusion
Hypotension
Hypovolaemic shock
Incontinence
Mean arterial pressure decreased
Peripheral circulatory failure
Presy ncope
Shock
Shock symptom
Syncope
Urinary  Incontinence
Category D:  Persistent Gastrointestinal Symptoms
Abdominal discomfort
Abdominal pain
Abdominal pain lower
Abdominal pain upper
Diarrhoea
Epigastric discomfort 
Gastrointestinal oedemaGastrointestinal pain
Intestinal angioedema
Nausea
Retching
Visceral pain
Vomiting
Abbreviations:  MedDRA = Medical Dictionary for Regulatory Activities.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 158
LY24398271Appendix 9. Allergic Reactions/Hypersensitivity  
MedDRA  Preferred Terms 
Allergic reactions/hypersensit ivities will be defined using the following MedDRA Preferred 
Terms as defined in MedDRA:
Broad and narrow terms in the Anaphylact ic react ion SMQ (20000021) 
Broad and narrow terms in the Angioedema SMQ (20000024) 
Broad and narrow terms in the Severe cutaneous adverse react ions SMQ (20000 020)
Broad and narrow terms in the Hypersensit ivity SMQ (20000214) excluding the 
preferred terms as noted below.
The fo llowing Preferred Terms (based on review of MedDRA Versio n 21.0) from  the 
Hypersensi tivity SMQ will  be excluded from  the analysis:  
Administration site dermatitis
Administration site eczema
Administration site rash
Admin i
stratio n site recall reaction
Allergic otitis externa
Allergic ot itis media
Allergic sinusitis
Allergic transfusion reaction
Allergy alert test positive
Allergy test positive
Allergy to surgical sutures
Allergy to vaccine
Anaphy lactic transfusion reaction
Antiallergic therapy 
Application site dermatitis
Application site eczema
Application site hypersensitivity
Application site rash
Application site recall reaction
Application site urticaria
Application site vasculitis
Arthritis allergic
Aspirin -exacerbated respiratory disease
Asthma-chro nic obstructive pulmonary disease 
overlap syndrome
Blepharitis allergic
Blood immunoglobulin E abnormal
Blood immunoglobulin E increas ed
Bromoderma
Catheter site dermatitis
Catheter site eczemaInjection site rash
Injection site recall reaction
Injection site urticaria
Injection site vasculitis
Instillation site hypersensitivity
Instillation site rash
Instillation site urticaria 
Iodine allergy
Mast cell degranulation present
Medical device site dermatitis
Medical device site eczema
Medical device site hypersensitivity
Medical device site rash
Medical device site recall reaction 
Medical device site urticaria
Nodular rash
Pathergy reaction
Radioallergosorbent test positive
Reaction to azo -dyes
Reaction to colouring
Rhinitis allergic
Shock
Shock sy mptom
Skin test positive
Solvent sensitivity
Stoma site hypersensitivity
Stoma site rash
Urticaria contact
Urticarial vasculitis
Vaccinatio n site dermatitis
Vaccinatio n site exfoliation
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 159
LY24398271Catheter site hypersensitivity
Catheter site rash
Catheter site urticaria
Catheter site vasculitis
Chro nic eosinophilic rhinosinusitis
Chro nic hy perplastic eosinophilic sinusitis
Circulatory collapse
Conjunctivitis allergic
Contact stomatitis
Complement factor decreased
Complement factor increased
Complement factor C1 decreased
Complement factor C1 increased
Complement factor C2 decreased
Complement factor C2 increased
Complement factor C3 dec reased
Complement factor C3 increased
Complement factor C4 decreased
Complement factor C4 increased
Complement fixation abnormal
Complement fixation test positive
Contrast media allergy
Contrast media reaction
Dennie -Morgan fold
Dermatitis acneiform
Dermatitis contact
Dermatitis herpetiformis
Dermatitis infected
Device allergy
Dialy sis membrane reaction
Distributive shock
Drug cross -reactivity
Drug provocation test
Eczema infantile
Eczema vaccinatum
First use syndrome
Fixed drug eruption
Giant conjuct ivitis
Hand dermatitis
Heparin -induced thrombocytopenia
Hereditary angioedema
Implant site dermatitis
Implant site hypersensitivity
Implant site rash
Implant site urticaria
Immune -mediated adverse reaction
Incisio n site dermatitis
Incisio n site rash
Infusi on site dermatitisVaccinatio n siteeczema
Vaccinatio n site hy persensitivity
Vaccinatio n site rash
Vaccinatio n site recall reaction
Vaccinatio n site urticaria
Vaccinatio n site vasculitis
Vaccinatio n site vesicles
Vessel puncture site rash
Vessel puncture site vesicles
Vulvovaginal rash
Acut e respiratory failure
Allergy to chemicals
Allergy to fermented products
Anti-insulin antibody increased
Anti-insulin antibody positive
Anti-insulin receptor antibody increased
Anti-insulin receptor antibody positive
Blood immunoglobulin A abnormal
Blood immunoglobulin A increased
Blood immunoglobulin D increased
Blood immunoglobulin G abnormal
Blood immunoglobulin G increased
Blood immunoglobulin M abnormal
Blood immunoglobulin M increased
Immune complex level increased
Immunoglobulins abnormal
Immunoglob ulins increased
Immunology test abnormal
Haemolytic transfusion reaction
Infantile asthma
Fixed eruption
Rhinitis perennial
Seasonal allergy
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 160
LY24398271Infus ion site eczema
Infusion site hypersensitivity
Infusion site rash
Infusion site recall r eaction
Infusion site urticaria
Infusion site vasculitis
Injection site dermatitis
Injection site eczema
Injection site hypersensitivity
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 161
LY24398271Appendix 10. Algorithm for Calculating Composite 
Psoriatic Disease A ctivity  Index (CPDA I)
Com posite Psori atic Disease Act ivity Index (CPDAI) i s a validated instrument to assess 
composite psori atic disease act ivity and response to therapy  (Mum taz et al . 2011).  Thi s 
instrum ent assesses individual do mains:
peripheral  arthri tis as assessed by the number of tender and swollen jo ints and the 
Health Assessment Questi onnaire –Disabilit y Index(HAQ -DI) 
skin as assessed by  the Psori asis Area and Severit y Index (PASI) and the 
Derm atology Life Qualit y Index (DLQI)
enthesitis as assessed by the number of sites with enthesit is and the HAQ -DI
dactylit is as assessed by  the number of di gits affected and the HAQ -DI
Spinal disease as assessed by the Bath Ankylo sing Spondylit is Disease Activit y Index
(BASDAI) and Ankylosing Spondylit is Qualit y of Life (ASQoL)
The table below shows the instruments for each domain and the range in their total score:
Domain Instrument Total Score Range
Peripheral arthritis TJC/SJC 0-68/0-66
HAQ -DI 0-3
Skin disease PASI 0-72
DLQI 0-30
Enthesitis LEI 0-6
HAQ -DI 0-3
Dactylitis Digit Score 0-20
HAQ -DI 0-3
Spinal disease BASDAI 0-10
ASQoL 0-18
Abbreviations:  ASQoL = Ankylosing Spondylitis Quality of Life; BASDAI = Bath Ankylosing Spondylitis Disease 
Activity  Index; DLQI = Dermatology Life Quality Index; HAQ -DI = Health Assessment Questionnaire –
Disability Index; LEI = Leeds Enthesitis Index; PASI = Psoriasis Area and Severity Index; SJC = swollen joint 
count; TJC = tender joint count.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 162
LY24398271Each domain is scored fro m 0 to 3.  In dividual domain scores are summed to give an overall 
composite CPDAI score.  The composite scores range from 0 to 15 for the assessment, with a 
higher score indicat ing higher disease act ivity.  See the tabl e bel ow for details:
Domain Not involved (0) Mild (1) Moderate (2) Severe (3)
Peripheral arthritis TJC and SJC = 0 TJC or SJC ≤4; and
HAQ -DI < 0.5 TJC or SJC ≤4 and 
HAQ -DI ≥0.5; or 
TJC or SJC > 4 and 
HAQ -DI < 0.5TJC or SJC > 4 and 
HAQ -DI ≥0.5
Skin disease Absence of plaque 
psoriasis as defined 
PASI = 0 PASI ≤10 and 
DLQI ≤ 10PASI ≤10 and 
DLQI > 10; or
PASI > 10 and 
DLQI ≤ 10PASI > 10 and 
DLQI > 10
Enthesitis Absence of 
enthesitis as defined 
(LEI = 0 LEI ≤3 sites;
HAQ -DI < 0.5LEI ≤3 sites and 
HAQ -DI ≥0.5; or 
LEI > 3 sites and 
HAQ -DI < 0.5LEI > 3 and HAQ -
DI ≥0.5
Dactylitis Absence of dactylitis 
as defined by the 
Digit score = 0 Digit score ≤3 
digits;
HAQ -DI < 0.5Digit score ≤3 and 
HAQ -DI ≥0.5; or 
Digit score > 3 and 
HAQ -DI < 0.5Digit score > 3 and 
HAQ -DI ≥0.5
Spinal disease BASDAI = 0 and 
ASQoL = 0BASDAI < 4;
ASQoL < 6BASDAI < 4 and 
ASQoL ≥6; or 
BASDAI ≥4 and 
ASQoL < 6BASDAI > 4 and 
ASQol ≥ 6
Abbreviations:  BASDAI = Bath Ankylosing Spondylitis Disease Activity Index ;DLQI = Dermatology Life Quality 
Index; HAQ -DI = ; LEI = Leeds Enthesitis Index; PASI = Psoriasis Area and Severity Index; SJC = swollen joint 
count; TCJ = tender joint count; 
The m odified CPDAI will sum up each domain with the exception of spinal diseas e.  The 
composite scores range from 0 to 12 for the assessment, with a higher score indicat ing higher 
disease act ivity.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 163
LY24398271Appendix 11. Lilly-defined MedDRA  V21.0 Preferred 
Terms for Inflammatory  Bowel Disease (IBD)
Condition Preferred Term (MedDRA version 21.0) Lilly Defined 
Classification
Inflammato ry bowel disease Inflammato ry bowel disease Narrow
Crohn’s disease Crohn’s disease Narrow
Ulcerative colitis Acute haemorrhagic ulcerative colitis Narrow
Colitis ulcerative Narrow
Proctitis ulcerative Narrow
Non-specific terms Abscess intestinal Broad
Anal abscess Broad
Anal fistula Broad
Anal fistula excision Broad
Anal fistula infection Broad
Anovulvar fistula Broad
Aorto -duodenal fistula Broad
Colitis Broad
Colon fistula repair Broad
Colonic fistula Broad
Diverticular fistula Broad
Duodenal fistula Broad
Enterocolitis haemorrhagic Broad
Enterocolonic fistula Broad
Enterocutaneous fistula Broad
Enterovesical fistula Broad
Gastrointestinal fistula Broad
Gastrointestinal fistula repair Broad
Fistula of small intestine Broad
Intestinal fistula Broad
Intestinal fistula infection Broad
Intestinal fistula repair Broad
Jejunal fistula Broad
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 164
LY24398271Condition Preferred Term (MedDRA version 21.0) Lilly Defined 
Classification
Large intestinal ulcer perforation Broad
Rectal fistula repair Broad
Faecal calprotectin abnormal Broad
Faecal calprotectin increased Broad
Proctitis haemorrhagic Broad
Pseudopolyposis Broad
Rectoprostatic fistula Broad
Rectourethral fistula Broad
Abbreviations:  MedDRA = Medical Dictionary for Regulatory Activities.
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 165
LY24398271Appendix 12. Lilly-defined MedDRA  V21.0 Preferred Terms 
for Opportunistic Infections (OI)
Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Pneumocystis jirovecii   (II) Pneumocystis jiroveci ipneumonia
Pneumocystis jiroveci iinfectionNarrow
Pneumocystis test positive
Blood beta -D-glucan  
Blood beta -D-glucan abnormal  
Blood beta -D-glucan increased
Gomori methenamine silver stain  
Carbon monoxide diffusing capacity decreased   
Carbon monoxide diffusing capacity  Broad
Human polyomavirus infection 
including BK virus disease including 
PVAN (V), and 
Progressive Multifocal 
Leukoencephalopathy (IV)Human polyomavirus infection  
Polyomavirus -associated nephropathy  
BK virus infection  
Progressive multifocal 
leukoencephalopathy
JC virus infection
JC virus granule cell neuronopathyNarrow
Anti-JC virus antibody index
Polyomavirus test 
Polyomavirus test positive  
Giant papillary conjuctivitis
JC virus test
JC virus test positive
JC polyomavirus testBroad
Cytomegalovirus disease (V) Cytomegalovirus chorioretinitis 
Cytomegalovirus colitis  
Cytomegalovirus duodenitis
Cytomegalovirus enteritis  
Cytomegalovirus enterocolitis  
Cytomegalovirus gastritis  
Cytomegalovirus gastroenteritis  
Cytomegalovirus gastrointestinal infection  
Cytomegalovirus gastrointestinal ulcer  
Cytomegalovirus hepatitis  
Cytomegalovirus infection  
Cytomegalovirus mononucleosis  
Cytomegalovirus mucocutaneous ulcer  
Cytomegalovirus myelomeningoradiculitis Bartonellosis 
(disseminated disease only) (V)
Cytomegalovirus nephritis
Cytomegalovirus oesophagitis
Cytomegalovirus pancreatitis  
Cytomegalovirus pericarditis  
Cytomegalovirus syndrome
Cytomegalovirus urinary trac t infection  
Cytomegalovirus viraemia  Narrow
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 166
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Disseminated cytomegaloviral infection
Encephalitis cytomegalovirus  
Pneumo nia cy tomegaloviral
Cytomegalovirus test  
Cytomegalovirus test positive   Broad
Post-transplant ly mphoproliferative 
disorder (EBV) (V)Epstein -Barr virus associated lymphoma 
Epstein -Barr virus associated lymphoproliferative 
disorder  
Epstein -Barr virus positive mucocutaneous ulcer
Post transplant lymphoproliferative disorder  Narrow
Epstein -Barr viraemia
Epstein -Barr virus infection
Lymphoproliferative disorder
Lymphoproliferative disorder in remission
Oral hairy leukoplakiaBroad
Barto nellosis (disseminated disease 
only) (V)Bacillary  angiomatosis
Peliosis hepatis  
Splenic peliosis
Systemic bartonellosis   
Trench feverNarrow
Barto nella test 
Barto nella test positive
Barto nellosis
Cat scratch disease Broad
Blastomycosis (IV) Blastomycosis  
Epididymitis blastomyces  
Osteomyelitis blastomyces  
Pneumo nia blastomy ces  Narrow
N/A Broad
Toxoplasmosis (myocarditis, 
pneumonitis, or characteristic 
retinochoroiditis only) (IV)Cerebral toxoplasmosis
Eye infection toxoplasmal  
Hepatitis toxoplasmal  
Meningitis toxoplasmal  
Myocarditis toxoplasmal 
Pneumo nia toxoplasmalNarrow
Toxoplasma serology  
Toxoplasma serology positive 
ToxoplasmosisBroad
Coccidioidomycosis. (II) Coccidioides encephalitis  
Coccidioidomycosis  
Cutaneous coccidioidomycosis 
Meningitis coccidioides  Narrow
N/A Broad
Histoplasmosis (II) Acute pulmonary histoplasmosis  
Chro nic pulmonary histoplasmosis  
Endocarditis histoplasma  
Histoplasmosis
Histoplasmosis cutaneous  
Histoplasmosis disseminated
Meningitis histoplasma
Pericarditis histoplasma
Retinitis histoplasma   Narrow
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 167
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Presumed ocular histoplasmosis syndrome Broad
Aspergillosis (invasive disease only) 
(II)Aspergillosis oral  
Cerebral aspergillosis  
Meningitis aspergillus  
Oro-phary ngeal aspergillosis  Narrow
Aspergillus infection  
Aspergillus test  
Aspergillus test positive  
Bronchopulmonary aspergillosis  
Sinusitis aspergillus  Broad
Candidiasis (invasive disease or oral
not limited to the tongue )(II)Candida endophthalmitis  
Candida osteomyelitis
Candida pneumonia  
Candida retinitis  
Candida sepsis
Cerebral candidiasis   
Endocarditis candida  
Fungal oesophagitis
Gastrointestinal candidiasis  
Hepatic candidiasis
Hepatosplenic candidiasis
Meningitis candida  
Oesophageal candidiasis  
Orophary ngeal candidiasis  
Perito neal candidiasis  
Splenic candidiasis  
Systemic candida  Narrow
Bladder candidiasis  
Candida infection  
Candida test  
Candida test positive  
Mucocutaneous candidiasis
Oral candidiasis
Oral fungal infection
Respiratory  moniliasisBroad
Cryptococcosis (II) Cryptococcal cutaneous infection  
Cryptococcal fungaemia  
Cryptococcosis  
Disseminated cryptococcosis 
Gastroenteritis cryptococcal  
Meningitis cryptococcal 
Neurocryptococcosis 
Osseous cryptococcosis
Pneumo nia cry ptococcalNarrow
Cryptococcus test  
Cryptococcus test positive  Broad
Other invasive fungi: Mucormycosis 
(=zygomycosis) [Rhizopus, Mucor, 
and Lichtheimia], 
Scedosporum/Pseudallescheria 
boydii , Fusarium (II)Allescheriosis
Fusarium infection
Mucormycosis
Scedosporium in fection 
Phaeohyphomycosis
Phaeohyphomycosis br ain abscessNarrow
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 168
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Pseudallescheria infection  
Pseudallescheria sepsis
See “Non -specific terms” below Broad
Legionellosis (II) Legionella infection
Pneumo nia legionella  
Pontiac feverNarrow
Legionella test  
Legionella test positive  Broad
Listeria monocytogenes (invasive 
disease only) (II)Listeria encephalitis  
Listeria sepsis  
Meningitis listeria  Narrow
Listeriosis  
Listeria test  
Listeria test positive  
ListeraemiaBroad
Tuberculosis (I) Adrenal gland tuberculosis  
Bone tuberculosis  
Choroid tubercles
Conjunctivitis tuberculous
Cutaneous tuberculosis  
Disseminated Bacillus Calmette -Guerin infection
Disseminated tuberculosis
Ear tuberculosis  
Epididymitis tuberculous  
Extrapulmonary tuberculosis  
Immune reconstitution inflammatory syndrome 
associated tuberculosis
Intestinal tuberculosis  
Joint tuberculosis  
Lymph node tuberculosis  
Male genital tract tuberculosis  
Meningitis tuberculous  
Oesophageal tuberculosis
Oral tuberculosis   
Pericarditis tuberculous  
Perito neal tuberculosis  
Prostatitis tuberculous  
Pulmonary tuberculoma  
Pulmonary tuberculosis  
Renal tuberculosis  
Salpingitis tuberculous
Silico tuberculosis   
Spleen tuberculosis  
Thyroid tuberculosis  
Tuberculid 
Tuberculoma of central nervous system
Tuberculosis   
Tuberculosis bladder  
Tuberculosis gastrointestinal  
Tuberculosis liver  
Tuberculosis of central nervous system  
Tuberculosis of eye  Narrow
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 169
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Tuberculosis of genitourinar y system  
Tuberculosis of intrathoracic lymph nodes  
Tuberculosis of peripheral lymph nodes  
Tuberculosis ureter  
Tuberculous abscess central nervous system  
Tuberculous endometritis  
Tuberculous laryngitis  
Tuberculous pleurisy  
Tuberculous tenosy novitis  
Interferon gamma release assay
Interferon gamma release assay positive
Mycobacterium tuberculosis complex test  
Mycobacterium tuberculosis complex test positive  
Tuberculin test 
Tuberculin test false negative  
Tuberculin test positive  Broad
Nocardiosis (II) Cutaneous nocardiosis
Nocardia sepsis  
Nocardiosis  
Pulmonary nocardiosisNarrow
Nocardia test positive  Broad
Nontuberculous mycobacterium 
disease (II)Atypical mycobacterial infection  
Atypical mycobacterial lower respiratory tract infection  
Atypical mycobacterial lymphadenitis  
Atypical mycobacterial pneumonia  
Atypical mycobacterium pericarditis
Borderline leprosy
Bovine tuberculosis
Indeterminate leprosy
Leprosy
Lepromatous leprosy
Mycobacterial infection 
Mycobacterial peritonitis  
Mycobacterium abscessus infection
Mycobacterium avium complex immune restoration 
disease  
Mycobacterium avium complex infection  
Mycobacterium chelonae infection
Mycobacterium fortuitum infecti on 
Mycobacterium kansasii infection
Mycobacterium marinum infection  
Mycobacterium ulcerans infection  
Superinfection mycobacterial  
Tuberculoid leprosy
Type 1 lepra reaction
Type 2 lepra reactionNarrow
Atypical mycobacterium test positive  
Mycobacterial disease carrier  Mycobacterium leprae 
test positive
Mycobacterium test  
Mycobacterium test positive      Broad
Salmo nellosis (invasive disease Aortitis salmonella Narrow
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 170
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
only)(II) Arthritis salmonella
Meningitis salmonella
Osteomyelitis salmon ella
Paraty phoid fever
Pneumo nia salmo nella
Salmo nella sepsis
Salmo nella bacteraemia
Typhoid fever
Salmo nella test positive  
Salmo nellosisBroad
HBV reactivation (IV) Hepatitis B reactivation Narrow
Asymptomatic viral hepatitis
Chro nic hepatitis B
HBV -DNA polymerase increased
Hepatitis B
Hepatitis B DNA assay 
Hepatitis B DNA assay positive 
Hepatitis B DNA increased
Hepatitis B antigen
Hepatitis B antigen positive  
Hepatitis B core antigen 
Hepatitis B core antigen positive
Hepatitis B e antigen  
Hepatitis B e antigen positive  
Hepatitis B surface antigen  
Hepatitis B surface antigen positive
Hepatitis B virus test  
Hepatitis B virus test positive 
Hepatitis infectious
Hepatitis post transfusion
Hepatitis viral 
Withdrawal hepatitis      Broad
Herpes simplex (invasive disease 
only)(IV)Colitis herpes 
Gastritis herpes 
Herpes oesophagitis  
Herpes sepsis
Herpes simplex colitis  
Herpes simplex encephalitis
Herpes simplex gastritis  
Herpes simplex hepatitis  
Herpes simplex meningitis  
Herpes simplex meningoencephalitis  
Herpes simplex meningomyelitis  
Herpes simplex necrotising retinopathy
Herpes simplex oesophagitis  
Herpes simplex pneumonia
Herpes simplex sepsis      
Herpes si mplex visceral
Herpes simplex viraemia
Meningitis herpes  
Meningoencephalitis herpetic
Meningomyelitis herpes  Narrow
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 171
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Pneumo nia herpes viral  
Eczema herpeticum
Herpes ophthalmic  
Herpes simplex
Herpes simplex DNA test positive
Herpes virus infection
Herpes virus test abnormal
Herpes simplex virus test positive
Ophthalmic herpes simplex    Broad
Herpes zoster (any form) (II) Disseminated varicella zoster vaccine virus infection
Encephalitis post varicella  
Genital herpes zoster  
Herpes zoster
Herpes zoster cutaneous disseminated  
Herpes zoster disseminated
Herpes zoster infection neurological  
Herpes zoster meningitis
Herpes zoster meningoencephalitis
Herpes zoster meningomyelitis    
Herpes zoster meningoradiculitis
Herpes zoster necrotising retinopathy  
Herpes zoster oticus
Herpes zoster pharyngitis  
Necrotising herpetic retinopathy  
Ophthalmic herpes zosterNarrow
Varicella zoster virus infection
Varicella virus test 
Varicella virus test positive  Broad
Stronglyoides (hyperinfection 
syndrome and disseminated forms 
only) (IV)Strongyloidiasis Narrow
N/A Broad
Paracoccidioides infections (V) Paracoccidioides infection  
Pulmonary paracoccidioidomycosisNarrow
N/A Broad
Penicillium marneffei (V) Penicillium infection Narrow
Penicillium test positive Broad
Sporothrix schenckii (V) Cutaneous sporotrichosis  
Pulmonary sporotrichosis
Sporotrichosis  Narrow
N/A Broad
Cryptosporidium species (chronic 
disease only) (IV)Biliary  tract infection cryptosporidial  Narrow
Cryptosporidiosis infection  
Gastroenteritis cryptosporidial  Broad
Microsporidiosis (IV) Microsporidia infection  Narrow
N/A Broad
Leishmaniasis (Visceral only) (IV) Visceral leishmaniasis    Narrow
Leishmaniasis Broad
Trypanosoma cruzi infection 
(Chagas’ Disease) (disseminated 
disease only) (V)Chagas’ cardiomyopathy
Meningitis trypanosomal   Narrow
American trypanosomiasis
TrypanosomiasisBroad
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 172
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Trypanosoma serology positive   
Campy lobacteriosis (invasive disease 
only) (V)Campy lobacter sepsis  Narrow
Campy lobacter infection
Campy lobacter test positive    Broad
Shigellosis (invasive disease only) 
(V)Shigella sepsis  Narrow
Shigella infection 
Shigella test positive  Broad
Vibriosis (invasive disease due to V. 
vulfnificus ) (V)N/A Narrow
Vibrio test positive  
Vibrio vulnificus infectionBroad
HCV progression (V) N/A  Narrow
Chro nic hepatitis C
Hepatitis C
Hepatitis C RNA  
Hepatitis C virus test  
Hepatitis C RNA increased
Hepatitis C RNA positive 
Hepatitis C RNA fluctuation  
Hepatitis C virus test positive  Broad
Non-specific terms N/A  Narrow
Abscess fungal 
Alternaria infection 
Arthritis fungal 
Biliary  tract infection fungal 
Central nervous system fungal infection
Cerebral fungal infection  
Encephalitis fungal  
Erythema induratum 
Eye infection fungal 
Fungaemia  
Fungal abscess central nervous system 
Fungal endocarditis 
Fungal labyrinthitis 
Fungal peritonitis 
Fungal pharyngitis 
Fungal retin itis 
Fungal sepsis
Hepatic infection fungal 
Meningitis fungal 
Mycotic endophthalmitis 
Myocarditis mycotic 
Orophary ngitis fungal 
Osteomyelitis fungal 
Otitis media fungal 
Pancreatitis fungal 
Parasitic lung infection
Parasitic pneumonia
Pericarditis fungal 
Phaehy phomycosis 
Pneumo nia fungal 
Pulmonary mycosis 
Pulmonary trichosporonosis Broad
I1F-MC-RHBF Statistical Analysis Plan Version 3 Page 173
LY24398271Opportunistic Infection Preferred Term
(MedDRA Version 21.0)Lilly Defined 
Classification
Sinusitis fungal  
Splenic infection fungal
Systemic mycosis
Abbreviations:  MedDRA = Medical Dictionary for Regulatory Activities.
Leo Document ID = e23de465-31a7-4763-9651-e1da7e0a70e4
Approver: 
Approval Date & Time: 25-Oct-2018 18:34:52 GMT
Signature meaning: Approved
PPD